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Life is not measured by the number of breaths we take, 
but by the moments that take our breath away.
George Carlin
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The quality of life of patients with advanced Chronic Obstructive Pulmonary Disease (COPD) 
is poor, and often even worse than patients with inoperable lung cancer.1 Patients with 
cancer commonly receive palliative care towards the end of life, incorporating their physical, 
psychological, social, and spiritual needs. Research has shown that an early or proactive approach 
to palliative care improves the quality of life of patients with cancer.2,3 However, for patients with 
COPD such care is not common practice.1,4 This thesis contains several studies in order to move 
towards the use of proactive palliative care for patients with COPD.
COPD
Definition and outline
COPD is defined as “a preventable and treatable disease with some significant extra-pulmonary 
effects that may contribute to the severity in individual patients. Its pulmonary component is 
characterized by airflow limitation that is not fully reversible. The airflow limitation is usually 
progressive and associated with an abnormal inflammatory response of the lung to noxious particles or 
gases.”5 Although smoking is a major risk factor for COPD, non-smokers may also develop the 
disease as a result of exposure to air pollution and/or a genetic predisposition.6-9 The severity of 
COPD is graded according to the degree of airflow limitation as mild, moderate, severe, or very 
severe.5 However, airflow limitation is only poorly correlated with the symptom burden and the 
other problems these patients encounter, such as functional limitation, number of exacerbations, 
and the presence of co-morbidities.10 The characteristic symptoms of COPD are chronic and 
progressive dyspnea, coughing and sputum production, while fatigue and anxiety are also highly 
prevalent in more advanced disease.11,12 The distress these symptoms cause is, beside functional 
impairment and poor psychological well-being, associated with impairment of quality of life.11 
COPD has an unpredictable course characterized by episodes of gradual decline punctuated 
by acute severe exacerbations.13 Patients with COPD often suffer from co-morbidities such as 
cardiovascular diseases, depression, osteoporosis, diabetes and lung cancer.14 The occurrence of 
exacerbations and co-morbidities contribute to the severity of the disease and have a significant 
impact on prognosis.14-16
Demographics and prognosis
The global prevalence of moderate to very severe COPD is estimated to be around 10% in 
people aged 40 years or older.17 The risk of developing COPD between the ages of 40 and 
80 was reported to be 12.7% for men and 8.3% for women.18 COPD is expected to be the 
fourth leading cause of death worldwide by 2030.19 The prognosis of patients with COPD is 
poor; the mortality rate in the year following hospitalization for an acute exacerbation of COPD 
(AECOPD) is around 22%.20,21 A large cohort study showed that after their first hospitalization 
for AECOPD, 50% of patients had died within 3.6 years, while 75% of patients had died within 
7.7 years.22 
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Managing COPD
The management of COPD is disease-oriented and mainly focuses on symptom control. It 
includes the reduction of risk factors, especially smoking cessation; pharmacological treatments, 
such as inhaled bronchodilators and glucocorticosteroids; and non-pharmacological treatments, 
including pulmonary rehabilitation, long-term oxygen therapy, and surgical treatment.5
Challenges for care
Generally speaking, clinicians are faced with the following challenges in the provision of quality 
care for patients with COPD: 
Addressing low socioeconomic status
Environmental risk factors for developing COPD, such as tobacco smoking and indoor and 
outdoor pollution, are more common in people with a lower socioeconomic status (SES), i.e., 
people with a lower average level of education and less financial means.23 As a result, having these 
social and economic disadvantages increases the risk of developing COPD.24 It is therefore not 
surprising that people of low SES account for the majority of all COPD patients.25 In addition, 
lower SES is associated with lower health literacy and poorer health outcomes.26,27 Patients with 
the lowest SES are twice as likely to experience poor health outcomes from COPD, such as 
morbidity and mortality, as those of the highest SES.23 Reducing these health disparities requires 
a multidisciplinary effort to encourage healthy lifestyles, target environmental risk factors, and 
optimize the prevention and management of COPD.28 
Informing patients about the progressive course of COPD
Patients with advanced COPD often have poor understanding of their disease.29 They sometimes 
assume that deterioration is a normal part of ageing instead of a disease-related factor,30 and tend 
to be unaware of the progressive course of COPD and the possibility of dying from this disease.29 
Informal caregivers of patients with COPD have also reported being under-informed about the 
diagnosis, expected course, and prognosis.31 Good clinician-patient communication addressing 
these topics is necessary to educate patients and their informal caregivers about COPD and to 
consequently enable them to take an active role in the management of the disease.29
Installing an integrated multidisciplinary collaboration
COPD has an unpredictable course.13 During the stable phase, patients are treated by a General 
Practitioner (GP), while during a severe acute exacerbation they are often hospitalized and treated 
by a pulmonologist. In addition, patients often face co-morbidities, such as cardiovascular disease 
or diabetes, which complicate the management of COPD.14,32 As a result, they are also treated by 
other medical specialists, such as cardiologists and endocrinologists. Consequently, an integrated 
multidisciplinary well-coordinated approach is necessary to manage the disease and provide the 
best care possible.33
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PALLIATIVE CARE
Definition
The World Health Organization (WHO) defines palliative care as “an approach that improves 
the quality of life of patients and their families facing the problem associated with life-threatening 
illness, through the prevention and relief of suffering by means of early identification and impeccable 
assessment and treatment of pain and other problems, physical, psychosocial and spiritual. Palliative 
care: provides relief from pain and other distressing symptoms; affirms life and regards dying as a 
normal process; intends neither to hasten or postpone death; integrates the psychological and spiritual 
aspects of patient care; offers a support system to help patients live as actively as possible until death; 
offers a support system to help the family cope during the patients illness and in their own bereavement; 
uses a team approach to address the needs of patients and their families, including bereavement 
counseling, if indicated; will enhance quality of life, and may also positively influence the course of 
illness; is applicable early in the course of illness, in conjunction with other therapies that are intended 
to prolong life, such as chemotherapy or radiation therapy, and includes those investigations needed to 
better understand and manage distressing clinical complications.”34
Quality of life
The main objective of palliative care is to improve the quality of life of patients with a life-
threatening illness and their families. The WHO defines quality of life as “an individual’s 
perception of their position in life in the context of the culture and value systems in which they live and 
in relation to their goals, expectations, standards and concerns. It is a broad ranging concept affected 
in a complex way by the person’s physical health, psychological state, level of independence, social 
relationships, and their relationship to salient features of their environment.”35
Advance care planning
Advance care planning (ACP) is an important aspect of palliative care which involves patient-
clinician communication about end-of-life care.36 ACP conversations inform patients about their 
diagnosis, prognosis, and treatment options, as well as the consequences of these options.30 If well 
informed, patients have the opportunity to express their values and preferences for life-sustaining 
treatments with the goal of improving the quality of their end-of-life care.30
History of palliative care
In the past, acute diseases were the primary causes of death. Since living conditions and healthcare 
have improved, people are living longer and the primary causes of death today are chronic 
diseases.37 This change from acute to chronic causes of death led to the development of palliative 
care.37 Initially, the focus of palliative care was on patients with incurable cancer.37,38 After cure 
of the cancer was not possible anymore, the emphasis of care shifted not only to symptom 
control but also incorporated psychological, social and spiritual support for patients and their 
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families.39 By the end of the 20th century, this kind of care was mainly provided by community 
services working alongside GPs, specialized palliative care teams and hospices.37 At the beginning 
of the present century, a consensus arose that access to palliative care should be based on needs 
rather than diagnosis, and that palliative care should become a gradually increasing part of care 
from diagnosis to death, rather than being concerned only with the terminal phase.37,38 In 2002 
the WHO incorporated this view into their new definition of palliative care, described above.34 
Palliative care options should therefore be considered early in the disease trajectory alongside 
disease-oriented care, and should be promoted for patients with non-malignant diseases too. As a 
result, palliative care has become more integrated into hospital and GP services.37
Effectiveness on quality of life 
In 2008, a systematic review was performed by Zimmermann and colleagues to investigate the 
effectiveness of specialized palliative care.40 They identified four studies specifying quality of life 
as a primary outcome,41-44 all of which focused on patients with cancer. In one of these studies, 
a structured multidisciplinary intervention was found to improve the quality of life of these 
patients.44 Between 2008 and 2012, two more studies examined the effectiveness of palliative 
care, with quality of life as a primary outcome measure.2,3 These studies undertaken by Bakitas 
and colleagues and Temel and colleagues concerned early or proactive approaches to palliative 
care for patients with cancer. In both studies, patients received palliative care concurrently with 
oncology treatments either upon diagnosis or with a life expectancy of at least six months. This 
early or proactive palliative care approach was found to improve not only their quality of life, 
but also the mood of the patients.2,3 Temel and colleagues even showed that patients receiving 
early or proactive palliative care had less aggressive care at the end of live but longer survival.3 No 
studies examining the effectiveness of palliative care on quality of life were found with a specific 
focus on patients with COPD.
PROACTIVE PALLIATIVE CARE FOR PATIENTS WITH COPD
Palliative care in general is still developing; however, for patients with non-malignant diseases, 
such as COPD, the delivery of palliative care is not yet common practice and is still in the initial 
phases. Patients with COPD are rarely offered palliative support and have limited access to 
specialized palliative care services.1 On occasions when they are offered palliative care it is often 
limited to a reactive instead of a proactive approach.45 Proactive palliative care is about the early 
identification of patients to be able to anticipate on their palliative care needs and wishes thereby 
preventing and relieving suffering.34 In this section the circumstances of patients with COPD 
and the barriers and challenges to developing a proactive palliative care approach for this patient 
group are outlined. 
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Symptom burden and quality of life
The symptoms experienced by patients with COPD in their last year of life are at least as severe 
as those of patients with lung cancer.4 Post-bereavement interviews with informal caregivers of 
patients with COPD and lung cancer were used to compare symptoms.4 Patients in both groups 
experienced breathlessness, anorexia, pain, low mood, insomnia, and coughing, and although 
patients with lung cancer were more likely to be anorexic, patients with COPD more frequently 
experienced and were troubled by breathlessness.4 Patients with advanced COPD also had an 
impaired quality of life.1 Self-reported quality of life questionnaires showed that patients with 
advanced COPD even had lower activity levels in their daily life and worse physical, emotional 
and social functioning than patients with inoperable lung cancer.1 
Disease trajectory
Although the symptom burden and quality of life of patients with advanced COPD are as bad 
as, or even worse than, those of patients with lung cancer, they less commonly receive palliative 
care.1,4 This disparity in care likely reflects distinct disease trajectories.46 For progressive chronic 
diseases three typical end-of-life disease trajectories have been described: cancer, organ failure, and 
the frail elderly trajectory (see Figure 1).13,47,48 During the course of their disease, patients with 
cancer often experience a steady progression and usually have a clear terminal phase involving a 
rapid decline until death (Figure 1, upper panel), whereas patients with frailty or dementia suffer 
a prolonged gradual decline until death (Figure 1, lower panel). In contrast, patients with organ 
failure, such as COPD, experience a gradual decline, punctuated by acute severe exacerbations 
and some recovery, with a more sudden, seemingly unexpected death (Figure 1, middle panel). 
The physical, psychological, social, and spiritual needs of patients and their caregivers are likely 
to vary between these distinct disease trajectories. Different models of care are therefore necessary 
to reflect the differences in care needs.13 This implies that patients with COPD require a different 
approach to palliative care than patients with cancer.
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Figure 1 End-of-life disease trajectories of progressive chronic diseases. Reproduced with permission.47 
Barriers and challenges
Patients with COPD experience a gradual functional decline punctuated by acute severe 
exacerbations during which disease-oriented care remains necessary and the need for palliative 
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care gradually increases.13,49 This implies that the traditional model of care based on a dichotomy 
involving an abrupt transition from active, life-sustaining care to palliative care does not work 
for patients with COPD.33 Since it is acknowledged that access to palliative care should be based 
on needs rather than diagnosis, this kind of care should also be made available for patients with 
COPD. Nowadays, palliative care can be delivered early in the disease trajectory alongside disease 
oriented care. However, the occurrence of acute severe exacerbations, any one of which may be 
fatal, complicates the delivery of proactive palliative care in two ways. First, the uncertainty of the 
prognosis in terms of survival caused by these exacerbations hinders the timely identification of 
patients who would benefit from proactive palliative care.36,50 Second, the healthcare professionals 
involved in the care of the patient during the stable phase differ from those involved in care 
during hospitalization for acute exacerbations, which endangers the continuity of palliative care 
delivery.51 
The disease trajectory of COPD often takes decades. Initially, the patient and the informal 
caregiver are capable of managing the disease themselves. In this stage it is important for 
clinicians to educate them about the disease and its course so they can take an active role in their 
own disease management.29 Starting palliative care or talking about the end of life during this 
stage seems unrealistic and might even be undesirable; however, as the disease progresses and the 
functional status of the patient declines, a time will come when the patient and the informal 
caregiver might benefit from a proactive palliative care approach. The timely identification of 
patients requiring such an approach not only enables adequate support for the patient and the 
informal caregiver, but also facilitates the initiation of ACP conversations and communication 
between healthcare professionals,30,36 which is necessary to ensure the continuity of the proactive 
palliative care delivery.52 However, it has not yet been determined how to identify patients with 
COPD in need of proactive palliative care and how to organize such a coordinated healthcare 
plan.33,53 In 2011, the Lung Alliance Netherland, the Dutch society for chronic lung diseases, 
developed a guide line which provides recommendations to support healthcare professionals 
involved with the palliative care of patients with COPD.54 This guideline describes the best care 
for patients with COPD in the palliative phase, while also recognizing the difficulties about 
when to begin palliative care and how it should be organized.54 Therefore, major challenges for 
delivery of proactive palliative care to patients with COPD are the identification of patients who 
need such care, and the organization of proactive palliative care itself.
Identification
General tools for the identification of patients in need of proactive palliative care have previously 
been developed.55,56 Most of these tools consist of a clinical prediction of survival by means of the 
surprise question (Would I, as healthcare professional, be surprised if my patient would die in the 
next year?), as well as general and disease-specific prognostic indicators of decline.56,57 However, 
these tools are not specifically intended for, or not validated in, the COPD population.55,56 
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Moreover, prognostic tools for use in stable COPD disease have been developed to enable the 
adjustment and optimization of care.58,59 However, these tools only have a poor to fair predictive 
performance for mortality within one year, indicating that they do not predict short-term 
survival well and are therefore not suitable for the identification of patients with COPD who 
might benefit from proactive palliative care.58,59
Since hospitalization for AECOPD is associated with significant mortality, research has focused 
on the identification of predictors of mortality after such an event.60,61 Recently several clinical 
important predictors of post-hospital mortality have been identified.60-62 Hospitalization for 
AECOPD may therefore create an opportunity to identify patients with poor prognosis who 
may profit from a proactive palliative care approach.60 In addition, during hospitalization for 
AECOPD patients have a poor health status and are probably more willing to talk about end-of 
-life issues.63 Consequently, since healthcare professionals are present, they have the opportunity 
to engage in conversations about palliative care needs with patients.30
Organization 
Towards the end of life, patients with COPD are faced with increasing symptom burden and 
functional limitations while also experiencing more frequent exacerbations.64 Decreases in mobility 
means they are often homebound until they enter an acute phase requiring hospitalization.36 
This unpredictable course requires community-based care with continuity of care during 
hospitalization.65 Continuity of palliative care can therefore only be achieved with a coordinated, 
integrated, multidisciplinary care approach.33,52 GPs, pulmonologists, respiratory nurse specialists, 
and palliative care specialists should collaborate to optimize palliative care delivery for patients 
with COPD. However, there is no consensus on how this coordinated care should be successfully 
organized across the entire illness trajectory.33 Since pulmonologist have a central role in COPD 
management, they are advised to take the lead in organizing this coordinated, integrated, 
multidisciplinary approach to palliative care and in developing services for patients with COPD.66 
Proactive assessment of problems and needs
A proactive approach to palliative care not only considers the current problems and needs of 
patients, but also anticipates future problems and needs to prevent and relieve suffering.34 This 
requires a thorough assessment in which the person, their disease, and their social context are 
considered. Important elements of this assessment include an evaluation of the patient’s physical, 
psychological, social, and spiritual problems and needs, an assessment of the family’s strength 
and burdens, a discussion of the expected disease scenarios and the advantages and disadvantages 
of several options for intervention, a discussion about the expected dying scenarios, and the 
evaluation of the patient’s ACP wishes. Such a multidimensional assessment can be quite 
challenging for clinicians. Recently, a tool was developed to help clinicians make a structured 
multidimensional overview of the patient’s current and possible future problems, needs, and 
ACP wishes (Figure 2).67 This simple tool can help clinicians to develop a proactive palliative care 
plan in which all dimensions are considered.68 
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Somatic domain Social and Financial domain
Actual problems:
Expected problems:
Scenario of dying:
Patient’s own wishes:
Actual problems:
Expected problems:
Patient’s own wishes 
ADL and Care provision Psychological and Existential domain
Actual problems:
Expected problems:
Patient’s own wishes 
Actual problems:
Expected problems:
Patient’s own wishes 
Figure 2 Multidimensional assessment tool for proactive palliative care planning. Modified from Thoonsen et al (2011).67
ACP conversations
A study investigating treatment preferences found that hospitalized patients with advanced 
COPD and lung cancer were equally likely to prefer a treatment based on comfort, yet patients 
with COPD were much more likely to be intubated or to receive cardiopulmonary resuscitation.69 
To improve care for patients with COPD, it is important that ACP conversations take place 
during which patients can discuss their preferences for end-of-life care with their physician. 
However, these ACP conversations occur only infrequently, and often take place late in the 
disease trajectory, such as in the intensive care unit.70,71 This implies that the patient and family 
did not have the chance to consider their future needs and wishes, and shared decision-making is 
often difficult in such an acute situation. There are several clinician and patient-related barriers to 
the timely communication of these topics.30,72 One important barrier is the difficulty predicting 
the prognosis, which can falsely reassure clinicians into thinking that they can postpone these 
difficult discussions..73 Clinicians also expressed concern that early ACP may take away patients’ 
hope and lead to unnecessary anxiety and depression. On the other hand, patients mentioned 
their assumption that clinicians will initiate these conversations, as well as their guilt about 
their smoking-related disease.30,72 Clinician awareness of these barriers to communication may 
improve occurrence and quality of discussions about end-of-life care.74 
Research
Research in vulnerable patient groups, such as patients in the palliative phase, must deal with significant 
ethical and methodological concerns.75,76 As a result studies investigating these patients have difficulties 
in gaining informed consent, poor recruitment rates and high attrition rates.75,76 This is an important 
reason why there is hardly any research into end-of-life care in patients with COPD, which in turn 
hinders service development.33 Good quality research into patients with COPD is therefore necessary 
to facilitate the improvement of outcomes and end-of-life care in this patient group.
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OBJECTIVES OF THIS THESIS
The objective of this thesis is: to explore the views, needs and wishes of pulmonologists concerning 
proactive palliative care for patients with COPD; to examine the identification of patients with 
COPD for proactive palliative care; and to examine the effectiveness of proactive palliative care 
on the well-being of patients with COPD.
A survey study, pilot study, and a pragmatic cluster controlled trial were designed to answer the 
following research questions:
1.  What is the view of pulmonologists regarding: proactive palliative care for patients with 
COPD in general; the identification of patients with COPD for proactive palliative care; 
the content of proactive palliative care for patients with COPD; and the organization of 
proactive palliative care for patients with COPD?
2.  Are potential indicators of poor prognosis documented consistently in the medical records 
of patients hospitalized for an AECOPD? 
3.  What is the effect of proactive palliative care on patients with COPD in terms of quality of 
life, psychological distress, the number and length of hospital admissions, survival and the 
number of patients who made ACP choices?
4.  Is it possible to develop a valid multivariable tool to identify patients with COPD in need of 
proactive palliative care and what is the discriminating power of this tool in predicting death 
for any cause within one year (as a proxy for palliative care needs)?
OUTLINE OF THIS THESIS
In Chapter 2 the views of pulmonologists in the Netherlands regarding palliative care for patients 
with COPD are described, particularly regarding the identification of patients with COPD for 
palliative care and the content and organization of palliative care for patients with COPD. 
Chapter 3 contains a detailed description of the methodology used to perform the pragmatic 
cluster controlled trial. To undertake this trial, we used a set of indicators to identify patients 
hospitalized for an AECOPD who have a poor prognosis and who might therefore benefit from 
proactive palliative care. These indicators were selected a priori, based on information from the 
literature. In Chapter 4 the results of a pilot study investigating the feasibility of using this set 
of indicators for our prospective trial are presented. In addition to elucidating the consistency 
of documentation for each indicator in the medical records, the percentage of patients with 
poor prognoses and the prognostic value of the set of indicators were also explored. Chapter 5 
presents the results of the pragmatic cluster controlled trial, in which we assessed the effects of 
proactive palliative care on the wellbeing of patients with COPD. The primary objective was 
to assess the effects of proactive palliative care on the quality of life of these patients, while the 
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secondary outcome measures were: psychological distress, the number and length of hospital 
readmissions for AECOPD, survival, and the number of patients who made ACP choices. 
Chapter 6 comprises a report on the development of a tool to identify patients with COPD who 
require proactive palliative care. In response to our paper describing this work, some authors 
wrote a letter to the editor; therefore, this chapter also includes this letter and our reply to it. 
Finally, Chapter 7 is the general discussion, in which the clinical implications of this thesis and 
future directions for education and research are discussed.
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ABSTRACT
Introduction: Early palliative care is not common practice for patients with Chronic Obstructive 
Pulmonary Disease (COPD). Important barriers are the identification of patients for palliative 
care and the organization of such care in this patient group.
Objective: Pulmonologists have a central role in providing good quality palliative care for 
patients with COPD. To guide future research and develop services their view on palliative care 
for these patients was explored.
Methods: A survey study was performed by members of the Netherlands Association of 
Physicians for Lung Diseases and Tuberculosis (NVALT). 
Results: The 256 respondents (31.8%) covered 85.9% of the hospital organizations in 
the Netherlands. Most pulmonologists (92.2%) indicated to distinguish a palliative phase 
in the COPD trajectory, but there was no consensus about the different criteria used for its 
identification. Aspects of palliative care in COPD considered important were Advance Care 
Planning conversation (82%), communication between pulmonologist and general practitioner 
(77%) and identification of the palliative phase (75.8%), while the latter was considered the 
most important aspect for improvement (67.6%). Pulmonologists indicated to prefer organizing 
palliative care for hospitalized patients with COPD themselves (55.5%), while 30.9% indicated 
to prefer cooperation with a Specialized Palliative Care Team (SPCT). In the ambulatory setting 
a multidisciplinary cooperation between pulmonologist, general practitioner and a respiratory 
nurse specialist was preferred (71.1%).
Conclusion: To encourage pulmonologists to timely initiate palliative care in COPD we 
recommend to conduct further research into more specific identification criteria. Furthermore, 
pulmonologists should improve their skills of palliative care and members of the SPCT should 
be better informed about the management of COPD to improve care during hospitalization. 
Communication between pulmonologist and general practitioner should be emphasized in 
training to improve palliative care in the ambulatory setting.
Keywords: Proactive palliative care, Pulmonologists, Identification, Organization, Cooperation 
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INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is a progressive life-threatening disease and 
the third leading cause of death worldwide.1 Symptoms at the end of life are as severe as or even 
worse than those of patients with advanced cancer.2 Even so, compared to patients with cancer, 
palliative care is not common practice for patients with COPD.3 This may be due to the fact that 
historically the focus of palliative care has been on oncology.4 But, according to the definition 
of the World Health Organization (WHO), palliative care is intended for any life-threatening 
disease by means of early identification, assessment and treatment of pain and other problems, 
physical, psychosocial and spiritual in order to prevent and relief suffering.5 The palliative phase 
thus comprises of a much longer period than the terminal or dying phase only. It implies that 
palliative care, as opposed to hospice care, is not limited to the terminal phase and can be given 
at an early stage alongside curative care. So, also patients with COPD may benefit from early 
palliative care without denying active disease-oriented treatment.
Important barriers in the provision of palliative care for patients with COPD are the identification 
of patients for palliative care and the organization of such care.6 COPD has a gradual decline 
punctuated by acute severe exacerbations, any one of which may be fatal.7,8 This unpredictable 
disease course hampers clinicians to timely initiate discussions about palliative care.9,10 A debate 
has started among professionals whether prognosis, curability, palliative needs or a combination 
of these factors should mark the start of a palliative trajectory in patients with COPD but 
consensus has not yet been established.11 Consensus also needs to be established about the optimal 
organization of palliative care.9 Patients with advanced COPD are often homebound until they 
enter an acute phase with hospitalization. This requires community-based care with continuity 
of care during hospitalization.12 Continuity of palliative care thus can only be achieved with 
a coordinated, collaborative, multidisciplinary care approach.13 Therefore, general practitioners 
(GPs), pulmonologists, respiratory nurse- and palliative care specialists should collaborate to 
optimize palliative care delivery for patients with COPD. How this coordinated care should be 
successfully organized across the entire illness trajectory is not yet decided.14,15
To facilitate delivery of palliative care to patients with COPD for clinicians, the Lung Alliance 
Netherland (LAN), the Dutch society for chronic lung diseases, developed a guideline on 
palliative care for patients with COPD in 2010.16 This guideline also provides recommendations 
about the start and the organization of palliative care based on literature but it is unknown to 
what extent clinicians use this guideline. 
Since pulmonologists have a central role in providing good quality care for patients with COPD, 
they are in the front line to recognize palliative care needs in this patient group. For that reason 
it has been advised that they take the lead in developing services.17 Therefore, the objective of 
this study was to explore the view of pulmonologist in the Netherlands on: 1) palliative care for 
patients with COPD in general, 2) identification of patients with COPD for palliative care, 3) 
important aspects of palliative care for patients with COPD, and 4) organization of palliative 
care for patients with COPD.
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METHODS
Study design
A national survey was performed to explore the view of pulmonologists in the Netherlands on 
palliative care for patients with COPD.
Study procedure
Mail and postal addresses of all pulmonologists and pulmonologists in training (it) were obtained 
from the Netherlands Association of Physicians for Lung Diseases and Tuberculosis. (NVALT). 
Of all 846 members registered at the NVALT 42 were excluded because they worked in a foreign 
practice (n=25), were a tuberculosis physician (n=15) or a epidemiologist (n=2) (see Figure 1). In 
total 804 members, 575 pulmonologists (66.1% male, 33.9% female) and 229 pulmonologists it 
(31% male, 69% female) were invited to participate in the study in April 2015. They received the 
digital NVALT newsletter with a link to a digital survey. An e-mail reminder was send two weeks 
later. In June 2015 a paper version of the survey was send to invite non-responders to participate. 
All questionnaires received before the 15th of August 2015 were included in the analysis.
Survey
The survey consisted of demographic characteristics and questions about proactive palliative 
care for patients with COPD (Supplementary material). The demographic characteristics were 
assessed based on the position (pulmonologist or pulmonologist it), clinician (active or non-
active), gender, name and place hospital, location hospital if appropriate, and the number and 
gender of pulmonologists working in their association of pulmonologists (or if not applicable, 
hospital).
The questions about proactive palliative care for patients with COPD concerned the view 
of pulmonologists or pulmonologist it on the following four main subjects: 1) palliative care 
for patients with COPD in general (five questions), 2) identification of patients with COPD 
for palliative care (one question) , 3) content of palliative care for patients with COPD (two 
questions), and 4) organization of palliative care for patients with COPD (five questions).
The questions about palliative care for patients with COPD in general concerned whether 
pulmonologists or pulmonologist it think that palliative care for patients with COPD is desirable, 
whether they distinguish a palliative phase in the COPD disease trajectory, if not why, whether 
they use the guideline palliative care for patients with COPD (2011) and, if not why. The view of 
pulmonologists and pulmonologists it concerning the organization of palliative care for patients 
with COPD started with the question whether the hospital has a Specialized Palliative Care Team 
(SPCT) at their disposal, and if yes, whether this team is also involved in the care of patients 
with COPD. Next, their opinion was asked about who should organize the delivery of palliative 
care for patients with COPD respectively during hospitalization and in the ambulatory setting.
516939-L-bw-duenk
Processed on: 13-2-2018 PDF page: 31
THE VIEW OF PULMONOLOGISTS
31
2
In total 13 questions were presented in this second part: 12 multiple choice- and one last open 
question about what aspects of palliative care in COPD they thought were missing or should be 
developed in the near future. In seven multiple choice questions only one answer was possible. 
In the other five multiple choice questions, multiple answers were possible and the opportunity 
was given for an open answer under the choice “other namely”. 
Statistical analyses
Descriptive statistics were conducted. Non-continuous variables were reported as frequencies. 
Statistical analyses were performed with SPSS 20.0 (IBM SPSS Statistics, Armonk, NY, USA).
RESULTS
Study population
In total 256 of 804 pulmonologists and pulmonologists it (31.8%) completed the survey (see 
Figure 1). The responding pulmonologists and pulmonologists it covered 73 of the 85 hospital 
organizations (85.9%) of all general and academic hospitals in the Netherlands. A hospital 
organization consists of one or more hospital locations which fall under the same board of 
directors. 
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Figure 1 Study flow diagram.
Abbreviations: it, in training.
Demographic characteristics
The characteristics of the study population are presented in Table 1. Of the study population of 
256 respondents, 197 were pulmonologists (60.4% male, 39.6% female) and 59 pulmonologist 
it (28.8% male, 71.2% female). Two pulmonologists were not active clinicians since one was a 
researcher and the other retired.
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Table 1 Characteristics of the study population
Study population (N=256) N (%)
Position
Pulmonologist 197 (77)
Pulmonologist it 59 (23)
Clinician
Active 254 (99.2)
Gender
Male 136 (53.1)
Work place
General hospital
Academic hospital
202 (78.9)
45 (17.6)
Categorical hospital *
Missing
8 (3.1)
1 (0.4)
Notes: * specialized pulmonary hospital (sleep, rehabilitation or cancer).
Abbreviations: it, in training.
Palliative care for patients with COPD in general
In total 253 respondents (98.8%) answered that palliative care for patients with COPD is 
desirable and 236 respondents (92.2%) answered that they distinguish a palliative phase in the 
COPD trajectory. The 19 respondents (7.4%) that did not distinguish a palliative phase in the 
COPD trajectory gave as reasons (more than one answer possible): that there is no distinction 
between curative and palliative care (63.2%), that they find the criteria for the start of palliative 
care difficult (26.3%), that an SPCT is not available for patients with COPD (5.3%), and/or 
other reasons (15.8%). 
 The percentage of pulmonologists that use the guideline palliative care for patients with 
COPD are presented in Figure 2.
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Use of the guideline  
‘palliative care for patients with COPD’ (N = 236)
Yes
No, not aware of the  
existence of the guideline
No, the guideline is  
lacking in content
No, for other reason
Missing
1.7%
11.4%
20%
12.7%
54.2%
Figure 2 The percentage of pulmonologists that use the guideline palliative care for patients with COPD.
Identification of patients with COPD for palliative care
Each of the formulated criteria mentioned in the survey to possibly identify patients with 
COPD for palliative care was indicated by a larger or smaller part of the 236 respondents who 
distinguished a palliative phase in the COPD trajectory. Besides, all respondents indicated to use 
more than one criteria. The criteria and the percentage of respondents that mentioned to use 
each criterion to identify patients with COPD for palliative care are presented in Figure 3. Of all 
respondents 11.4% mentioned to use also other criteria such as: a combination of factors (2.5%), 
no treatment options left (2.1%) and the surprise question (=negative answer to the question: 
would I (as pulmonologist) be surprised if the patient would die in the next year?) (1.7%).
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Figure 3 The criteria and the percentage of respondents that mentioned to use each criterion to identify patients with 
COPD for palliative care.
Abbreviations: AECOPD, acute exacerbation COPD; BMI, body mass index; CCQ, Clinical COPD Questionnaire; 
FEV1, forced expiratory volume in 1 second; MRC dyspnea, Medical Research Council dyspnea questionnaire; NIV, 
non invasive ventilation; NPPV, non invasive positive pressure ventilation. 
Aspects of palliative care for patients with COPD
Important aspects
Each formulated aspect of palliative care was at least chosen once. Besides, each respondent 
indicated more than one aspect. (see Figure 4). Of all respondents 2% also mentioned other 
aspects to be important. These were mainly remarks of involved pulmonologists concerning the 
aspect content of palliative care such as the response “involvement of informal caregivers”.
Improvement desirable
Each formulated aspect of palliative care was chosen by at least one respondent as being 
desirable to improve. Besides, each respondent chose more than one aspect (see Figure 4). Of all 
respondents 2% mentioned that improvement is desirable for other aspects. These were mainly 
remarks of involved pulmonologists concerning improvement of the aspect content of palliative 
care such as the response “options for relief of suffering”
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Figure 4 The aspects of palliative care for patients with COPD and the percentage of respondents that mentioned which 
aspects were important and for which aspects improvement is desirable.
Abbreviations: ACP, advance care planning; GP, general practitioner; ICU, intensive care unit; N/A, not applicable.
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The organization of palliative care for patients with COPD
Specialized Palliative Care Team (SPCT)
Of all respondents 87.1% indicated the presence of an SPCT in the hospital, while 53.1% 
indicated the involvement of the SPCT in the care of patients with COPD. (Figure 5). 
Respondents from 70 of the in total 73 hospital organizations (95.9%) indicated that they have 
an SPCT at their disposal but within 11 hospital organizations (15.1%) respondents were not in 
full agreement about this. Within these 70 hospital organizations the respondents of 32 hospital 
organizations (45.7%) were not unanimous when asked whether the SPCT in their organization 
was involved in the care of patients with COPD. Besides, some of the pulmonologists who 
confirmed this question placed a remark saying: theoretically this is possible but in practice it is 
less common.
Presence of a SPCT in the hospital and involvement in the  
care of patients with COPD (N = 256)
Yes, and involved in the  
care of patients with COPD
Yes, but not involved in the  
care of patients with COPD
No
Missing
2%
10.9%
34% 53.1%
Figure 5 The percentage of respondents that indicated the presence of an SPCT in the hospital and the involvement of 
the SPCT in the care of patients with COPD.
Abbreviations: SPCT, specialized palliative care team.
During hospitalization
The opinion of respondents about who should organize palliative care for patients with COPD 
during hospitalization is presented in Figure 6. Most respondents (55.5%) considered the 
pulmonologist to perform this task. 
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In the ambulatory setting
The opinion of respondents about who should organize palliative care for patients with COPD 
in the ambulatory setting is presented in Figure 6. Most respondents (71.1%) considered a 
multidisciplinary cooperation between pulmonologist, GP and respiratory nurse specialist to 
perform this task.
Organization during hospitalization
(N = 256)
The personal pulmonologist
Specialized pulmonologists who 
take part of a SPCT
A SPCT in cooperation with 
pulmonologists
A SPCT
Missing
N/A
1.2% 2%
1,2%
9,4%
30,9%
55,5%
The GP
The pulmonologist
The respiratory nurse specialist
The GP and the respiratory  
nurse specialist
Missing
A multi disciplinary  
cooperation
2%
71,1%
6,6%
0,8%
2,3%
17,2%
Organization in the ambulatory setting
(N = 256)
Figure 6 The opinion of respondents about who should organize palliative care for patients with COPD during 
hospitalization and in the ambulatory setting.
Abbreviations: GP, general practitioner; N/A, not applicable; SPCT, specialized palliative care team. 
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DISCUSSION
Palliative care for patients with COPD is not yet common practice.3 Since pulmonologists have 
a central role in providing good quality palliative care for patients with COPD their view on 
this subject is important.17 There are already survey studies that explore their current working 
situation regarding palliative care for patients with COPD.18,19 This survey study however is the 
first to also take the view and wishes of pulmonologists into account in order to guide future 
research and service development. 
Almost all pulmonologists indicated that palliative care for patients with COPD is desirable. To 
ensure that the best available evidence is translated into everyday clinical practice a Dutch clinical 
guideline palliative care for patients with COPD has been developed in 2010.16 However, about 
half of the pulmonologists indicated not to use this clinical guideline, most often because they 
were not aware of its existence. This is cause for concern since low awareness of clinical guidelines 
may subsequently result in low adherence to guideline recommendations and potentially 
suboptimal healthcare.20 In general adherence to COPD guidelines are sub-optimal and as a 
consequence barriers to guideline adherence in COPD have been identified.20 We recommend to 
take such barriers into account in order to optimize strategies to ensure effective implementation 
and better use of clinical guidelines in COPD.
To facilitate timely identification of palliative care in COPD, prognostic models to estimate 
survival have been developed.21 Unfortunately, these population models are of little value to 
predict survival for individual patients. As such, validated evidence-based criteria to determine 
the prognosis in advanced COPD are not yet available.9,21 A discussion has started among 
clinicians whether a transition point for the initiation of palliative care in the COPD trajectory 
exists.22-25 Some clinicians argue that in response to the prognostic difficulty more specific criteria 
of end-stage COPD need to be explored.23 Other clinicians argue that searching further for 
prognostic criteria that may not exist, will lead to prognostic paralysis.24,25 Instead, they promote 
an integrated early palliative care approach according to needs alongside disease-oriented care.25 
Nevertheless, the majority of pulmonologists in our study indicated that they do distinguish a 
palliative phase in the COPD trajectory (92.2%). 
Several tools have been proposed to identify patients with COPD for palliative care.9,21,26,27 
The formulated identification criteria in our survey were selected on basis of this literature. All 
pulmonologists indicated to use several criteria. Four criteria were mentioned by about three 
quarters of the pulmonologists, being: repeated hospital admissions for an acute exacerbation of 
COPD (AECOPD), feeling / experience of the pulmonologist that palliative care is needed, wish 
of the patient, and severe comorbidity. All other formulated criteria were mentioned by about one 
third of the pulmonologists while some pulmonologists also mentioned as additional aspects no 
treatment options left and a negative answer to the surprise question (would I, as pulmonologist, 
be surprised if my patient would die in the next year?). The fact that criteria of prognosis as well as 
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curability and palliative needs were chosen by the pulmonologists reflects the absence of consensus 
about the way of identification of patients with COPD for palliative care.11
The pulmonologists also indicated which aspects of palliative care for patients with COPD they 
considered important and for which aspects improvement is desirable. Aspects mentioned to be 
important by over three-quarters of the pulmonologists were: Advance Care Planning (ACP) 
conversation, communication between pulmonologist and GP, and identification of patients for 
palliative care. For improvement, only one aspect, identification of patients for palliative care, 
was mentioned by almost three quarters of the pulmonologist. The aspects thereafter mentioned 
for improvement by about two fifth of the pulmonologists were: ACP conversation, organization 
of palliative care, communication between pulmonologist and GP, and defining the coordinating 
role. It seems that pulmonologists not only consider identification of patients for palliative 
care important but also the most important aspect for improvement. Therefore, we suggest to 
conduct further research into more specific criteria to timely initiate the palliative trajectory. 
Having such criteria might encourage pulmonologists less familiar with palliative care in COPD 
to get started. Recently variables have been identified that could be indicative of poor prognosis 
for patients hospitalized for an AECOPD and possibly be useful to identify patients for palliative 
care.28 However, the problem of identification of patients with COPD for palliative care is not 
to predict individual prognosis but to timely start palliative care. Future prospective studies 
which incorporate these potentially relevant variables should therefore focus on identifying 
criteria for a timely start of palliative care in order to assure that patients with COPD in need 
of a palliative approach are not missed out. We think that this way an integrated early use of 
palliative care alongside disease-oriented care can be accomplished. Beside identification of 
patients for palliative care, other areas of concern for improvement should preferentially be ACP 
conversations, communication between pulmonologist and GP, defining the coordinating role 
and the organization of palliative care. 
In order to be able to answer the question, how to organize palliative care in COPD, it is necessary 
to know the facilities available in the Netherlands. The percentage of hospitals with an SPCT at 
their disposal for instance has increased from 39% in 2013 to 77% in 2015.29 This growth will 
probably continue since it is the standard of a foundation emphasizing collaboration in oncology 
(Stichting Oncologische Samenwerking; SONCOS), that every hospital should have an SPCT 
by January 2017.30 According to this standard an SPCT should at least consist of two medical 
specialists and one nurse specialist palliative care. In our survey 87.1% of the pulmonologists, 
representing 70 of the 73 participating hospital organizations (95.9%), indicated the presence of 
an SPCT in their hospital. However pulmonologists within 11 hospital organizations (15.7%) 
were not unanimous. The fast increase of hospitals with an SPCT and the fact that we did 
not define the composition of a SPCT may be the reason of this inconsistency. In the hospital 
organizations with an SPCT 61% of the pulmonologists, representing 53 of the 70 hospital 
organizations, indicated the involvement of the SPCT in the care of patients with COPD. 
This percentage should however be considered with caution since the pulmonologist within 32 
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hospital organizations (45.7%) were not unanimous. Some pulmonologists even indicated that 
theoretically consultation is possible but in practice less common. So, although palliative care by 
an SPCT in hospitals is in development it seems that the involvement in care of patients with 
COPD is not yet common practice.
When asked who should organize palliative care for patients with COPD during hospitalization, 
more than half of the pulmonologists mentioned the pulmonologist. About three-tenth of 
the pulmonologists preferred to organize this in cooperation with a SPCT while about one-
tenth preferred specialized pulmonologists who take part of an SPCT. An SPCT, as primarily 
responsible entity, was hardly mentioned. It shows that during hospitalization pulmonologists 
want to be involved in the organization of palliative care for patients with COPD while there is 
also room for the involvement of an SPCT. In practice the input of an SPCT is often demanded 
in more complex disease trajectories.31 Since palliative care in COPD is not common practice 
this implies that pulmonologists should improve their skills of palliative care and members of the 
SPCT should be better informed about the management of COPD.11
To ensure continuity of palliative care for patients with COPD in the ambulatory setting a 
coordinated multidisciplinary care approach has been recommended.14 Almost three quarters 
of the pulmonologists in our study recognized this since they preferred a multidisciplinary 
cooperation between pulmonologist, GP and respiratory nurse specialist in the ambulatory setting. 
To accomplish successful cooperation, we recommend emphasizing the aspects communication 
between pulmonologist and GP and defining the coordinating role in training.
Finally, as palliative care is multidisciplinary care, we recommend to also explore the view of 
other health care professionals involved in palliative care for patients with COPD, as well as their 
incentives and barriers regarding the provision of early palliative care.
Several strengths and limitations should be considered to be able to interpret the findings. This 
is the first survey study to explore the view and wishes of pulmonologists regarding palliative 
care for patients with COPD. Furthermore, 85.9% of hospital organizations were represented by 
the responding pulmonologists. Like in most surveys, we did not use a validated questionnaire. 
It is possible that certain questions were not totally unambiguously and therefore not always 
interpreted in the same way. Although comparable with other survey studies,32,33 the overall 
response rate of 31.8% is low and raises concerns whether the results can be generalized to the 
Dutch population of pulmonologists. Those pulmonologists who participated were probably 
more interested in palliative care in COPD than non-responders and will have provided a more 
favorable view. For this reason, the low response rate will not have influenced our findings that 
the identification of patients with COPD for palliative care and the organization of such care 
need improvement. 
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CONCLUSION
Pulmonologists considered palliative care for patients with COPD desirable. Still many of 
them did not know about the existence of the guideline palliative care for people with COPD. 
We therefore recommend that more attention should be paid to the implementation of such 
guidelines. Most of the pulmonologists distinguished a palliative phase in the COPD trajectory. 
Many different criteria were used and there was no consensus whether prognosis, curability 
and/or palliative needs should mark the start of palliative care in COPD. The identification of 
patients with COPD for palliative care was not only seen as important but also seen as the most 
important aspect for improvement. We therefore recommend to conduct further research into 
more specific criteria to timely initiate the palliative trajectory. 
The organization of palliative care was also mentioned as an aspect for improvement. During 
hospitalization, pulmonologists indicated that they wanted to be involved in the organization of 
palliative care for patients with COPD while there was also room for input of an SPCT. Since 
palliative care in COPD is not common practice we recommend pulmonologists to improve their 
skills of palliative care and members of the SPCT to be better informed about the management 
of COPD. In the ambulatory setting, most pulmonologists preferred a multidisciplinary 
cooperation between pulmonologist, GP and respiratory nurse specialist. Since pulmonologist 
indicated ACP conversations, communication between pulmonologist and GP and defining the 
coordinating role as improvement aspects, we recommend to emphasize these aspects in training.
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SUPPLEMENTARY MATERIAL
Survey for pulmonologists
Demographic situation:
1. What is your position?
  Pulmonologist
  Pulmonologist in training 
2. Are you clinically active?
  Yes
  No
3. Name hospital
 ……………………………………………………………
4. Location (if applicable)
 ……………………………………………………………
5. Place of residence hospital
 ……………………………………………………………
6. Gender
  Male
  Female
7. a. How many pulmonologists work in your association of pulmonologists (or hospital)?
 ……………………………………………………………
 b. Number of males / females?
     ………… Males
     ………… Females
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Questions palliative care for patients with COPD: 
1. Is in your opinion palliative care for patients with COPD desirable?
  Yes
  No
2. Do you distinguish a palliative phase in the COPD disease trajectory? 
  Yes  (go to question 4)
  Sometimes  (go to question 4)
  No  (go to question 3)
3.  If not, what is the reason of this? (more than one answer possible) (go to question 7) 
  In my opinion, there is no distinction between curative and palliative care in COPD
  I don’t have time for it
  I find the criteria for the start of palliative care in COPD difficult
  A Specialized Palliative Care Team (SPCT) is not available for patients with COPD 
  Other, namely……………………………….
4. Do you use the guideline palliative care for people with COPD (2011)? 
  Yes  (go to question 6)
  No  (go to question 5)
5. If not, what is the reason for this? (more than one question possible)
  I was not aware of the existence of this guideline
  I find this guideline unclear 
  Applying the guideline takes too much time 
  The scientific basis of the guideline is to my opinion questionable
  The criteria for the start of palliative care in COPD are unclear
  Other, namely……………………………….
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6.  What criterion/criteria do you use for the start of palliative care in patients with COPD?
 (more than one answer possible)
  First hospital admission for an acute exacerbation COPD (AECOPD)
  Repeated hospital admissions for an AECOPD
  Hypoxemia (stable and/or at discharge)
  Hypercapnia (stable and/or at discharge)
  NIV / NPPV necessary during hospitalization
  Professional home care service needed for personal care
  Severe comorbidity 
  Low value FEV1 
  Low BMI or unplanned weight loss
  Old age
  High score CCQ (= Clinical COPD Questionnaire)
  High score MRC dyspneu questionnaire
  Feeling/experience of pulmonologist 
  Wish of patient
  Other, namely……………………………….
  None
7.  In your opinion, what are important aspects of palliative care for patients with COPD? 
 (more than one answer possible)
  Identification of patients for palliative care
  Bad news conversation
  Advance Care Planning (ACP) conversation about resuscitation policy 
  ACP conversation about treatment agreements
      (e.g. enteral tube feeding, antibiotics, hospitalization, palliative sedation, mechanical 
ventilation) 
  ACP conversation about ICU policy
  Content of palliative care
  Organization of palliative care
  Defining the coordinating role 
      (e.g. pulmonologist/ respiratory nurse specialist/ specialized palliative care team/ GP)
  Communication with other professionals within the hospital
  Communication between pulmonologist and GP
  Transfer of care in the weekend/ evening
  Other, namely.……………………………….
  N/A
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8.  In your opinion, for which aspects of palliative care for patients with COPD is improvement 
desirable? (more than one answer possible)
  Identification of patients for palliative care
  Bad news conversation
  Advance Care Planning (ACP) conversation about resuscitation policy 
  ACP conversation about treatment agreements
      (e.g. enteral tube feeding, antibiotics, hospitalization, palliative sedation, mechanical 
ventilation) 
  ACP conversation about ICU policy
  Content of palliative care
  Organization of palliative care
  Defining the coordinating role 
      (e.g. pulmonologist/ respiratory nurse specialist/ specialized palliative care team/ GP)
  Communication with other professionals within the hospital
  Communication between pulmonologist and GP
  Transfer of care in the weekend/evening
  Other, namely.……………………………….
  N/A
9. Does the hospital have a Specialized Palliative Care Team (SPCT) at their disposal? 
  Yes
      If yes, are they also involved in the care of patients with COPD?
       Yes
       No
  No
10.  Who should in your opinion organize the delivery of (proactive) palliative care for patients 
with COPD during hospitalization? (only one answer possible)
   The personal pulmonologist. Every pulmonologist provides (proactive) palliative care to 
their own patients with COPD
  A specialized pulmonologist who take part of a SPCT 
  A SPCT in close cooperation with pulmonologists
  N/A
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11.  Who should in your opinion organize the delivery of (proactive) palliative care for patients 
with COPD in the ambulatory setting? (only one answer possible)
   The GP
   The pulmonologist
   The respiratory nurse specialist
   The GP and the respiratory nurse specialist
   A multi disciplinary cooperation (GP / pulmonologist / respiratory nurse specialist)
   N/A
12.  What aspects of palliative care in COPD did you miss or do you think should be developed 
in the near future?
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ABSTRACT
Background: Proactive palliative care is not yet common practice for patients with COPD. 
Important barriers are the identification of patients with a poor prognosis and the organization 
of proactive palliative care dedicated to the COPD patient. Recently a set of indicators has been 
developed to identify those patients with COPD hospitalized for an acute exacerbation who 
are at risk for post-discharge mortality. Only after identification of these patients with poor 
prognosis a multi disciplinary approach to proactive palliative care with support of a specialized 
palliative care team can be initiated. 
Methods/design: The PROLONG study is a prospective cluster controlled trial in which 6 
hospitals will participate. Three hospitals are selected for the intervention condition based on 
the presence of a specialized palliative care team. The study population consists of patients with 
COPD and their main informal caregivers. Patients will be included during hospitalization 
for an acute exacerbation. All patients in the study receive standard care (usual care). Besides, 
patients in the intervention condition who meet two or more criteria of the set of indicators for 
proactive palliative care will have additionally regular consultations with a specialized palliative 
care team. The objectives of the PROLONG study are: 1) to assess the discriminating power of 
the proposed set of indicators (indicator study) and 2) to assess the effects of proactive palliative 
care for qualifying patients with COPD on the wellbeing of these patients and their informal 
caregivers (intervention study). The primary outcome measure of the indicator study is time to 
death for any cause. The primary outcome measure of the intervention study is the change in 
quality of life measured by the St George Respiratory Questionnaire (SGRQ) three months after 
inclusion. 
Discussion: The PROLONG study may lead to better understanding of the conditions to start 
and the effectiveness of proactive palliative care for patients with COPD. Innovative aspects of 
the PROLONG study are the use of a set of indicators for proactive palliative care, the active 
involvement of a specialized palliative care team and the use of a patient-tailored proactive 
palliative care plan. 
Trial registration: Netherlands Trial Register (NTR): NTR4037
Keywords: COPD, Exacerbation, Indicators, Prognosis, Proactive palliative care, Quality of life 
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BACKGROUND
In 2002 the World Health Organization (WHO) introduced a new definition of palliative 
care. They emphasized in this definition the importance of early identification and impeccable 
assessment and treatment of pain and other problems, physical, psychosocial and spiritual in 
order to prevent and relief suffering.1 This means that palliative care is not limited to the terminal 
phase and can be delivered beside curative care to patients with a life-threatening illness. It 
implicates that palliative care is not only restricted to reactive symptom relief. By anticipating 
on expected disease scenario’s and the specific needs and wishes of a patient, problems can be 
prevented and hence quality of life improves. The clinical use of this proactive palliative care 
is growing in care for patients with cancer. Still a proactive approach is not very common for 
patients with Chronic Obstructive Pulmonary Disease (COPD), even though the symptoms 
that occur in the end stage of COPD are as severe or even worse than in the final stage of lung 
cancer.2,3 Both groups of patients prefer a treatment with the emphasis on comfort instead of life 
prolongation, but to patients with COPD this is offered less frequently.4 For instance patients 
with COPD receive less opioids and benzodiazepines than patients with lung cancer for their 
dyspnea complaints,5 and they die more often at an Intensive Care Unit (ICU).6 
Several barriers are described with respect to offering proactive palliative care to patients with 
COPD.7 A first important barrier is the identification of patients with COPD who can benefit 
from proactive palliative care, as it is difficult to predict the remaining length of survival of these 
patients.8 For that reason, recognizing the appropriate time to start proactive palliative care may 
not be obvious for clinicians. A second important barrier is the organization of proactive palliative 
care for COPD patients. The majority of hospitals in Europe have no formalized approach 
regarding palliative care issues for patients with COPD: these patients have less universal access 
to specialist palliative care services than those with malignant lung diseases.9-11
In general, an important problem in the transition or referral to palliative care services is that 
the term “palliative care” is often associated with terminal or end stage care only. This can be 
an impediment to early implementation of proactive palliative care as proposed by the WHO. 
Especially for patients with COPD who do not perceive COPD as an illness that disrupts life.12 
Hence the term ‘supportive care’” may be a term more conducive to referral and may facilitate 
integration between curative care and palliative care for patients with COPD.13-15 Therefore, in 
this study we will speak of supportive care in contact with participating patients with COPD.
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Figure 1 COPD disease trajectory.
Identification of patients with COPD for proactive palliative care
COPD illustrates the ‘organ failure’ end-of-life trajectory in which a gradual decline is punctuated 
by acute severe exacerbations, any one of which may be fatal.16,17 The patient may survive the 
majority of these exacerbations as long as he shows resilience and rebounds to (at least part 
of ) his former condition. As it is unclear which exacerbation will be fatal, death may seem to 
occur suddenly (Figure 1).18 This uncertain prognosis makes it difficult for clinicians to initiate 
discussions about palliative care and end–of–life care planning.19,20 In stable COPD, population 
models of 6 month survival do exist but they are of limited value to predict death for individual 
patients.21 It is therefore proposed to address proactive palliative care at certain milestones in the 
course of the disease,22 such as the occurrence of an acute exacerbation COPD (AECOPD).20 An 
AECOPD is defined as ‘an acute worsening of the patient’s condition from the stable state, which 
is sustained and may warrant the patient to seek additional treatment’.23 Exacerbations cluster in 
time with a high risk of recurrence within 8 weeks of recovery,24 and show an increasing frequency 
as the disease progresses.25 Recovery after an AECOPD is often to a suboptimal condition as before 
the exacerbation and after each exacerbation more care may be required to support the patient 
and the family. Therefore each admission to the hospital for an AECOPD creates an opportunity 
to identify patients at high risk of subsequent readmission or post-discharge mortality and 
hence who can benefit from a proactive palliative care approach. Several studies focused on the 
identification of predictive factors associated with hospital readmission or mortality for patients 
with an AECOPD. The findings of these studies are summarized in a recent review.26 One of 
the conclusions is that in-hospital mortality is related to the patient’s acute physiological state 
and to the development of acute comorbidity while post-discharge mortality particularly reflects 
the severity of the underlying COPD, as well as concomitant specific comorbidities. Important 
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factors influencing the frequency of readmission include functional limitation and poor health-
related quality of life. A profile emerges of the types of patients hospitalized for an AECOPD at 
high risk of subsequent readmission or post-discharge mortality.19 
In accordance with these findings and based on existing literature,19, 26-29 we developed a 
set of indicators for lung specialists to improve the identification of patients hospitalized for 
an AECOPD for whom proactive palliative care might be beneficial. We hypothesize that the 
presence of two or more of the following indicators (or prognostic conditions) should be a reason 
to start proactive palliative care: 1) hypoxaemia or hypercapnia at discharge; 2) treatment of 
the exacerbation with Non Invasive Ventilation (NIV); 3) patient needs professional home care 
service for personal care after discharge; 4) a negative answer to the surprise question: ‘Would I 
(as lung specialist) be surprised if this patient would have a subsequent readmission for AECOPD 
within 8 weeks and/or would die in the next year?; 5) the diagnosis of a severe comorbidity such 
as: a) non-curable malignity or b) cor pulmonale (proven or non proven) or c) proven Chronic 
Heart Failure (CHF) or d) diabetes mellitus with neuropathy or e) renal failure, clearance < 
40 Glomerular Filtration Rate (GFR); 6) Clinical COPD Questionnaire (CCQ) total, day 
version > 3 ; 7) Medical Research Council dyspnea questionnaire (MRC dyspnea) = 5; 8) Forced 
Expiratory Volume in 1 second (FEV1), measured before AECOPD < 30% of predicted; 9) 
Body Mass Index (BMI) < 21 or unplanned weight loss (> 10% weight loss in last 6 months or 
> 5% in last month); 10) previous hospital admissions for AECOPD (last 2 years > 2 and/or last 
year > 1); 11) Age > 70 years. 
In this study the discriminating power of this set of indicators will be examined. We hypothesize 
that the set of indicators can predict readmission within 8 weeks and/or death within 1 year for 
patients hospitalized for an AECOPD.
Organization of proactive palliative care for patients with COPD
Provision of palliative care for patients with COPD in Europe is variable, and overall very small.11 
The majority of hospitals in Europe do not have a formalized approach to palliative care issues 
for patients with chronic lung disease. Besides patients with advanced non-malignant respiratory 
disease have less universal access to specialist palliative care services than those with malignant 
lung disease.9-11 In a survey performed in the UK, the minority of hospital units had a formal 
referral pathway for palliative care and only about 13% had a policy of initiating end-of-life 
discussions with appropriate patients.30 Although variation in care may be influenced by many 
factors including availability, access and reimbursement issues, such geographic variations suggest 
a lack of consensus concerning the best approach to palliative care for patients with COPD.19 
Therefore, recent studies have focused on the best approach and content of palliative care for 
patients with COPD. It is suggested to start palliative care early beside curative care.31 Furthermore, 
good proactive palliative care should at least consist of: 1) a standardized inventory of current 
and future care needs and a structured organization of proactive palliative care; 2) advance care 
planning (ACP), which involves the patient(-family)-clinician communication about end-of-life 
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care and the completion of advanced directives.20 Important components of ACP are discussions 
about the expected course of the disease and prognosis and counseling concerning preferences for 
care at the end of life, including spiritual care;19 3) development and implementation of a patient-
tailored proactive palliative care plan. There are several problems from the patient as well as from 
the clinician perspective when it comes to satisfactory implementation of ACP and a patient-
tailored proactive palliative care plan.7 First, there are clinician and patient related barriers to 
discuss ACP.32 Patients for instance avoid ACP discussions out of fear of suboptimal treatment 
in case of emergencies while clinicians are concerned that early ACP will take away patients’ 
hope.20 Discussions about ACP are therefore unlikely to occur and when they do occur they are 
likely to be of poor quality.19 Second, not all clinicians have a special interest in or are qualified to 
perform proactive palliative care. Finally, delivering proactive palliative care beside curative care 
for patients with COPD may increase the workload and clinicians may be faced with shortage 
of time.7 In order to overcome these problems it is suggested that a multidisciplinary approach 
to proactive palliative care with better access to specialist palliative care services will help patients 
with COPD navigate through the continuum of chronic disease management and will improve 
quality of end-of-life care.7, 10
Unfortunately, no research data is available on the beneficial effects of a multidisciplinary 
approach to proactive palliative care for patients with COPD in terms of reducing the healthcare 
utilization (for example, hospital readmission) or improving quality of life. However, in a study in 
male patients predominantly diagnosed with cancer but also with cardiovascular and pulmonary 
diseases, the benefits of palliative care provision appeared effective compared with usual care.33 
Patients receiving palliative care were less likely to be admitted to the ICU during hospitalization, 
had lower inpatient cost per day and received better medical care provision compared to usual 
care patients. Hence proactive palliative care may avoid admission to the ICU for patients with 
COPD and may help to reduce health care costs. More research data is available concerning the 
beneficial effects of an early introduction of palliative care for patients with cancer. In a recent 
study,34 the effect of introducing early palliative care among patients diagnosed with metastatic 
non-small-cell lung cancer was examined in a randomized controlled trial (RCT). As compared 
to patients receiving standard care, patients receiving early palliative care had a better quality of 
life, less depressive symptoms, less aggressive care at the end of life and longer survival.
In the present study the effects of proactive palliative care performed by a specialized palliative 
care team for patients with COPD on the wellbeing of these patients and their informal caregivers 
will be examined. We hypothesize that proactive palliative care for patients with COPD will: 
increase the quality of life of these patients, decrease the number and length of acute hospital 
admissions and ICU admissions, prolong survival of these patients, decrease the number of 
patients that die in the ICU, and decrease the level of overburdening of their informal caregivers.
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METHODS/DESIGN
Objectives
The PROLONG study exists of two parts, an indicator study and an intervention study, each 
with its own primary and secondary objectives:
Objectives indicator study
1.  The primary objective is to assess the discriminating power of a set of indicators that indicates 
the start of proactive palliative care for patients with COPD.
2.  The secondary objective is to examine to what extend individual indicators (or clusters) 
indicative are for the need of proactive palliative care.
Objectives intervention study
1.  The primary objective is to assess the effects of proactive palliative care delivered by a 
specialized palliative care team on the wellbeing of patients with COPD with poor prognosis 
and their informal caregivers.
2.  The secondary objective: is to assess survival rate in COPD patients with proactive palliative 
care integrated with standard care versus standard care only.
Study design
The study consists of a controlled trial (assessment) with hospital as cluster, with a pre- and a post-
test assessment. In total 6 hospitals will participate, 3 hospitals in the intervention condition and 
3 hospitals in the control condition. Hospitals are selected for the intervention condition based on 
the presence of a specialized palliative care team. In the hospitals in the control condition standard 
care (usual care) will be delivered to patients with COPD by their treating lung specialists. In 
the hospitals in the intervention condition all patients with COPD will receive standard care by 
their treating lung specialist and those patients that are indicated for proactive palliative care by 
our set of indicators will also be supported by a specialized palliative care team on a regular base. 
Baseline measurements of the intervention study will be assessed from all participating patients 
during hospitalization for AECOPD before start of the intervention. Follow-up measurements 
will take place every three months, starting from the moment of discharge for a period of one 
year or until death. The primary outcome measure of the indicator study is time to death for any 
cause. The primary outcome measure of the intervention study is the change in quality of life 
measured by the St George Respiratory Questionnaire (SGRQ) at three month after baseline. As 
pre-test assessment, data will be obtained from the databases of the participating hospitals over 
a one year period preceding the assessment. These data on hospital-level are necessary to be able 
to compare hospitals at baseline. As post-test assessment, retrospectively the medical files of all 
participating patients will be examined over the assessment period. The assessment will take 18 
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month; 6 month for inclusion and 12 months for follow-up. The post-test assessment will be 
performed in the 3 months after the assessment.
Study population
Patients with a hospital admission for AECOPD will be invited to participate. If they agree to 
participate, their main informal caregiver will also be asked to participate.
Inclusion criteria
In order to be eligible to participate, a patient must meet the following criteria:
1. Being admitted to the hospital for AECOPD, and 
2. Aged 18 years or older.
Exclusion criteria
A patient that meets any of the following criteria will be excluded from participation:
Not speaking the Dutch language, or
1. Having severe cognitive disorders, or
2. At moment of inclusion being treated by a specialized palliative care team.
Intervention
In the hospitals in the intervention condition, members of the specialized palliative care teams 
will receive a special training in the provision of proactive palliative care for patients with COPD. 
The training will be provided by academic palliative care professionals of the Radboudumc in 
Nijmegen. These trainings consist of two consecutive meetings of three hours each. The first 
meeting will take place in the month before start of the assessment. The second meeting will take 
place in the first month of the assessment. The following topics will be discussed:
• How to communicate end of life aspects with patient and family; 
• How to create a patient-tailored proactive palliative care plan; 
• How to anticipate on illness- and dying scenarios proactively; 
• How to organize transfer of care to lung specialist and general practitioner (GP); 
• How to perform a proactive palliative care plan in cooperation with the lung specialist.
During the controlled trial patients in the intervention condition who are assigned for proactive 
palliative care will meet with a member of the specialized palliative care team within one week 
after enrollment and at least monthly thereafter in the outpatients setting for at least one year 
or until death. The main informal caregiver of the patient will be asked to be present at those 
meetings. Guidelines for the proactive palliative care meetings in the ambulatory setting are 
adapted from the general guidelines palliative care in the Netherlands.35 
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Study parameters
Outcome measures indicator study
1. Primary outcome measures: 
 •  Length of time from the moment that a patient hospitalized for AECOPD meets two or 
more criteria of the set of indicators to death for any cause.
2. Secondary outcome measures:
 •  Length of time from the moment that a patient hospitalized for AECOPD meets two or 
more criteria of the set of indicators to the first unexpected readmission to the hospital 
for AECOPD. 
 •  The sensitivity and specificity of the set of indicators, that indicate the start of proactive 
palliative care for patients hospitalized for COPD, in predicting death for any cause 
within 1 year.
 •  The sensitivity and specificity of the set of indicators, that indicate the start of proactive 
palliative care for patients with COPD, in predicting the first unexpected readmission to 
hospital for AECOPD within 8 weeks.
 •   Length of time from the moment that a patient hospitalized for AECOPD meets two or 
more criteria of the set of indicators to death as a result of pulmonary insufficiency. 
 •   The sensitivity and specificity of the set of indicators, that indicate the start of proactive 
palliative care for patients hospitalized for COPD, in predicting death as a result of 
pulmonary insufficiency within 1 year.
 •  The contribution of individual indicators (or clusters), in predicting death for any cause 
within 1 year.
 •  The contribution of individual indicators (or clusters), in predicting the first unexpected 
readmission to hospital for AECOPD within 8 weeks.
 •  The contribution of individual indicators (or clusters), in predicting death as a result of 
pulmonary insufficiency within 1 year.
Outcome measures intervention study
1. The primary outcome measure is:
 •  Change in quality of life (St George Respiratory Questionnaire (SGRQ))36 of the patient 
3 months after inclusion 
2. The secondary outcome measures are: 
 Patient-related
 •   Change in quality of life (SGRQ) of the patient 6, 9 and 12 months after inclusion 
 •   Change in quality of life at the end of life (McGill Quality of Life questionnaire (McGill 
QOL))37 3, 6, 9 and 12 months after inclusion
 •   Change in psychological wellbeing (Hospital Anxiety and Depression Scale (HADS))38 3, 
6, 9 and 12 months after inclusion
 •   Change in illness understanding 3, 6, 9 and 12 months after inclusion
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 •  Number and length of unexpected hospital admissions
 •  Number and length of unexpected ICU admissions
 •  Are the choices of Advance Care Planning (ACP) documented in the medical file? (when 
yes/when no)
 •  Place of death (ICU/hospital/hospice/nursing home/at home)
 •  Is preferred place of death known? (when yes/when no)
 •  Has this wish come true? (when yes/when no)
 •  Length of survival of COPD patients with proactive palliative care integrated with 
standard care versus standard care only
 Informal caregiver-related
 •  Change in informal caregiver burden (Self-Perceived Pressure from Informal Care 
questionnaire (SPPIC))39 3, 6, 9 and 12 months after inclusion
 •  Change in psychological wellbeing (HADS) at 3, 6, 9 and 12 months after inclusion 
 •  Change in illness understanding at 3, 6, 9 and 12 months after inclusion
Other study parameters
In order to take account of possible confounding variables, other parameters are: age, gender, 
marital status, socio-economic status, smoking history, condition of living (single, or living 
together), and place of living (home, residential home, or nursing home).
Randomization
Randomization will not take place. Hospitals will be selected for the intervention condition 
based on the presence of a specialized palliative care team in the hospital. In order to be able to 
compare the hospitals in the control- and the intervention condition a pre-test assessment will 
be performed. 
Study procedure
A description of the procedure is given to assess the defined study parameters.
 
Pre-test assessment
The following data on hospital level will be obtained from the databases of the participating 
hospitals retrospectively over a period of one year (1-1-2013 till 1-1-2014):
•  Number of hospitalizations for AECOPD (including ICU admissions)
•  Number of unique patients hospitalized for AECOPD (including ICU admissions)
•  Total number of days of hospitalization of patients with an AECOPD (including ICU 
admissions)
•  Number of hospitalizations in the ICU (exclusively) for AECOPD
•  Number of unique patients hospitalized for AECOPD in the ICU (exclusively)
•  Total number of days of hospitalization of patients with an AECOPD in the ICU (exclusively)
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•  Total number of patients hospitalized for AECOPD that have died in the hospital (in the 
ICU or on the nursing unit)
Training 
Before start of the controlled trial (see Figure 2), members of the specialized palliative care 
teams in the hospitals in the intervention condition will receive a special training in provision of 
proactive palliative care for patients with COPD.
Controlled trial (assessment)
Patient
Patients in the control condition will receive standard care (usual care) only. Patients in the 
intervention condition will receive standard care and, only if they meet two or more criteria 
of the set of indicators for proactive palliative care they will receive proactive palliative care 
integrated with standard care. The procedure in the control condition will be first described 
before describing the procedure in the intervention condition. 
In the hospitals in the control condition eligible patients will be recruited the second day after 
hospital admission. The treating lung specialist will give each eligible patient oral and written 
information about the study. The written information consists of an information leaflet and two 
informed consent forms: one for the patient and one for the informal caregiver. In the information 
leaflet a description of the study, including the nature of participation and phone numbers for 
study contacts, are given for the patient and the informal caregiver. The lung specialist will obtain 
written informed consent from the patient prior to enrollment. If a patient has consented, a lung 
nurse will distribute questionnaires for completion on the sixth day of hospital stay or in case 
the patient is discharged earlier on the day before leaving the clinic. After hospital discharge the 
patient will be asked by the study coordinator to complete questionnaires every 3 month until 
the end of the study or until death. The questionnaires will be sent to the patient by mail. A 
stamped retour envelope will be enclosed.
In the hospitals in the intervention condition the same procedure will be followed as in the 
hospitals in the control condition. In addition lung specialists will check if a patient meets two 
or more criteria of the set of indicators for proactive palliative care on the sixth day of hospital 
admission or in case the patient is discharged earlier on the day before leaving the clinic. If so, 
the lung specialist will inform the specialized palliative care team. Patients who are assigned for 
proactive palliative care will preferably meet for the first time with a physician of the specialized 
palliative care team before being dismissed from the hospital. If this is not possible the first 
meeting will take place within 1 week after enrolment. Thereafter, the specialized palliative care 
team will meet with the patient monthly in the outpatients setting for at least 1 year or until 
death.
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Post-test assessment (retrospective medical file study) in the 3 intervention- and the 3 control hospitals 
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 the presence or absence of a specialized palliative care team in a hospital
Figure 2 Study schema of the controlled trial (assessment) and the post-test assessment for PROLONG.
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Informal caregiver
During hospital stay, each eligible patient will identify a main informal caregiver, a relative or 
friend whom he or she relies upon most for help. By sharing the written information with the 
informal caregiver, the patient will provide the informal caregiver with information about the 
study. The informal caregiver can only participate if the patient is also participating. Once the 
informal caregiver has consented questionnaires will be distributed during hospital stay and every 
3 month after hospital discharge of the patient. These questionnaires will be sent in the same 
envelop as the patient questionnaires.
Lung specialist
The treating lung specialist will provide standard care (usual care) to the patients hospitalized for 
an AECOPD. After the patient has filled out and returned the questionnaires the lung specialist 
in the control- and the intervention condition will fill out a case report form (CRF). The CRF 
consists of questions about the measurement results of each indicator of the set of indicators. The 
set of indicators is represented in Table 1. Only in the intervention condition the lung specialist 
will check if a patient meets two or more criteria of the set of indicators for proactive palliative 
care. 
Specialized palliative care team 
The specialized palliative care teams in the hospitals in the intervention condition consist of 
specially trained teams of professionals who provide care and support in inpatient and outpatient 
settings. A team consists of at least a physician who is specialized in palliative care, a nurse who is 
specialized in palliative care, and preferably a psychologist and a spiritual counselor. 
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Table 1 Set of indicators for proactive palliative care
A patient hospitalized for AECOPD is eligible for proactive palliative care when meeting two or more criteria 
of the following set of indicators
1. Hypoxaemia (PaO2 < 8 kPa) or hypercapnia (PaCO2 > 6 kPa) at discharge
2. Treatment of the exacerbation with Non Invasive Ventilation (NIV)
3. Patient needs professional home care service for personal care after discharge
4. Negative answer to the surprise question: 
‘Would I (as lung specialist) be surprised if this patient would have a subsequent readmission for AECOPD 
within 8 weeks and/or would die in the next year?
5. The diagnosis of a severe co-morbidity such as: 
a.   Non-curable malignancy or
b.   Cor pulmonale (proven or non proven) or 
c.   Proven Chronic Heart Failure (CHF) or 
d.   Diabetes mellitus with neuropathy or 
e.   Renal failure, clearance < 40 (GFR: in ml/min)
6. CCQ total, day version > 3 
7. MRC dyspnea = 5
8. FEV1 (measured before AECOPD) < 30% of predicted
9. BMI < 21 or unplanned weight loss (> 10% in last 6 months or > 5% in last month)
10. Previous hospital admissions for AECOPD (last 2 years > 2 and/or last year > 1)
11. Age > 70 years
Abbreviations: AECOPD, acute exacerbation Chronic Obstructive Pulmonary Disease; BMI, body mass index; CCQ, 
Clinical COPD Questionnaire; FEV1, forced expiratory volume in 1 second; GRF, glomerular filtration rate; kPa, 
kilopascal; MRC dyspnea, Medical Research Council dyspnea questionnaire; PaO2, arterial partial pressure of oxygen; 
PaCO2, arterial partial pressure of carbon dioxide.
Post-test assessment
A post-test assessment will be performed in all participating hospitals. The medical files of all 
participating patients will be examined retrospectively regarding the assessment period on the 
following measures: 
•  Number and length of hospitalization of unexpected hospital admissions for AECOPD
•  Number and length of hospitalization of unexpected ICU admissions for AECOPD
•  Are the choices of Advance Care Planning (ACP) documented in the medical file? (when 
yes/when no)
•  Place of death (ICU/hospital/hospice/nursing/home/at home)
•  Is preferred place of death known? (when yes/when no)
•  Has this wish come true? (when yes/when no)
•  Length of survival after meeting conditions for proactive palliative care
•  The primary and secondary measures of the indicator study
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In order to take account of possible confounding variables, other parameters are: age, gender, 
marital status, type of admission, (acute or planned), condition of living (single, or living 
together), place of living (home, residential home, or nursing home), Gold stage, comorbidities, 
and date of diagnosis.
Tools to help the clinical decision making
 In order to help the clinical decision making, the specialized palliative care team will make use 
of two additional tools: 1) the Problems and Needs in Palliative Care questionnaire short version 
(PNPC-sv) and 2) the Proactive Palliative Care Planning Card (PPCPC).
 The PNPC-sv patient is a concise, patient-centered tool that helps to identify the problems 
affecting the patient’s quality of life and (unmet) needs for care. This self-report questionnaire is 
covering all dimensions of palliative care. The questionnaire consists of 36 items and is a reliable 
and valid tool.40
 The PPCPC is a tool that can be used by members of the specialized palliative care team to 
structure the discussion with the patient and his/her informal caregiver. This tool is especially 
useful when exploring the actual en potential problems and needs of the patient.41
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Table 2 Overview of outcome measures per time point in the PROLONG study
Outcome Measures B 3  
m
6  
m
9  
m
12 
m
R 
Questionnaires
Patient
CCQ X
MRC dyspnea X
SGRQ X X X X X
McGill QOL X X X X X
HADS X X X X X
Illness understanding X X X X X
Demographic questionnaire X
Informal caregiver
SPPIC X X X X X
HADS X X X X X
Illness understanding X X X X X
Demographic questionnaire X
Lung specialist
CRF X
Medical files 
Number of hospitalizations of unexpected hospital admissions for AECOPD X
Number of days of unexpected hospital admissions for AECOPD X
Number of hospitalizations of unexpected ICU admissions for AECOPD X
Number of days of unexpected ICU admissions for AECOPD X
Are the choices of ACP documented in the medical file at baseline? (when yes/
when no)
X
Are the choices of ACP documented in the medical file after one year or at 
time of death? (when yes/when no)
X
Did the patient die within one year after inclusion? (when yes/when no) X
Date of death X
Place of death (ICU/hospital/hospice/nursing home/at home) X
Is preferred place of death known? (when yes/when no) X
Has this wish come true? (when yes/when no) X
Primary cause of death (pulmonary insufficiency/other cause) X
Secondary cause of death (pulmonary insufficiency/other cause) X
Did the patient have an unexpected hospital readmission for AECOPD within 8 
weeks? (when yes/when no) 
X
Date of first unexpected hospital readmission for AECOPD. X
Abbreviations: B= baseline; m= month; R=retrospectively
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Data collection
Data collection will take place by administration of questionnaires to the participating patients 
and their informal caregivers and by retrospectively collecting data from the medical files of the 
participating patients over the assessment period. The type of questionnaires for patients and 
informal caregivers, the frequency of their administration and the retrospectively collected data 
are detailed in Table 2.
Instrument selection
Questionnaires used as indicator
In order to be able to decide whether or not to start proactive palliative care, questionnaires used 
as indicator will be filled out by the patient .
We will use the CCQ day version to measure health status of patients. The CCQ is a questionnaire 
for self-administration specially developed to measure health status in patients with COPD and 
is valid, responsive, and reliable.42, 43 The CCQ consists of 10 questions rated on a seven point 
Likert scale. Higher scores represent a worse health status. Questions are divided into three 
domains: symptoms (4 questions), functional status (4 questions), and mental state (2 questions). 
The MRC dyspnea scale has been in use for many years for grading the effect of breathlessness 
on daily activities.44 The MRC dyspnea scale consists of 5 questions and provides a simple and 
valid method of categorizing patients in terms of their disability due to COPD.44 The patient’s 
dyspnea is rated from 1-5 in terms of severity, with the higher the grade, the more severe the 
dyspnea. During the study MRC dyspnea will be measured by asking about the circumstances 
two weeks before hospital admission.
 
Questionnaires used as outcome measures
Patient questionnaires
The SGRQ is a specific quality of life questionnaire for obstructive respiratory diseases.36 It 
consists of 50 questions from which a total score is calculated. It is divided into three subscales: 
symptoms (8 items related to patients’ recollection of their symptoms), activities (16 items on 
physical activities which are caused or limited by dyspnea), and impacts (26 items on the social 
and physiologic effects of the disease). The final score obtained ranges from zero to 100. A higher 
score indicates a lower quality of life. A score change of 4 points or more is considered significant 
in the quality of life of the patient.45 The SGRQ is a reliable and valid measure of the quality of 
life in patients with COPD.46 
The McGill QOL is designed to assess quality of life in patients with a life-threatening illness.37 
The questionnaire consists of 16 items with an 11-point scale (0-10) with appropriate anchors. It 
includes 5 domains: physical symptoms, physical well-being, psychological well-being, existential 
issues and support. The mean of all 5 domains is presented as McGill QOL total score. The 
acceptability, internal consistency, reliability and validity of the McGill QOL have been assessed 
in patients receiving palliative care.47
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The HADS will be used to assess psychological wellbeing in patients. The HADS is a self-
assessment 14-item questionnaire. It has two 7-item subscales assessing depression and anxiety 
in the preceding week. The format consists of four answering categories (0-3) that quantify the 
degree to which a particular emotion is experienced by the patient. The score on each subscale 
ranges from 0 to 21 and a score larger than 11 is considered to be consistent with definitive 
depression and anxiety. A score less than 7 is normal and a score of 8-10 is considered borderline 
for depression and anxiety.38 
Patients with COPD tend to be poorly informed about the long-term prognosis of COPD and 
what to expect toward the end of life.48 They may not realize that COPD is incurable and 
fatal. They also may not always attribute repeated exacerbations to advancing disease but instead 
seeing them as temporary setbacks caused by activities, environmental factors, faltering self-
management, or infection. Toward the end of life this lack of understanding may impair quality 
of life.2, 49 There are no validated tools to assess illness understanding in patients with COPD. 
Therefore, we adapted an illness understanding questionnaire used in studies of patients with 
advanced cancer.50 The questionnaire consists of 4 self-report items which can be answered by 
yes or no. 
Patients will be asked in a demographic questionnaire to indicate their sex, age, marital status, 
education, smoking history, living situation, name of main informal caregiver and kind of 
relationship with their main informal caregiver.
Informal caregiver questionnaires
The Self-Perceived Pressure from Informal Care questionnaire (SPPIC) is a non-disease specific 
instrument assessing the demands of the informal caregiver situation.39 This instrument consists 
of nine statements that form a hierarchical scale that varies from less to more pressure. The 
statements are all related to the subjective perception of the informal caregiver. It is a validated 
and easy to use instrument since completing it takes less than 5 minutes.
The HADS (see patient questionnaires) will also be used in informal caregivers to assess 
psychological wellbeing. An adapted version of the illness understanding questionnaire for 
patients will be used for the informal caregivers as well. Finally, informal caregivers will be asked 
to indicate their sex, age and education in a demographic questionnaire.
 
Sample size calculation
The primary outcome in the intervention study is the quality of life of the patients measured with 
the SGRQ. More specifically the change in SGRQ three month after inclusion is the variable of 
interest. Koff et all.,51 published a difference in change of 9 between the two groups (standard 
care, standard care with proactive palliative care) with a common standard deviation of the 
change of 16. Then 64 patients would be needed in each group to obtain a power of 80% (two-
sided t-test, alpha=0.05). To adjust for the clustering at hospital level (ICC=0.01, three hospitals 
per arm) and to allow for an additional loss to follow up of 10% a total of 86 patients are needed 
in each arm. This means that in each hospital 29 patients with an AECOPD are needed who 
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have a poor prognosis according to our criteria. We expect to have to include between 60 and 90 
patients with an AECOPD in each hospital to get sufficient patients that meet at least 2 criteria 
of the set of indicators.
Statistical analysis
Study parameter(s) indicator study
Non-continuous data will be reported as frequencies. Continuous variables normally distributed 
will be reported as mean + standard deviation (SD). Not normally distributed data will be 
reported as median (interquartile range, IQR). The analytical plan consists of two steps. The 
first step will be to explore the discriminating power of meeting two or more criteria of the set 
of indicators for predicting death within one year and predicting unexpected hospital admission, 
respectively. The sensitivity and specificity for both death within one year and for unexpected 
admission to hospital will be presented. The second step will be to explore the discriminating 
power of individual indicators (or clusters) in predicting death within one year or unexpected 
admission to hospital. Univariable and multivariable logistic regression will be performed 
to examine which variables or cluster of variables are associated with death within one year 
(unexpected admission to hospital respectively). Variables will be eliminated one by one from 
the model based on likelihood ratio tests. Variables are eligible for inclusion into the final model 
if they are significantly associated with death within one year (unexpected admission to hospital 
respectively), with a p-value of < 0.10.
Study parameter(s) intervention study 
Frequencies, means and standard deviations will be used to describe the study variables. 
Differences between the study groups in baseline characteristics and clinical outcomes will be 
assessed and tested for statistical significance with the use of two-sided Fisher’s exact tests and chi-
square tests for categorical variables and independent-samples t-tests for continuous variables. 
The primary study outcome measure of the intervention study is the change in the score on the 
SGRQ from baseline to 3 months: a paired t-test will be used to test the difference between the 
groups for statistical significance. Linear mixed models, with adjustment for baseline scores, will 
be used to study the effect of proactive palliative care on SGRQ outcomes during the follow-up 
period. The analysis follows the principle of intention to treat. Survival time will be calculated 
from the date of enrollment to the date of death with the use of the Kaplan-Meier method. A 
Cox proportional-hazard model will be used to assess the effect of proactive palliative care on 
survival, with adjustment for demographic characteristics.
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Ethical considerations
Patients with COPD who participate in the study may be vulnerable but are certainly capacitated 
adults. Since this is a therapeutic research the participants, patients and informal caregivers, 
may even benefit from participation. The potential risks of this study are quite small. They 
relate to the burden of filling in questionnaires. This will take the patient about 20-30 minutes 
every three months. The potential benefits on the other hand are comparatively large. First, 
participating patients with severe COPD and their informal caregivers in the intervention 
condition will get, if indicated for it, extra proactive palliative care. Second, this study may lead 
to better understanding of the conditions to start and the effectiveness of proactive palliative 
care for patients with COPD. Third, there is a potentially benefit for society since results of this 
study may ultimately lead to different and improved clinical approaches to care of patients with 
severe COPD.
This Study has been approved by the Medical Ethics Committee (CMO) of the Radboud 
University Nijmegen Medical Centre (METC protocol number 2012/260).
DISCUSSION
Research on the effectiveness of palliative care for the COPD patient is scarce and inconclusive.52 
The PROLONG study is the first prospective controlled trial evaluating the effectiveness of a 
multidisciplinary approach to palliative care in COPD disease. The outcomes of this study will 
give insight in the discriminating power of a set of indicators for proactive palliative care and the 
effectiveness of proactive palliative care for patients with COPD.
In the Netherlands, COPD is on the sixth place of causes of death for people older than 45 years. 
In 2011 6,535 patients died with COPD as primary cause of death while in 2010 the number 
of hospitalizations of patients with COPD as diagnosis was 22,5440. The prevalence of COPD 
in the Netherlands is high (361,800 in 2011) and will, with the aging of the population, further 
increase the coming years.53 Up to now patients with COPD hardly receive palliative care. The 
above mentioned numbers reveal the social relevance of introducing palliative care for patients 
with COPD. Furthermore, introducing palliative care for patients with COPD can possibly be 
cost-saving since palliative care may lead to reduction of acute care.33, 54, 55
We have chosen a cluster controlled design for the PROLONG study to prevent cross-
contamination of the intervention within a hospital. At the moment of recruitment of hospitals 
the minority of hospitals in the Netherlands had the availability of a specialized palliative care 
team. Therefore, it was not an option to perform a randomized cluster controlled trial. Hospitals 
are selected for the intervention condition based on the presence of a specialized palliative 
care team in the hospital. In order to be able to compare the hospitals in the control- and the 
intervention condition at baseline a pre-test assessment will be performed. 
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Recruitment for trials of patients with poor prognosis is often difficult. In order to ensure a 
sufficiently large sample for the PROLONG study broad inclusion criteria will be used. All 
patients hospitalized with an AECOPD over 17 years old can be screened for the study. This 
will facilitate lung specialists to include patients. Only after inclusion the distinction between 
patients with poor or better prognosis will be made in order to decide who is eligible for the 
intervention condition. 
The PROLONG study may lead to better understanding of the conditions to start and the 
effectiveness of proactive palliative care for patients with COPD. The innovative aspects of the 
PROLONG study are: 1) the use of a set of indicators to identify patients hospitalized with an 
AECOPD who are in need of proactive palliative care, 2) the active involvement of a specialized 
palliative care team in the development and the implementation of proactive palliative care for 
patients with COPD and, 3) the use of a patient-tailored proactive palliative care plan in which 
lung specialist and a specialized palliative care team work together to optimize proactive palliative 
care for the COPD patient. This patient-tailored proactive palliative care plan is intended to 
meet and to adjust to the individual needs, wishes, possibilities and limitations of the patient and 
the informal caregiver.
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ABSTRACT
Objectives: To identify patients hospitalized for an acute exacerbation COPD who have a poor 
prognosis and might benefit from proactive palliative care, a set of indicators had been developed 
from the literature. A patient is considered eligible for proactive palliative care when meeting ≥ 2 
criteria of the proposed set of eleven indicators. In order to develop a doctor-friendly and patient-
convenient tool our primary objective was to examine whether these indicators are documented 
consistently in the medical records. Besides, percentage of patients with a poor prognosis and 
prognostic value were explored.
Methods: We conducted a retrospective medical record review of 33 patients.
Results: Five indicators; NIV, comorbidity, BMI, previous admissions for AECOPD, and age 
were always documented. Three indicators, hypoxaemia and/or hypercapnia, professional home 
care, and actual FEV1% were documented in more than half of the records, while CCQ, MRC 
dyspnea, and the surprise question were never registered. Besides, 78.8% of the patients met ≥ 2 
criteria and there was a significant association between meeting ≥ 2 criteria and mortality within 
1 year (one-sided Fisher’s Exact Test, p = .04). 
Conclusions: The set of indicators for proactive palliative care in patients with COPD appeared 
to be user-friendly and feasible.
Keywords: COPD, Exacerbation, Indicators, Prognosis, Proactive palliative care
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BACKGROUND
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease with a high 
prevalence1 and the third leading cause of death worldwide.2  The symptoms that occur in the 
end stage of COPD are as severe as or even worse than in the final stage of lung cancer.3, 4 
However, patients with COPD are less likely than those with cancer to receive palliative care.5, 
6 This may be due to the fact that historically the initial focus of palliative care has been on 
oncology7 but also to the different disease trajectory.8 The unpredictable disease course of COPD 
can virtually paralyse lung specialists and prevent them from starting palliative care.9 But, since 
patients with advanced COPD experience similar palliative care needs as patients with advanced 
cancer10 they probably might also benefit from palliative care.
There is evidence that, for patients with cancer, provision of palliative care improved outcomes 
in the domain of pain and symptom control, and reduced hospital admissions.11 Besides, 
early integration of palliative care improved quality of life, reduced depressive symptoms and 
even prolonged survival of patients with non-small-cell lung cancer.12, 13 Recently, it has been 
demonstrated that early integration of palliative care improved breathlessness mastery for patients 
with diseases other than cancer, including COPD.14 Further research specifically aimed at COPD 
is needed.15 For this reason a prospective study has been set up to examine identification of 
patients with COPD with poor prognosis and implementation of proactive palliative care.16
Identification of patients with COPD for proactive palliative care is a challenge. In stable COPD 
population models of survival do exist but they are of limited value to predict survival for 
individual patients.17 Therefore, a patient centered approach to palliative care has been proposed 
not based on prognosis but on palliative needs of the patient.18 Although good palliative care 
indicators tools have been developed, such as the Supportive and Palliative Care Indicators Tool 
(SPICT), they are not specifically intended for patients with COPD, do not use criteria for 
the indicators and/or do not use a clear moment to be applied.18, 19 Since COPD has a gradual 
decline that is punctuated by acute severe exacerbations, any one of which may be fatal.8, 20, a 
hospitalization for an acute exacerbation COPD (AECOPD) might be such a clear moment 
to identify a need for palliative care.21, 22 Not only is the patient during hospitalization literally 
present for the lung specialist, the patient is probably also more willing to address palliative 
issues. Several studies focused on the identification of predictive factors associated with poor 
prognosis for patients hospitalized for an AECOPD.23 One of the conclusions in a recent 
review on this topic was that post-discharge mortality reflects the severity of COPD, as well as 
concomitant specific comorbidities while functional limitation and poor health-related quality 
of life influence the frequency of readmissions.23 In accordance with these findings and based 
on existing literature23-27 we developed a concept set of indicators for lung specialists to identify 
patients hospitalized for an AECOPD who have a poor prognosis. Poor prognosis was defined 
as having a hospital readmission for an AECOPD within 8 weeks or mortality within 1 year. We 
hypothesized that meeting ≥ 2 criteria of this set of indicators could be reason to start proactive 
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palliative care.28, 29 Since palliative care needs increase during the course of COPD, the prediction 
of poor prognosis will be used to ensure not to miss out patients with COPD hospitalized for an 
acute exacerbation who are in need of proactive palliative care. The final tool therefore should 
have a high sensitivity (near 100) and a high as possible specificity. 
The use of this set of indicators was examined in this retrospective pilot study to get an indication 
of its applicability in our prospective study. Since we want to develop a doctor-friendly and 
patient-convenient tool that is easy to implement our primary objective was to examine whether 
these indicators are documented consistently in the medical records of patients hospitalized 
for an AECOPD. Secondary objectives were to get an indication of the percentage of patients 
hospitalized for an AECOPD that meet ≥ 2 criteria of the set of indicators and the prognostic 
value of meeting ≥ 2 criteria of the set of indicators regarding readmission within 8 weeks and/
or mortality within 1 year.
METHODS
Study design
A retrospective medical record review was conducted in October 2013.
Study population
All patients who were admitted to the Radboud University Medical Centre in Nijmegen, the 
Netherlands, with the clinical diagnosis COPD in the period January 2012 until March 2012 
were considered. This period was chosen to ensure one year follow up data of each patient. A 
clinical diagnosis COPD was defined as chronic airway obstruction as determined by spirometry 
prior to hospitalization with an FEV1/FVC ratio < 70%. Next, only medical records of those 
patients hospitalized for an AECOPD were selected. An AECOPD was defined as ‘an acute 
worsening of the patient’s condition from the stable state, which is sustained and may warrant 
the patient to seek additional treatment 30. Excluded from the analysis were medical records 
of patients who were not hospitalized and patients who came to the pulmonary rehabilitation 
centre of the Radboud University Medical Centre for current pulmonary rehabilitation.
This study was approved by the Medical Ethics Committee (CMO) of the Radboud University 
Nijmegen Medical Centre (METC registration number 2013/449). Informed consent was not 
obtained, since we only used data from an existing, clinical database, that was anonymized and 
de-identified prior to analysis.
516939-L-bw-duenk
Processed on: 13-2-2018 PDF page: 81
PILOT STUDY
81
4
Table 1 Variables needed to explore the documentation of the set of indicators
Indicator Variable looked for in medical records
1. Hypoxaemia at discharge
Hypercapnia at discharge
PaO2 (kPa), oxygen administration, and O2 saturation 
at admission and discharge
PaCO2 (kPa) at admission and discharge
2. NIV Noted as NIV or NPPV
3. Professional home care Existence of professional home care after admission
4. Surprise question Surprise question answered with ‘yes’or ‘no’
5. Severe comorbidity Existence of non-curable malignancy 
Existence of cor pulmonale
Existence of proven CHF 
Existence of diabetes mellitus with neuropathy
Renal failure, clearance (GFR: in ml/min)
6. CCQ CCQ total, day version (0-6)
7. MRC dyspnea MRC dyspnea (1-5)
8. FEV1 FEV1 % predicted
9. BMI
Weight change
BMI (kg/m2), or length (m) and weight (kg)
Weight loss in last 6 months (%)
10. Previous hospital admissions Previous hospital admissions AECOPD in last 2 years
11. Age Birth date and admission date
Abbreviations: AECOPD, acute exacerbation Chronic Obstructive Pulmonary Disease; BMI, body mass index; CCQ, 
Clinical COPD Questionnaire; CHF, Chronic Heart Failure; FEV1, forced expiratory volume in 1 second; GRF, 
glomerular filtration rate; kPa, kilopascal; MRC dyspnea, Medical Research Council dyspnea questionnaire; NIV, non 
invasive ventilation; NPPV, non invasive positive pressure ventilation; PaCO2, partial pressure of carbon dioxide in 
arterial blood; PaO2, partial pressure of oxygen in arterial blood.
Data collection
Data from the medical records were obtained from the Electronic Patient Record (EPR). We 
searched for the following variables: 1) demographic variables namely age, gender, marital status, 
condition of living and place of living; 2) COPD related variables namely GOLD stage and 
smoking history; 3) variables needed to explore the documentation of the set of indicators for 
proactive palliative care (see Table 1); and 4) date of first readmission for AECOPD and date of 
death if appropriate. 
To explore the documentation of hypoxaemia and/or hypercapnia at discharge two methods 
were used, a strict and a clinical method. In the strict method only measurement documented at 
discharge were used, whereas in the clinical method also measurements documented at admission 
were considered. Hypoxaemia was defined as having oxygen administration, or a PaO2 < 8 kPa 
(without oxygen administration) or an O2 saturation < 90% (without oxygen administration)31. 
Hypercapnia was defined as having a PaCO2 > 6 kPa. 
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Statistical analysis
Derived variables were calculated to see if ≥ 2 criteria of the set of indicators for proactive palliative 
care (see Table 2) were met. In order to decide if the criteria of the indicator hypoxaemia and/or 
hypercapnia at discharge were met the documentation according to the strict method was used.
Table 2 Set of indicators with criteria for proactive palliative care
A patient hospitalized for AECOPD is eligible for proactive palliative care when meeting two or more criteria 
of the following set of indicators
1. Hypoxaemia (PaO2 < 8 kPa) or hypercapnia (PaCO2 > 6 kPa) at discharge
2. Treatment of the exacerbation with Non Invasive Ventilation (NIV)
3. Patient needs professional home care service for personal care after discharge
4. Negative answer to the surprise question: 
‘Would I (as lung specialist) be surprised if this patient would have a subsequent readmission for AECOPD 
within 8 weeks and/or would die in the next year?
5. The diagnosis of a severe co-morbidity such as: 
a.   Non-curable malignancy or
b.   Cor pulmonale (proven or non proven) or 
c.   Proven Chronic Heart Failure (CHF) or 
d.   Diabetes mellitus with neuropathy or 
e.   Renal failure, clearance < 40 (GFR: in ml/min)
6. CCQ total, day version > 3 
7. MRC dyspnea = 5
8. FEV1 (measured before AECOPD) < 30% of predicted
9. BMI < 21 or unplanned weight loss (> 10% in last 6 months or > 5% in last month)
10. Previous hospital admissions for AECOPD (last 2 years > 2 and/or last year > 1)
11. Age > 70 years
Abbreviations: AECOPD, acute exacerbation Chronic Obstructive Pulmonary Disease; BMI, body mass index; CCQ, 
Clinical COPD Questionnaire; FEV1, forced expiratory volume in 1 second; GRF, glomerular filtration rate; kPa, 
kilopascal; MRC dyspnea, Medical Research Council dyspnea questionnaire; PaO2, arterial partial pressure of oxygen; 
PaCO2, arterial partial pressure of carbon dioxide.
The statistical program SPSS version 20 was used to analyze the data. Non-continuous variables 
were reported as frequencies. Normally distributed continuous variables were reported as mean + 
standard deviation (SD). Not normally distributed continuous variables were reported as median 
(interquartile range, IQR). In order to get an indication of the prognostic power of meeting ≥ 
2 criteria of the set of indicators the differences between study groups in baseline characteristics 
and clinical outcomes were assessed and tested for statistical significance with the use of one-
sided Fisher’s exact tests for categorical variables and independent sample t-tests for continuous 
variables. Differences were considered significant with a p-value of < 0.05. If appropriate the 
sensitivity and the specificity for death within one year and unexpected hospital admission 
within 8 weeks were explored.
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RESULTS
Study population
The medical records of 149 patients with the clinical diagnosis COPD were considered. 
Excluded from the analysis were 116 medical records of patients who were not hospitalized or 
who were included in a clinical pulmonary rehabilitation program. Finally, the medical records 
of 33 patients hospitalized for an AECOPD were examined. The characteristics of the study 
population are presented in Table 3.
Table 3 Characteristics of the study population
Study population (N = 33)
Mean (+SD)
Age 72 (+10.4)
Duration of hospitalization 11 (+7.6)
Pack years 33.1 (+18.7)
N (%)
Sex
Male 19 (58)
Female 14 (42)
Marital status
Married 18 (55)
Unmarried 3 (9)
Divorced 3 (9)
Widow 8 (24)
Unknown 1 (3)
Condition of living
Non single 22 (67)
Single 11 (33)
Place of living
Home 29 (88)
Residential home 0 (0)
Nursing home 4 (12)
Gold stage
I 0 (0)
II 11 (33)
III 7 (21)
IV 14 (43)
Unknown 1 (3)
Smoking at admission
Yes 9 (27)
No 24 (73)
Abbreviations: SD, standard deviation.
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Documentation of the set of indicators
Of the eleven indicators for proactive palliative care, fi ve were always documented in the medical 
records (see Figure 1). These were NIV, comorbidity, BMI, previous admissions for AECOPD 
and age. According to the strict method hypoxaemia, hypercapnia, and hypoxaemia and/or 
hypercapnia at discharge were documented respectively in 85%, 36% and 85% of the cases. For 
the clinical method these numbers were respectively 100%, 97% and 100%. Having professional 
home care and actual FEV1% were recorded half of the time (respectively 57.5% and 54.5%). 
The surprise question, CCQ and MRC dyspnea were never documented (0%).
	 Figure 1 Documentation of each indicator in the medical records and the number of patients that met or did not met 
the criterion of each indicator for proactive palliative care.
Meeting ≥ 2 criteria of the set of indicators
Of the 33 patients hospitalized for AECOPD, 26 patients (78,8%) met ≥ 2 criteria of the set 
of indicators for proactive palliative care. The number of patients that met or did not met the 
criterion of each documented indicator is presented in Figure 1.
Exploration of the prognostic value of the set of indicators
Deceased vs. Non deceased. 
There was a signifi cant association between meeting the criteria for proactive palliative care and 
whether or not the patient died (one-sided Fisher’s Exact Test, p = .04). All patients who died 
within one year after admission (n = 11) met the criteria of the set of indicators for proactive 
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palliative care (see Table 4) meaning that the sensitivity of the set of indicators in predicting death 
within one year was 100%. From the 22 patients who survived seven patients did not meet the 
criteria of the set of indicators for proactive palliative care meaning that the specificity of the 
set of indicators in predicting death in one year was 31.8%. Deceased patients met significantly 
more indicators (M = 4.27, SE = .24) than patients who survived (M = 2.41, SE = .36), t(31) = 
-3.47, p = .002+, r = .53. 
Readmission vs. No readmission within 8 weeks. 
There was no association between meeting criteria for palliative care and whether or not the 
patient had a readmission for an AECOPD within 8 weeks (one-sided Fisher’s Exact Test, 
p = .718). The contingency table is presented in Table 5.
Table 4 Contingency table showing the number of patients deceased within 1 year in patients who meet or do not meet 
criteria for palliative care
> 2 indicators < 2 indicators Total
Deceased 11     (42.3%) 0     (0%) 11     (33.3%)
Non Deceased 15     (57.7%) 7     (100%) 22     (66.7%)
Total 26     (100%) 7     (100%) 33     (100%)
Table 5 Contingency table showing the number of patients with a readmission for an AECOPD within 8 weeks in 
patients who meet or do not meet criteria for palliative care
> 2 indicators < 2 indicators Total
Readmission   4    (15.4%) 1     (14.3%)   5     (15.2%)
No Readmission 22    (84.6%) 6     (85.7%) 28     (84.8%)
Total 26    (100%) 7     (100%) 33     (100%)
DISCUSSION
This study explored the use of a set indicators to get an indication of its applicability in a 
prospective study. This set of indicators has been developed from literature to identify patients 
hospitalized for an AECOPD who have a poor prognosis and might benefit from proactive 
palliative care.
Documentation of indicators
Five of the eleven indicators were documented consistently in the medical records, three in more 
than half of the records, and three not at all. The consistent documentation of age and BMI was 
as expected, since this is basic patient information written down every time a patient visits the 
hospital. Previous admissions for AECOPD, NIV and comorbidity were also always documented 
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when appropriate. The presence or absence of hypoxaemia and/or hypercapnia at discharge was 
documented in 85% of the cases. At admission the necessary measurements of arterial blood gas 
(ABG) were consistently documented. At discharge these measurements were sometimes missing 
(15% for hypoxaemia and 64% for hypercapnia). It is recommended to have ABG documented 
before hospital discharge for all patients with an AECOPD complicated by respiratory failure.32 
Taking into account this recommendation, the necessary ABG measurements of only one patient, 
who was admitted being hypercapnic, was not documented at discharge (3%). Hence, no ABG 
documented before hospital discharge in most cases meant that the patient was not hypoxaemic 
or hypercapnic at admission. Professional home care and actual FEV1% were documented half 
of the time. A possible explanation of these missing documentations is for professional home 
care that this is not documented if the patient is independent of such care and for actual FEV1% 
that if unknown at admission it cannot be assessed in an instable phase such as an AECOPD 
and therefore is not documented. An answer to the surprise question was never documented. 
Although widely known by palliative care specialists, no validation studies on the use of the 
surprise question to identify patients with COPD who can benefit from a palliative care approach 
have been published, which explains its absence in the medical record. Besides, up to now the 
surprise question has mainly be used in research. Also the CCQ and MRC dyspnea were never 
documented. This confirms the finding that these disease specific tools are mainly used in clinical 
trials or when selecting patients for treatment, but less often in usual care.18
Most indicators are fairly consistently documented in the medical records. This suggests that 
lung specialists already use these variables in clinical practice. With respect to these variables no 
extra measurements seem to be necessary to identify patients with COPD with poor prognosis. 
Only an answer to the surprise question, the CCQ and MRC dyspnea are variables never 
documented. For our prospective study this implies that these variables should be specifically 
asked for and measured. The surprise question, the CCQ and MRC dyspnea are short, easy to 
use questionnaires. We decided to include them into the concept set of indicators since they 
provide valuable information about respectively the view of the lung specialist, the severity of 
the dyspnea and the health status of the patient. The measurement of health status (CCQ) is 
important since functional limitation and poor health-related quality of life is recognized to 
influence the frequency of readmissions.23 Beside anxiety, part of the mental state domain of the 
CCQ, is associated with mortality and may be a variable that influences early readmission rates.25 
Whether the surprise question, the CCQ and MRC dyspnea are also included into the final 
version of the set of indicators will depend on the outcome of the prospective study. 
Meeting ≥ 2 criteria
In this pilot, 78.8% of the patients hospitalized for an AECOPD met > 2 criteria of the set of 
indicators. This suggests that 3 out of 4 patients hospitalized for an AECOPD could have a 
poor prognosis and may have an indication for proactive palliative care. Although it seems to 
be a high number it is in line with the recent tendency of reducing demand for unscheduled 
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hospital admissions by admitting the more physically ill patients with an AECOPD and avoiding 
admissions for psychosocial reasons by optimizing care at home.33
Prognostic exploration
Finally, we explored the prognostic value of meeting > 2 criteria of the set of indicators for 
proactive palliative care. Meeting > 2 criteria of the set of indicators was associated with risk of 
mortality within 1 year. The sensitivity of the set of indicators proved to be 100% in predicting 
mortality in this small sample. None of the patients who met less than two criteria of the set of 
indicators died within 1 year. The specificity of the set of indicators in predicting mortality proved 
to be 31.8%. So, meeting > 2 criteria of the set of indicators did not always necessarily mean that 
the patient died within 1 year. However, in order to use this set of indicators in a prospective 
study to investigate the potential benefit of proactive palliative care, the risk of missing people 
in need of this care should be as minimal as possible. Of all the patients who were hospitalized 
for an AECOPD 33.3% died within 1 year stressing the risk for this specific population. This 
number is in line with the risk of death presented in a recent review on predictors of mortality in 
hospitalized patients with an AECOPD.27 According to this review the risk of death was 3.6% 
for short-term mortality (not more than 90 days after exacerbation) and 31.0% for long-term 
mortality (between 90 days and 2 years after exacerbation). Meeting > 2 criteria of the set of 
indicators was not associated with a risk of readmission for an AECOPD within 8 weeks. There is 
a considerable variability in exacerbation susceptibility between patients with COPD.34 A history 
of COPD exacerbations showed to be the best predictor of future events independent of the 
severity of airflow limitation.35 It has been assumed that some patients with a distinct and stable 
COPD phenotype are at high risk of recurrent exacerbations.35 However, it seems that our set of 
indicators did not select this COPD phenotype and therefore was not able to make a distinction 
between patients with infrequent and frequent exacerbations. Nevertheless, in this small sample 
the majority of patients with early readmission seems also to be selected by our criteria.
Strengths and limitations
This is the first time that the use of a set of indicators for proactive palliative care in COPD was 
examined in order to be used in a prospective study. Still, some considerations, concerning the 
external validity and the statistical power, need to be addressed. This pilot study was performed 
in an academic hospital. Mortality rates have shown to be higher in academic hospitals than 
in general hospitals.36 We therefore expect that in general hospitals the percentage of patients 
hospitalized for an AECOPD who have a poor prognosis will be less and as a consequence the 
percentage of those patients who die within 1 year will be less too. Furthermore, in this pilot 
study a small sample size was used which may have resulted in less statistical power to detect an 
effect. However, this pilot study was performed to get an indication of the applicability in practice 
of a set of indicators in advance of a prospective study. The results of such a study will prove the 
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actual characteristics and prognostic value of the set of indicators for proactive palliative care. 
Thereafter it will be decided which indicators have to be included into the final tool.
CONCLUSIONS
In a prospective study, it seems feasible to use a set of indicators for proactive palliative care in 
patients with COPD in a prospective study. The three indicators that were not documented, 
being an answer to the surprise question, the CCQ and MRC dyspnea, are tools mainly used for 
clinical trials and less in usual care. They will specifically be requested in the prospective trial. 
Three out of four patients hospitalized for an AECOPD had a poor prognosis according to our 
set of indicators. Besides, meeting > 2 criteria of the set of indicators was associated with risk of 
mortality within 1 year. The sensitivity of the set of indicators in predicting mortality within 1 
year was 100% and the specificity 31.8%. For a prospective study this suggests that the risk of 
missing patients with COPD in need of proactive palliative care is small. Which indicators will 
be included into the final tool will depend on the outcomes of the prospective study.
516939-L-bw-duenk
Processed on: 13-2-2018 PDF page: 89
PILOT STUDY
89
4
REFERENCES
1.  Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD 
Study): a population-based prevalence study. Lancet. 2007;370(9589):741-750.
2.  Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 
1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-
2128.
3.  Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive 
pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax. 
2000;55(12):1000-1006.
4.  Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart 
disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31(1):58-69.
5.  Claessens MT, Lynn J, Zhong Z, et al. Dying with lung cancer or chronic obstructive pulmonary disease: insights 
from SUPPORT. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. J Am 
Geriatr Soc. 2000;48(5 Suppl):S146-153.
6.  Beernaert K, Cohen J, Deliens L, et al. Referral to palliative care in COPD and other chronic diseases: a population-
based study. Respir Med. 2013;107(11):1731-1739.
7.  Addington-Hall J HK. Non-cancer patients as an underserved group. In: Cohen J DL, ed. A public health perspective 
on end of life care: Oxford University Press; 2012:151-159.
8.  Murray SA, Kendall M, Boyd K, Sheikh A. Illness trajectories and palliative care. BMJ. 2005;330(7498):1007-
1011.
9.  Stewart S, McMurray JJ. Palliative care for heart failure. BMJ. 2002;325(7370):915-916.
10.  Bausewein C, Booth S, Gysels M, Kuhnbach R, Haberland B, Higginson IJ. Understanding breathlessness: cross-
sectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and 
cancer. J Palliat Med. 2010;13(9):1109-1118.
11.  Higginson IJ, Evans CJ. What is the evidence that palliative care teams improve outcomes for cancer patients and 
their families? Cancer J. 2010;16(5):423-435.
12.  Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung 
cancer. New Engl J Med. 2010;363(8):733-742.
13.  Pirl WF, Greer JA, Traeger L, et al. Depression and survival in metastatic non-small-cell lung cancer: effects of early 
palliative care. J Clin Oncol. 2012;30(12):1310-1315.
14.  Higginson IJ, Bausewein C, Reilly CC, et al. An integrated palliative and respiratory care service for patients with 
advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respir Med. 2014;2(12):979-
987.
15.  Rocker GM, Sinuff T, Horton R, Hernandez P. Advanced chronic obstructive pulmonary disease: innovative 
approaches to palliation. J Palliat Med. 2007;10(3):783-797.
16.  Duenk RG, Heijdra Y, Verhagen SC, Dekhuijzen RP, Vissers KC, Engels Y. PROLONG: a cluster controlled trial 
to examine identification of patients with COPD with poor prognosis and implementation of proactive palliative 
care. BMC Pulm Med. 2014;14:54.
17.  Coventry PA, Grande GE, Richards DA, Todd CJ. Prediction of appropriate timing of palliative care for older 
adults with non-malignant life-threatening disease: a systematic review. Age Ageing. 2005;34(3):218-227.
18.  Boyd K, Murray SA. Recognising and managing key transitions in end of life care. BMJ. 2010;341:c4863.
19.  Highet G, Crawford D, Murray SA, Boyd K. Development and evaluation of the Supportive and Palliative Care 
Indicators Tool (SPICT): a mixed-methods study. BMJ Support Palliat Care. 2014;4(3):285-290.
20.  Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM. Patterns of functional decline at the end of life. JAMA. 
2003;289(18):2387-2392.
21.  Reinke LF, Engelberg RA, Shannon SE, et al. Transitions regarding palliative and end-of-life care in severe chronic 
obstructive pulmonary disease or advanced cancer: themes identified by patients, families, and clinicians. J Palliat 
Med. 2008;11(4):601-609.
22.  Patel K, Janssen DJ, Curtis JR. Advance care planning in COPD. Respirology. 2012;17(1):72-78.
23.  Steer J, Gibson GJ, Bourke SC. Predicting outcomes following hospitalization for acute exacerbations of COPD. 
QJM. 2010;103(11):817-829.
24.  Murray SA, Pinnock H, Sheikh A. Palliative care for people with COPD: we need to meet the challenge. Prim Care 
Respir J. 2006;15(6):362-364.
516939-L-bw-duenk
Processed on: 13-2-2018 PDF page: 90
CHAPTER 4
90
25.  Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155-161.
26.  Kocks JW, Asijee GM, Tsiligianni IG, Kerstjens HA, van der Molen T. Functional status measurement in COPD: 
a review of available methods and their feasibility in primary care. Prim Care Respir J. 2011;20(3):269-275.
27.  Singanayagam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation 
of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10(2):81-89.
28.  Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J. 2008;32(3):796-803.
29.  Carlucci A, Guerrieri A, Nava S. Palliative care in COPD patients: is it only an end-of-life issue? European Respir 
Rev. 2012;21(126):347-354.
30.  Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s-53s.
31.  Fraanje WL GP, Knobbe K, Van Putten AM, Draijer LW. Farmacotherapeutische richtlijn Geneesmiddelen en 
zuurstof in spoedeisende situaties. Huisarts Wet 2012;50(5):210-220.
32.  National Institute for Health and Clinical Excellence. Chronic Obstructive Pulmonary Disease: Management 
of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London: National Clinical 
Guideline Centre - Acute and Chronic Conditions.; 2010.
33.  Coventry PA, Gemmell I, Todd CJ. Psychosocial risk factors for hospital readmission in COPD patients on early 
discharge services: a cohort study. BMC Pulm Med. 2011;11:49.
34.  Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New 
Engl J Med. 2010;363(12):1128-1138.
35.  Beeh KM, Glaab T, Stowasser S, et al. Characterisation of exacerbation risk and exacerbator phenotypes in the 
POET-COPD trial. Respir Res. 2013;14:116.
36.  Heijink R, Koolman X, Pieter D, van der Veen A, Jarman B, Westert G. Measuring and explaining mortality in 
Dutch hospitals; the hospital standardized mortality rate between 2003 and 2005. BMC Health Serv Res. 2008;8:73.
516939-L-bw-duenk
Processed on: 13-2-2018 PDF page: 91
PILOT STUDY
91
4
516939-L-bw-duenk
Processed on: 13-2-2018 PDF page: 92
516939-L-bw-duenk
Processed on: 13-2-2018 PDF page: 93
Proactive Palliative Care for Patients with COPD 
(PROLONG): A Pragmatic Cluster Controlled 
Trial
Ria Duenk, Stans Verhagen, Ewald Bronkhorst, Patricia van Mierlo, Marielle 
Broeders, Saskia Collard, Richard Dekhuijzen, Kris Vissers, Yvonne Heijdra, 
Yvonne Engels
International Journal of Chronic Obstructive Pulmonary Disease. 
5
516939-L-bw-duenk
Processed on: 13-2-2018 PDF page: 94
CHAPTER 5
94
ABSTRACT
Background and aim: Patients with advanced Chronic Obstructive Pulmonary Disease (COPD) 
have poor quality of life. We assessed the effects of proactive palliative care on the well-being of 
these patients. 
Trial registration: This trial is registered with the Netherlands Trial Register, NTR4037.
Patients and methods: A pragmatic cluster controlled trial (quasi-experimental design) 
was performed with hospital as cluster (3 intervention, 3 control) and a pre-trial assessment. 
Hospitals were selected for the intervention condition based on the presence of a specialized 
palliative care team (SPCT). To control for confounders a pre-trial assessment was performed 
in which hospitals were compared on baseline characteristics. Patients with COPD with poor 
prognosis were recruited during hospitalization for acute exacerbation. All patients received usual 
care while patients in the intervention condition received additional proactive palliative care 
in monthly meetings with an SPCT. Our primary outcome was change in quality of life score 
after 3 months, which was measured using the St George Respiratory Questionnaire (SGRQ). 
Secondary outcomes were, among others, quality of life at 6, 9 and 12 months; readmissions; 
survival; and having made advance care planning (ACP) choices. All analyses were by intention-
to-treat.
Results: During the year 2014, 228 patients were recruited (90 intervention, 138 control) and 
at 3 months, 163 patients (67 intervention, 96 control) completed the SGRQ. There was no 
significant difference in change scores of the SGRQ total at 3 months between groups (-0·79 
[95% CI -4·61 to 3·34], p=0·70). However, patients who received proactive palliative care 
experienced less impact of their COPD (SGRQ impact subscale) at 6 month (-6·22 [-11·73 to 
-0·71], p=0·04), and had more often made ACP choices (adjusted odds ratio 3·26 [1·49 to 7·14], 
p=0·003). Other secondary outcomes were not significantly different. 
Conclusion: Proactive palliative care did not improve overall quality of life of patients with 
COPD. However, patients more often made ACP choices which may lead to better quality of 
care towards the end of life.
Keywords: COPD, Proactive palliative care, Quality of life, Advance care planning, Readmission, 
Survival
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INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide 
and caused 3.1 million deaths (5.6% of total deaths) in 2012.1,2 This progressive life-threatening 
lung disease has an unpredictable course characterized by episodes of gradual decline punctuated 
by acute severe exacerbations.3 After the first hospitalization for an acute exacerbation of COPD 
(AECOPD), 50% of patients die within 3.6 years.4 Patients with advanced COPD have a high 
symptom burden, including breathlessness, fatigue, cough, and anxiety.5 Their quality of life is 
poor and often even worse than patients with lung cancer.6
Early or proactive palliative care can improve quality of life of patients with cancer,7-9 and heart 
failure.10,11 This kind of care is not restricted to end-of-life care but can be delivered earlier in 
the disease course by anticipating on wishes and needs of patients, in order to prevent and relief 
suffering from problems in the physical, psychosocial, and spiritual domain. 2 Patients with lung 
cancer receiving proactive palliative care even had longer survival while receiving less aggressive 
treatments.8 Prolonged survival has also been observed in patients with refractory breathlessness 
(cancer, COPD, chronic heart failure, and interstitial lung disease).12 In this study of Higginson 
et al, early introduction of a palliative breathlessness support service improved breathlessness 
mastery, a quality of life domain of the Chronic Respiratory Disease Questionnaire.12 Although 
proactive palliative care has been shown to improve quality of life and prolong survival of patients 
with various life-threatening diseases, it is still not common for patients with COPD to receive 
this care.13 Since little is known about the effects of proactive palliative care in COPD, research 
is needed to be able to improve care for this patient group.13
We report a pragmatic cluster controlled trial of proactive palliative care in patients with 
COPD. A cluster design was chosen to prevent contamination and to minimize ethical concerns 
of patients and clinicians with respect to randomization and gate keeping. We hypothesized 
that patients with COPD who received proactive palliative care integrated with usual care 
compared to patients who received usual care only would have better quality of life, lower levels 
of psychological distress, fewer and shorter hospital admissions for an AECOPD, prolonged 
survival, and that receiving proactive palliative care would increase the number of patients with 
whom advance care planning (ACP) choices were made.
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METHODS
Study design
A pragmatic cluster controlled trial (quasi-experimental design) was performed in the Netherlands 
with general hospital as cluster (3 control, 3 intervention). Patients were recruited between Jan 
6, 2014 - Jan 8, 2015, and each patient was followed for 1 year. Hospitals were selected for the 
intervention condition based on the presence of a specialized palliative care team (SPCT). A 
pre-trial assessment was performed to be able to control for confounders on hospital level. All 
outcome measures were on patient level.
Participants
Patients with COPD, 18 years or older, who had a hospital admission for an AECOPD were 
considered for the PROLONG study.14 Patients were excluded if they could not speak Dutch, had 
severe cognitive disorders or if they were being treated by an SPCT at the moment of inclusion. 
The attending pulmonologist selected and approached potential participants. Exclusion because 
of severe cognitive disorder was based on judgment of the pulmonologist. If the patient agreed 
to participate, an informed consent was signed. For the intervention study described here, 
only patients with poor prognosis were regarded. To identify these patients, the pulmonologist 
completed a standard checklist consisting of a set of 11 indicators derived from the literature.14 If 
meeting two or more indicators the patient was considered to have a poor prognosis and eligible 
to participate in the study. The set of indicators of poor prognosis are presented in Table 1.15,16
The study protocol was approved by the Medical Ethics Committee (METC) of the Radboud 
University Medical Center, Nijmegen (METC protocol number 2012/260). Thereafter, 
research approval was received in all participating hospitals. Our protocol followed CONSORT 
recommendations,14 but there were two protocol deviations. First, patients participating in other 
COPD-related studies were withdrawn from the intention-to-treat analysis from the moment 
they entered the other study. Second, patients who signed the informed consent but died in 
hospital during inclusion were also excluded as the pulmonologist was not able to complete 
the checklist because it consisted of indicators for post-hospital mortality. A comprehensive 
description of the methods is given in the published protocol.14
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Table 1 Set of indicators for proactive palliative care
A patient hospitalized for AECOPD is eligible for proactive palliative care when meeting >2 of the following 
indicators:
1. Hypoxaemia (PaO2 < 8 kPa) or hypercapnia (PaCO2 > 6 kPa) at discharge
2. Treatment of the exacerbation with Non Invasive Ventilation (NIV)
3. Patient needs professional home care service for personal care after discharge
4. Negative answer to the surprise question: 
‘Would I (as lung specialist) be surprised if this patient would have a subsequent readmission for AECOPD within 
8 weeks and/or would die in the next year?
5. The diagnosis of a severe co-morbidity such as: 
a.   Non-curable malignancy or
b.   Cor pulmonale (proven or non proven) or 
c.   Proven Chronic Heart Failure (CHF) or 
d.   Diabetes mellitus with neuropathy or 
e.   Renal failure, clearance < 40 (GFR: in ml/min)
6. CCQ total, day version > 3 
7. MRC dyspnea = 5
8. FEV1 (measured before AECOPD) < 30% of predicted
9. BMI < 21 or unplanned weight loss (> 10% in last 6 months or > 5% in last month)
10. Previous hospital admissions for AECOPD (last 2 years > 2 and/or last year > 1)
11. Age > 70 years
Abbreviations: AECOPD, acute exacerbation Chronic Obstructive Pulmonary Disease; BMI, body mass index; CCQ, 
Clinical COPD Questionnaire; FEV1, forced expiratory volume in 1 second; GRF, glomerular filtration rate; kPa, 
kilopascal; MRC dyspnea, Medical Research Council dyspnea questionnaire; PaO2, arterial partial pressure of oxygen; 
PaCO2, arterial partial pressure of carbon dioxide.
Randomization
A cluster design was chosen to prevent contamination and to minimize ethical concerns of patients 
and clinicians with respect to randomization and gate keeping. Contamination would certainly 
have taken place because our intervention involved a close cooperation between pulmonary team 
and SPCT. At the time of hospital recruitment, a minority of hospitals in the Netherlands had 
the availability of an SPCT. Since only four hospitals with an SPCT were willing to participate, 
it was not possible to create comparable groups through randomization in our trial. Instead we 
performed a pragmatic cluster controlled trial (quasi-experiment), in which three hospitals with 
an SPCT were selected for the intervention and three hospitals without an SPCT for the control 
condition. To control for confounders on hospital level a pre-trial assessment was performed in 
which hospitals were compared on baseline characteristics over the year before trial (number of 
hospitalizations and hospitalization days for AECOPD per patient, and percentage of patients 
hospitalized for an AECOPD who died in hospital). All outcome measures were on patient level 
and patients performed a pre and post intervention measurement.
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The study was single-blinded. Clinicians were aware of treatment allocation, while patients were 
unaware of the existence of another group.
Interventions
All patients received usual care. In the intervention condition patients received additional 
proactive palliative care from an SPCT. Patients had a first consultation with the SPCT during 
the initial hospitalization, or the latest within 1 week after hospital discharge. Thereafter, the 
SPCT had monthly meetings with the patient in the outpatient setting, preferably face to face 
but alternatively by telephone, for 1 year or until death.
Since delivering proactive palliative care for patients with COPD was not common for members 
of the SPCTs, they received a training, aimed at the specific problems in this patient group, 
which was provided by academic palliative care professionals of the Radboud University Medical 
Center, Nijmegen. Training was based on the specific guidelines for palliative care in COPD,17 
and consisted of two three-hour meetings. The first meeting took place in the month before 
trial and the second during the first month of trial. The training consisted of the following 
topics: how to communicate future care planning and end-of-life aspects with the patients and 
their families; how to create a patient-tailored proactive palliative care plan; how to proactively 
anticipate on illness- and death scenarios; how to organize transfer of care to the pulmonologist 
and general practitioner (GP); and how to perform a proactive palliative care plan in cooperation 
with the pulmonologist. 
Data collection
Data collection took place using questionnaires completed by the patients, and by retrospectively 
collecting data from their medical files over the trial period (see Table 2).18-21
ACP choices documented in medical files were defined as agreements about: Not To Be 
Resuscitated (NTBR) policy, Intensive Care Unit (ICU) admission, palliative dyspnea treatment, 
palliative sedation, treatment of future infections with antibiotics (AB), and preferred place of 
death. Those ACP choices were our objective outcome measures which served as a proxy for 
measuring whether ACP conversations had taken place.
Outcomes
The primary outcome was change in quality of life from baseline after 3 months measured 
with the St George Respiratory Questionnaire (SGRQ). Secondary questionnaire outcomes 
were change of the SGRQ from baseline after respectively 6, 9, and 12 months and change of 
the McGill Quality of Life questionnaire (McGill) and the Hospital Anxiety and Depression 
Scale (HADS) from baseline after respectively 3, 6, 9, and 12 months. Secondary outcomes 
retrospectively retrieved from the medical files of the patients over the trial period are presented 
in Table 2.
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Table 2 Overview of data collection per time point
Data collection B 3 
m
6 
m
9 
m
12 
m
R 
Questionnaires:
Demographic questionnaire
(age, pack years, sex, marital status, place and groups of living and education)
X
SGRQ (COPD quality of life questionnaire)
(symptoms, activities and impacts subscales)
X X X X X
McGill (palliative quality of life questionnaire)
(phys symptoms, phys and psych well-being, existential and support subscales) 
X X X X X
HADS (psych well-being questionnaire)
(anxiety and depression subscales)
X X X X X
Medical files (information over the 1 year trial period):
Number of readmissions to hospital X
Number of readmissions to hospital for AECOPD X
Date of first readmission for AECOPD X
Number of days of readmission to hospital for AECOPD X
Choices of ACP documented in the medical file at baseline X
Choices of ACP documented in the medical file after one year or at death X
Did the patient die within one year after inclusion? X
Date of death X
Note: X’s indicate the times that that type of data was collected. 
Abbreviations: ACP, advance care planning; AECOPD, acute exacerbation Chronic Obstructive Pulmonary Disease; 
B, baseline; HADS, Hospital Anxiety and Depression Scale;21 m, month; McGill, McGill quality of life questionnaire;20 
phys, physical; psych, psychological; R, retrospectively; SGRQ, St George Respiratory Questionnaire18,19.
Statistical analysis
 Based on our primary outcome, change in quality of life measured with the SGRQ from baseline 
after 3 months, we estimated that 64 patients were needed in each arm to detect a mean difference 
of 9 (SD 16) with a p value of 0.05 at a power of 80%.22 To adjust for clustering at hospital level 
(Intraclass Correlation Coefficient (ICC)=0.01, three hospitals per arm) and to allow for an 
additional loss to follow up of 10% a total of 86 patients were required in each arm. 
We used the valid CASTOR data management system to ensure Good Clinical Practice.23 Data 
were analyzed using R software, version 3.1.2. Frequencies, means and standard deviations were 
used to describe the study variables. Linear mixed models with a random intercept for hospitals 
to account for clustering were used to study the effects of proactive palliative care on the primary 
and secondary outcomes. The models contained an adjustment for baseline scores of which 
selection was based on theoretical background and differences between groups at baseline. The 
analysis followed the principle of intention-to-treat. Missing data were handled using available 
case analysis.
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Survival was plotted using the Kaplan-Meier method. We calculated survival rates until 365 days 
from enrolment in both groups. A Cox proportional-hazard test was used to assess the effect of 
proactive palliative care on survival with adjustment for baseline characteristics. Again, mixed 
models with a random intercept for hospitals were used.
 
Hospital 6Hospital 4
Control condition
135 Pt assessed99 Pt assessed 172 Pt assessed
21 (0, 13, 8) Pt not met > 2 criteria of the 
set of indicators for palliative care
33 (10, 10, 13) Pt not met > 2 criteria of 
the set of indicators for palliative care
    0 (0, 0, 0) Pt not met inclusion criteria
  48 (17, 0, 31) Pt met exclusion criteria
    0 (0, 0, 0) Pt already treated by SPCT
    1 (0, 1, 0) Pt died before consenting
183 (37, 107, 39) Pt refused
    6 (0, 5, 1) Pt not met inclusion criteria
  70 (1, 45, 24) Pt met exclusion criteria
    4 (0, 4, 0) Pt already treated by SPCT
    4 (3, 0, 1) Pt died before consenting
176 (34, 105, 37) Pt refused
42 (11, 17, 14) Pt not filled out SGRQ at 3 months
· 	 11 (4, 6, 1) Pt died in the 3 month after inclusion
· 	 18 (3, 8, 7) Pt insufficiently filled out SGRQ at 3 m 
· 	 13 (4, 3, 6) Pt did not fill out SGRQ at 3 m 
23 (6, 11, 6) Pt not filled out SGRQ at 3 months
· 	 5   (2, 3, 0) Pt died in the 3 month after inclusion
· 	 11 (3, 6, 2) Pt insufficiently filled out SGRQ at 3 m
· 	 7   (1, 2, 4) Pt did not fill out SGRQ at 3 m
3 (0, 2, 1) Pt excluded from analysis
· 	 2 (0, 2, 0) Pt took part in the Columbus study
· 	 1 (0, 0, 1) Pt took part in the MEA study 
3  (2, 1, 0) Pt excluded from analysis
· 	 3   (2, 1, 0) Pt died in hospital during inclusion
Hospital 5
Total 406 Pt assessed for eligibility
Hospital 3Hospital 1
Intervention condition
100 Pt assessed67 Pt assessed 207 Pt assessed
Hospital 2
Total 374 Pt assessed for eligibility
37 Pt considered29 Pt considered 48 Pt considered
Total 114 Pt considered for study participation
65 Pt considered45 Pt considered 64 Pt considered
Total 174 Pt considered for study participation
29 Pt assigned29 Pt assigned 35 Pt assigned
Total 93 Pt assigned for proactive palliative care
52 Pt assigned35 Pt assigned 54 Pt assigned
Total 141 Pt assigned for usual care
29 Pt included27 Pt included 34 Pt included
Total 90 Pt included in intention-to-treat analysis
51 Pt included35 Pt included 52 Pt included
Total 138 Pt included in intention-to-treat analysis
23 Pt filled out21 Pt filled out 23 Pt filled out
Total 67 Pt filled out SGRQ at 3 months
37 Pt filled out24 Pt filled out 35 Pt filled out
Total 96 Pt filled out SGRQ at 3 months
 
	  
Figure 1 Trial profile.
Abbreviations: m, months; Pt, patient; SGRQ, St George Respiratory Questionnaire; SPCT, specialized palliative care 
team.
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RESULTS
In six general hospitals, 780 patients were screened, of whom 228 (90 intervention, 138 control) 
were included in the intention-to-treat analysis (see Figure 1).
Baseline characteristics at hospital level over the year before trial (2013) are presented in Table 3.
Tables 4 and 5 respectively show the demographics and baseline characteristics of the study 
population. In the intervention condition, compared to the control condition, more patients had 
severe dyspnea scores, were living alone, and were suffering from CHF. No substantial differences 
were seen between groups on baseline outcome measures. 
Important change scores relative to baseline and the associated tests of effects between groups 
are presented in Table 6.24 The outcomes of the McGill and HADS subscales are presented in 
the supplement. In the linear mixed models the baseline scores on patient level adjusted for 
were: baseline questionnaire score, sex, condition of living, level of education, packyears, MRC 
dyspnea score, forced expiratory volume in 1 second percentage of predicted value (FEV
1
%), 
presence of comorbidity, number of indicators met, and number of admissions for AECOPD in 
the previous 2 years. To account for differences at baseline on hospital level we also adjusted for 
number of hospitalizations AECOPD per patient in the year before the trial (2013).
Incorrectly filled out questions were noticed at the McGill physical symptoms subscale. In an open 
text field, patients had to describe a troublesome physical symptom and indicate its seiousness on 
a visual analogue scale (VAS). This question proved to be subject to misinterpretation. Patients 
often listed not a physical symptom but a disease (eg diabetes), or a complaint of other origin (eg 
snoring partner). To prevent from too many missing values, we calculated the McGill total score 
by taking the mean of the remaining four of the five subscales.
Table 3 Baseline characteristics at hospital level over the year before trial (2013)
Characteristics Intervention condition Control condition
Hospital 
1
Hospital 
2
Hospital 
3
Mean Hospital 
4
Hospital 
5
Hospital 
6
Mean
Hospitalizations 
AECOPD per patient (n) 1.32 1.60 1.24 1.39 1.23 1.51 1.21 1.32
Hospitalization days for 
AECOPD per patient (n) 9.21 10.58 10.15 9.98 9.30 12.32 10.43 10.68
Patients with AECOPD 
who died in hospital (n) 0.08 0.07 0.07 0.073 0.06 0.12 0.06 0.08
Abbreviations: AECOPD, acute exacerbation of Chronic Obstructive Pulmonary Disease.
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Table 4 Demographics of the intention-to-treat population
Demographics Overall
 
(n=228)
Intervention
condition
(n=90)
Control 
condition 
(n=138)
Age 68.54 (9.34) 68.67 (9.08) 68.45 (9.54)
Pack years 40.00 (31.76) 41.58 ((28.95) 38.92 (33.62)
Sex
Male 110 (48.2%) 46 (51.1%) 64 (46.4%)
Marital status a
Unmarried
Married
Divorced
Widowed
16 (7.0%)
145 (63.6%)
25 (11.0 %)
39 (17.1%)
5 (5.6%)
51 (56.7%)
12 (13.3%)
22 (24.4%)
11 (8.0%)
94 (68.1%)
13 (9.4%)
17 (12.3%)
Living situation a 
Single
Non single
71 (31.1%)
145 (63.6%)
36 (40.0%)
49 (54.4%)
35 (25.4%)
96 (69.6%)
Place of living a
Home, independent of homecare
Home, dependent of homecare
Residential home
Nursing home
144 (63.2%)
74 (32.5%)
3 (1.3%)
1 (0.4%)
60 (66.7%)
27 (30.0%)
1 (1.1%)
1 (1.1%)
84 (60.9%)
47 (34.1%)
2 (1.4%)
0 (0%)
Highest level of education a
No education
Elementary school
Secondary school
Primary education
Secondary education
Higher/University education
2 (0.9%)
38 (16.7%)
57 (25.0%)
45 (19.7%)
57 (25.0%)
23 (10.1%)
1 (1.1%)
16 (17.8%)
18 (20.0%)
17 (18.9%)
30 (33.3%)
8 (8.9%)
1 (0.7%)
22 (15.9%)
39 (28.3%)
28 (20.3%)
27 (19.6%)
15 (10.9%)
Notes: Data are given as n (%) or mean (SD). a Because of missing values, some numbers do not add up to 100%.
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The primary outcome of change scores in SGRQ total at 3 months did not differ significantly 
between groups (mean observed change score in intervention condition -1.84 (SD 12.20) vs 
control condition 0.20 (12.05), p=0.70.
There was a significant difference between groups in the change scores of the impact subscale 
of the SGRQ at 6 months (-5.73 (16.21) vs 0.86 (18.73), p=0.04). We also noted a significant 
difference between groups in number of patients that made ACP choices during the year of trial 
(76.7% vs 59.4%, adjusted OR 3.26 [95% CI 1.49 to 7.14], p=0.003). Of the 36.8% of patients 
(30.0% intervention, 41.3% control) who had not made ACP choices at baseline, 85.7% (100% 
intervention, 78.9% control) made ACP choices within the next year. Whereas, of the 63.2% of 
patients (70.0% intervention, 58.7% control) who had already made ACP choices at baseline, 
54.9% (66.7% intervention, 45.7% control) made additional ACP choices within the next year. 
All other secondary outcome measures were not significantly different between groups. One 
year after enrolment 52 patients with poor prognosis (22.8%) had died. The Kaplan Meier 
curve is presented in Figure 2. The Cox proportional-hazard test showed that survival was not 
significantly different between groups (adjusted HR 0.74 [95% CI 0.34 to 1.62], p=0.45).
DISCUSSION
This is the first study to explore the effects of proactive palliative care in a large group of patients 
with COPD with poor prognosis (n=228). We did not find an effect on our primary outcome: 
the change in quality of life measured using the SGRQ from baseline to 3 months was not 
different between groups. However, patients receiving proactive palliative care experienced less 
impact of their COPD (SGRQ impact subscale) at 6 months than patients receiving usual care. 
The change in symptoms and activity level (SGRQ symptoms and activity subscale) were not 
different between groups at 3, 6, 9, and 12 months. Moreover, there was a relevant difference in 
number of patients that made ACP choices during the year of trial, in favor of the intervention 
condition. We did not find a difference in other questionnaire outcomes, nor in number and 
length of hospital admissions or in survival between groups. 
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Table 5 Baseline characteristics of the intention-to-treat population
Characteristics Overall
(n=228)
Intervention
condition
(n=90)
Control 
condition 
(n=138)
Clinical characteristics
FEV
1 
(l)
Predicted FEV
1
 (%)
VC (l)
Predicted VC (%)
1.07 (0.49)
42.51 (18.87)
2.60 (0.82)
79.84 (20.67)
1.05 (0.47)
40.79 (16.09)
2.63 (0.83)
79.75 (21.90)
1.08 (0.50)
43.70 (20.55)
2.58 (0.82)
79.90 (19.89)
GOLD stage a b
0
I
II
III
IV
10 (4.4%)
7 (3.1%)
51 (22.4%)
87 (38.2%)
63 (27.6%)
4 (4.4%)
2 (2.2%)
16 (17.8%)
43 (47.8%)
24 (26.7%)
6 (4.3%)
5 (3.6%)
35 (25.4%)
44 (31.9%)
39 (28.3%)
Comorbidity
Non-curable Malignancy
Cor pulmonale
CHF
DM with neuropathy
Renal failure
Comorbidity total
12 (5.3%)
12 (5.3%)
16 (7.0%)
9 (3.9%)
13 (5.7%)
58 (25.4%)
8 (8.9%)
3 (3.3%)
11 (12.2%)
2 (2.2%)
2 (2.2%)
24 (26.7%)
4 (2.9%)
9 (6.5%)
5 (3.6%)
7 (5.1%)
11 (8.0%)
34 (24.6%)
Hospitalization for AECOPD 
in previous 2 year (n) 1.95 (2.57) 2.28 (3.1) 1.73 (2.14)
Indicators met (n) 4.35 (1.64) 4.42 (1.51) 4.30 (1.72)
MRC dyspnea a
0
1
2
3
4
5
4 (1.8%)
6 (2.6%)
6 (2.6%)
31 (13.6%)
44 (19.3%)
134 (58.8%)
3 (3.3%)
3 (3.3%)
1 (1.1%)
5 (5.6%)
15 ((16.7%)
63 (70.0%)
1 (0.7%)
3 (2.2%)
5 (3.6%)
26 (18.8%)
29 (21.0%)
71 (51.5%)
CCQ Total 3.45 (0.97) 3.48 (0.88) 3.44 (1.03)
Outcome measures
SGRQ total score
SGRQ symptoms score
SGRQ activity score
SGRQ impacts score
McGill total score
McGill physical well-being
McGill physical symptoms
McGill psychological
McGill existential
McGill support
HADS total score
HADS anxiety
HADS depression 
68.12 (14.43)
69.80 (17.39)
86.84 (13.65)
57.57 (19.56)
5.16 (1.18)
4.03 (2.26)
3.08 (1.84)
5.82 (2.61)
5.55 (1.67)
7.39 (1.91)
16.87 (7.80)
8.78 (4.48)
8.12 (4.29)
69.00 (13.37)
70.93 (15.06)
87.38 (13.61)
58.16 (18.77)
5.06 (0.98)
4.28 (2.28)
2.91 (1.77)
5.92 (2.60)
5.61 (1.47)
7.61 (1.63)
16.48 (7.88)
8.75 (4.53)
7.74 (4.12)
67.50 (15.15)
69.06 (18.78)
86.47 (13.72)
57.16 ((20.13)
5.25 (1.31)
3.87 (2.23)
3.21 (1.89)
5.76 (2.63)
5.51 (1.80)
7.24 (2.07)
17.13 (7.78)
8.80 (4.47)
8.37 (4.40)
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Notes: Data are given as n (%) or mean (SD). a Because of missing values some numbers do not add up to 100%. 
b GOLD stage according to last known data in medical file; inclusion in study based on judgment pulmonologist.
Abbreviations: AECOPD, acute exacerbation Chronic Obstructive Pulmonary Disease; CCQ, Clinical COPD 
Questionnaire; CHF, Congestive Heart Failure; DM, Diabetes Mellitus; FEV
1
, forced expiratory volume in 1 second; 
GOLD, Global initiative on Obstructive Lung Disease; HADS, Hospital Anxiety and Depression Scale; MRC dyspnea, 
Medical Research Council dyspnea questionnaire; SGRQ, St George Respiratory Questionnaire; McGill, McGill quality 
of life questionnaire; VC, vital capacity.
There are several possible reasons at the level of identification, organization, patient, outcome 
measure, and disease course that may explain the failure to show an improvement of quality 
of life in patients with COPD by means of proactive palliative care in our study. First, 22.8% 
of patients identified as having a poor prognosis died; it is possible that our criteria for poor 
prognosis were too broad. Second, patients with advanced COPD are often homebound until 
they enter an acute phase with hospitalization.25 Continuity of palliative care can therefore only 
be achieved with a coordinated, multidisciplinary care approach.26 This requires collaboration 
between primary and secondary health care professionals. Although GPs were informed about 
the intervention and the SPCT was encouraged to collaborate with GPs, it is unknown to what 
extent this occured. Third, patients with COPD generally have a lower Social Economic Status 
(SES), i.e. on average a lower level of education and less financial means compared to other 
patient groups.27 These aspects have an impact on COPD health outcomes.27 Indeed, some 
patients in our study had difficulties understanding certain questions, which resulted in the 
return of incomplete questionnaires. Besides, some patients lacked financial means to afford 
transportation to the hospital, physical therapy, or even a walker. Fourth, for some patients 
with advanced COPD, filling in questionnaires may have been too demanding. Although all 
enrolled patients did consent to fill out questionnaires, about one out of five patients did not 
fully complete or return them. Incomplete data collection in advanced COPD has also been 
reported before.28,29 Perhaps in this population the use of a qualitative instead of a quantitative 
approach is preferable for measuring changes in patient-reported outcomes.28 Finally, there are 
differences in the palliative trajectory between patients with cancer and those with COPD. The 
palliative trajectory of COPD is less predictable since episodes of gradual decline are punctuated 
by acute severe exacerbations;3 therefore, these acute exacerbations may have influenced findings 
defined at fixed time points. 
Patients who received proactive palliative care experienced less impact of their COPD at 6 months. 
Although this may have been a chance finding, as it was a secondary outcome, merely an effect 
on the SGRQ impact subscale was also observed in the Glasgow supported self-management trial 
for patients with moderate to severe COPD.29 Also Higginson and colleagues found no effect on 
quality of life from early introduction of a palliative breathlessness support service for patients 
with refractory breathlessness (including COPD), but they did find improved breathlessness 
mastery, a quality of life domain of the Chronic Respiratory Disease Questionnaire.12 In contrast 
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Table 6 Change scores relative to baseline of the primary outcome (SGRQ Total at 3 months) and secondary outcomes 
and associated tests of effects between groups
Outcomes Descriptives 
Intervention
 
Control
Analysis of difference between groups 
for changes over time a
n Mean observed 
change from 
baseline (SD
n Mean observed 
change from 
baseline (SD)
Estimated difference  
(95% CI)
Effect  
size b
p value
SGRQ Total f
3 months 62 -1.84 (12.20) 88 0.20 (12.05) -0.79 (-4.61 to 3.34)  0.17 0.70
6 months 55 -4.66 (12.09) 70 -1.64 (13.11) -2.20 (-6.63 to 2.22)  0.24 0.36
9 months 53 -3.94 (11.34) 69 0.29 (11.90) -4.26 (-8.55 to 0.03)  0.36 0.07
12 months 45 -2.88 (13.14) 63 -0.50 (12.48) -1.70 (-6.71 to 3.32)  0.19 0.54
SGRQ Symptoms f
3 months 72 -4.34 (15.79) 109 -6.78 (20.92) 3.62 (-1.71 to 9.01) -0.13 0.21
6 months 65 -6.17 (17.41) 86 -4.40 (19.77) -0.54 (-6.27 to 5.20)  0.09 0.86
9 months 59 -6.08 (19.88) 85 -6.37 (20.70) -0.47 (-6.78 to 5.85) -0.01 0.89
12 months 53 -5.55 (18.34) 77 -6.88 (20.90) 3.77 (-4.72 to 12.25) -0.07 0.49
SGRQ Activity f
3 months 63 -1.74 (14.88) 91 -0.37 (10.92) 0.31 (-3.40 to 4.01)  0.11 0.87
6 months 57 -2.60 (12.67) 77 -1.78 (12.22) 0.83 (-2.96 to 4.61)  0.07 0.69
9 months 57 -2.03 (11.92) 77 0.17 (11.25) -0.70 (-4.34 to 2.95)  0.19 0.72
12 months 47 -2.45 (12.45) 70 -0.44 (11.86) -2.06 (-6.10 to 1.98)  0.17 0.35
SGRQ Impact f
3 months 73 -2.10 (15.94) 107 0.10 (19.42) -2.69 (-7.62 to 2.24)  0.12 0.31
6 months 63 -5.73 (16.21) 85 0.86 (18.73) -6.22 (-11.73 to -0.71)  0.37 0.04
9 months 59 -4.36 (14.58) 81 1.24 (16.53) -5.30 (-10.71 to 0.11)  0.36 0.07
12 months 51 -1.27 (18.24) 78 0.25 (20.74) -2.78 (-9.49 to 3.93)  0.08 0.45
McGill Total c g
3 months 60 0.08 (1.62) 79 0.13 (1.73) 0.26 (-0.30 to 0.83)  0.03 0.43
6 months 51 -0.04 (1.50) 70 -0.10 (1.59) 0.22 (-0.24 to 0.69) -0.04 0.38
9 months 44 0.05 (1.49) 62 -0.22 (1.56) 0.14 (-0.45 to 0.73) -0.18 0.71
12 months 44 -0.17 ((1.55) 56 -0.23 (1.65) 0.30 (-0.40 to 1.00) -0.04 0.44
HADS Total f
3 months 76 0.22 (6.81) 112 0.27 (6.30) -0.29 (-2.19 to 1.61)  0.01 0.78
6 months 66 0.46 (7.20) 90 0.39 (6.43) -0.28 (-2.39 to 1.83) -0.01 0.81
9 months 62 -0.01 (7.20) 87 0.33 (6.50) -0.49 (-2.92 to 1.94)  0.05 0.71
12 months 55 0.85 (6.99) 81 1.50 (6.62) -1.01 (-3.52 to 1.51)  0.10 0.46
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Readmissions for 
AECOPD (n) 90 1.72 (1.76) 135 1.65 (2.00) -0.08 (-0.39 to 0.23) e  0.04 0.62
Days of readm for 
AECOPD (n) 62 20.27 (18.12) 91 17.57 (14.27) 0.07 (-0.25 to 0.39) d  0.17 0.57
n No (%) n No (%) Adjusted OR (95% CI) p value
Patients who 
made ACP choices
90 69/90 (76.7%) 138 82/138 (59.4%) 3.26 (1.49 to 7.14)  NA 0.003
n No (%) n No (%) Adjusted HR (95% CI) p value
Patients who died 90 20/90 (22.2%) 138 32/138 (23.7%) 0.74 (0.34 to 1.62)  NA 0.45
Notes: Associated tests of effects between groups were estimated by linear mixed models, adjusted for baseline covariates. 
Analyses were by intention-to-treat. Missing data were handled using available case analysis. Descriptive data are mean 
(SD) unless otherwise stated. The ICC’s of the questionnaire outcome measures were all very small near 0 or 0 and 
therefore not displayed. a Associated tests of effects between groups were estimated by linear mixed models, adjusted for 
baseline covariates. b Effect sizes are Cohen’s d, 0.20 is small, 0.50 is moderate, and 0.80 is large.24 c McGill Total score 
was calculated without the McGill physical symptoms subscale. d Because of skewness of distribution a logarithm of the 
variable ‘number of days of readmission for AECOPD’ was used. e Negative binomial regression analysis. f Change score 
interpretation: low score better. g Change score interpretation: high score better.
Abbreviations: ACP, advance care planning; AECOPD, acute exacerbation Chronic Obstructive Pulmonary Disease; 
CI, confidence interval; HADS, Hospital Anxiety and Depression Scale; HR, hazard ratio; ICC, intraclass correlation 
coefficient; McGill, McGill quality of life questionnaire; OR, odds ratio; SD, standard deviation; SGRQ, St George 
Respiratory Questionnaire. 
to patients with cancer in the palliative trajectory, for patients with advanced COPD in the 
palliative trajectory disease oriented care remains necessary until the last weeks of life. It is 
possible that resilience to improve overall quality of life (especially symptoms and activity) is 
exhausted in this patient group, but further research is needed to test this hypothesis.
We did not find a difference in number and length of hospital readmissions. Previous research 
has demonstrated that the frequency of readmissions for an AECOPD is associated with 
functional limitation and poor health-related quality of life.30 The fact that there was no change 
in either of the conditions (SGRQ activity score and SGRQ total) between groups may explain 
our finding. Furthermore, post-discharge mortality is associated with COPD severity as well as 
specific comorbidities, especially cardiac disease.30 More patients in the intervention compared 
to the control condition had severe dyspnea scores and CHF; however, we controlled for these 
confounders and found no difference in 1 year survival between groups.
During ACP conversations, patients are informed about their diagnosis, prognosis, their 
treatment options and treatment consequences. Besides, patients can express their values and 
preferences for life-sustaining treatments with the goal of improving the quality of their end-
of-life care.31 In our study more patients in the intervention condition made ACP choices and 
consequently had ACP conversations during the year. As follow up of patients was too short, 
we were not able to confirm earlier findings that those ACP conversations actually increased the 
quality of end-of-life care.32,33 Further research is needed.
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Our study has strengths and limitations. Although our pragmatic cluster controlled design 
completely ruled out contamination, this design was subject to selection bias at hospital level. 
However, by using outcomes of a pre-trial assessment we were able to control for confounders at 
hospital level. Besides, the small ICCs indicate that differences between hospitals not noteworthy 
contributed to the concerned study outcomes. Next, pulmonologists were aware of treatment 
allocation which may have caused bias. Our baseline data suggest that in the intervention 
condition pulmonologists may have included patients with more advanced COPD since those 
patients would profit from extra support whereas pulmonologists in the control condition may 
have included patients with less advanced COPD in order to not additionally burden more 
vulnerable patients. We used these differences in patients’ baseline characteristics to control 
for confounders at patient level. However, it is unclear whether all important differences 
were taken into account and the true effect may therefore be underestimated in this study. 
Furthermore, attrition is common in long duration trials testing palliative interventions and 
does not necessarily reflect poor design or conduct.34 The proportion of missing data typically 
increases with study duration;34 however our proportion of missing data (28.5% at 3 months) 
was relatively low compared to the weighted estimate for missing data at primary endpoint of 
the palliative interventions (23.1% at 28 days, median time), reported in a systematic review.34 
Nevertheless, the width of 8 of the 95% CI of the primary outcome proved that, if present, 
our study had the power to detect the necessary minimal important difference (MID) of 4.35 
Since the attrition rates in both groups were comparable, the threat to compromise the internal 
validity was minimal.34 We also have no reason to assume that the participating hospitals are not 
representative of other hospitals; consequently, our findings can be generalized to other general 
hospitals.
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Figure 2 Kaplan-Meier plot of survival according to study group. 
Note: The Cox proportional-hazard test showed that survival was not significantly different between the intervention 
and control condition, adjusted HR 0.74 [95% CI 0.34 to 1.62], p=0.45.
Abbreviations: CI, confidence interval; HR, hazard ratio.
CONCLUSION
In this study, proactive palliative care did not improve quality of life of patients with COPD at 3 
months, as measured with the SGRQ. There are several possible reasons for this on identification, 
organization, patient, outcome measure, and disease course levels. Therefore, we recommend 
that future research on the effectiveness of proactive palliative care on quality of life in this 
patient group take our findings into account. However, this study did demonstrate that proactive 
palliative care increased the number of patients that made ACP choices, and we therefore suggest 
that proactive palliative care in COPD should place emphasis on supporting patients through 
ACP conversations to improve their quality of care towards the end of life.32,33
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SUPPLEMENTARY MATERIAL
Table 7 Change scores relative to baseline of McGill and HADS subscales and associated tests of effects between groups.
Outcomes Descriptives 
Intervention
 
Control
Analysis of difference between groups 
for changes over time a
n Mean observed 
change from 
baseline (SD)
n Mean observed 
change from 
baseline (SD)
Estimated difference 
(95% CI)
Effect 
size b
p value
McGillc physical well-being
3 months 61 0.15 (2.95) 85 0.72 (2.87) 0.15 (-0.64 to 0.95) -0.21 0.72
6 months 52 -0.35 (2.60) 73 -0.37 (2.88) 0.54 (-0·16 to 1.23) 0.01 0.16
9 months 47 0.43 (2.94) 64 -0.39 (2.75) 0.69 (-0.13 to 1.51) 0.29 0.13
12 months 44 -0.16 (2.82) 59 0.08 (2.97) -0.14 (-1.22 to 0.93) -0.08 0.82
McGillc physical symptoms
3 months 34 0.65 (2.50) 39 -0.03 (2.32) 0.66 (-0.37 to 1.68) 0.28 0.27
6 months 28 0.57 (2.20) 37 -0.03 (2.42) 1.09 (0.08 to 2.11) 0.26 0.12
9 months 30 0.69 (2.91) 37 -0.41 (2.52) 0.97 (-0.05 to 1.99) 0.41 0.11
12 months 24 -0.19 (2.15) 32 -0.57 (2.46) -0.13 (-1.20 to 0.82) 0.16 0.85
McGillc psychological
3 months 73 0.21 (2·82) 110 0.33 (2.67) -0.01 (-0.79 to 0.76) -0.04 0.97
6 months 66 0.16 (2·97) 91 0.23 (2.70) 0.15 (-0.70 to 0.99) -0.02 0.77
9 months 61 0.38 (2·43) 87 0.09 (2.64) 0.35 (-0.49 to 1.20) 0.11 0.44
12 months 55 0.27 (2·18) 80 -0.17 (2.95) 0.49 (-0.38 to 1.37) 0.17 0.30
McGillc existential
3 months 75 0.37 (1.75) 111 0.24 (2.29) 0.36 (-0.22 to 0.95) 0.06 0.27
6 months 67 0.29 (1.61) 92 0.38 (2.17) -0.01 (-0.52 to 0.49) -0.05 0.99
9 months 63 0.08 (2.03) 89 0.14 (2.18) -0.26 (-0.96 to 0.45) -0.03 0.58
12 months 55 0.08 (2.18) 82 -0.01 (2.21) 0.03 (-0.70 to 0.75) 0.04 0.94
McGillc support
3 months 73 -0.48 (1.96) 104 -0.63 (2.46) 0.37 (-0.27 to 1.01) 0.07 0.28
6 months 65 -0.93 (2.32) 89 -0.36 (2.17) -0.34 (-1.01 to 0.32) -0.26 0.39
9 months 59 -0.63 (1.97) 86 -0.98 (2.29) 0.21(-0.50 to 0.93) 0.16 0.58
12 months 53 -0.66 (2.25) 78 -0.99 (2.10) 0.52 (-0.25 to 1.28) 0.15 0.21
HADSd anxiety
3 months 76 -0.29 (4.03) 111 -0.27 (3.77) -0.12 (-1.21 to 0.97) -0.01 0.83
6 months 66 -0.46 (4.35) 90 -0.52 (3.75) 0.02 (-1.26 to 1.29) 0.01 0.98
9 months 62 -1.23(4.29) 87 -0.26 (3.79) -0.65 (-2.11 to 0.81) -0.24 0.41
12 months 55 -0.38 (4.34) 81 0.17 (3.82) -0.12 (-1.55 to 1.32) -0.14 0.88
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HADSd depression
3 months 76 0.51 (3.65) 111 0.53 (3.59) -0.25 (-1.33 to 0.83) -0.01 0.66
6 months 66 0.91 (3.83) 89 0.90 (3.67) -0.30 (-1.43 to 0.82) 0.00 0.61
9 months 62 1.20 (3.91) 87 0.59 (3.55) 0.15 (-1.11 to 1.41) 0.16 0.82
12 months 55 1.21 (3.88) 80 1.20 (3.79) -0.78 (-2.30 to 0.74) 0.00 0.42
Notes: Associated tests of effects between groups were estimated by linear mixed models, adjusted for baseline covariates. 
Analyses were by intention-to-treat. Missing data were handled using available case analysis. Descriptive data are mean 
(SD) unless otherwise stated. The ICC’s of the questionnaire outcome measures were all very small near 0 or 0 and 
therefore not displayed. a Associated tests of effect between groups were estimated by linear mixed models, adjusted 
for baseline covariates. b Effect sizes are Cohen’s d, 0·20 is small, 0·50 is moderate, and 0·80 is large. c Change score 
interpretation high score better. d Change score interpretation: low score better. 
Abbreviations: CI, confidence interval; HADS, Hospital Anxiety and Depression Scale; ICC, intraclass correlation 
coefficient; McGill, McGill Quality of Life Questionnaire; SD, standard deviation.
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ABSTRACT
Background: Our objective was to develop a tool to identify patients with COPD for proactive 
palliative care. Since palliative care needs increase during the disease course of COPD, the 
prediction of mortality within 1 year, measured during hospitalizations for acute exacerbation 
COPD (AECOPD), was used as a proxy for need of proactive palliative care.
Patients and methods: Patients were recruited in three general hospitals in the Netherlands in 
2014. Data of 11 potential predictors, a priori selected based on literature, were collected during 
hospitalization for AECOPD. After 1 year the medical files were explored for date of death. An 
optimal prediction model was assessed by Lasso logistic regression, with 20-fold cross validation 
for optimal shrinkage. Missing data were handled using complete case analysis.
Results: Of 174 patients 155 patients were included; of those 30 (19·4%) died within 1 year. The 
optimal prediction model was internally validated and had good discriminating power (AUC = 
0·82, 95% CI 0·81 to 0·82). This model relied on seven predictors: the surprise question, Medical 
Research Council dyspnea questionnaire (MRC dyspnea), Clinical COPD Questionnaire (CCQ), 
FEV
1
% of predicted value, Body Mass Index (BMI), previous hospitalizations for AECOPD, 
and specific co-morbidities. To ensure minimal miss out of patients in need of proactive palliative 
care we proposed a cut-off in the model that prioritized sensitivity over specificity (respectively 
0·90 over 0·73). Our model (ProPal-COPD tool) was a stronger predictor of mortality within 
1 year than the CODEX (comorbidity, age, obstruction, dyspnea and previous exacerbations) 
index.
Conclusion: The ProPal-COPD tool is a promising multivariable prediction tool to identify 
patients with COPD for proactive palliative care.
Keywords: COPD, Exacerbation, Proactive palliative care, Prognosis, Mortality
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INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is a progressive life threatening lung disease.1 
During the disease course the need for disease-oriented care remains unchanged while the need 
for proactive palliative care increases for patients with COPD.2 Proactive palliative care which 
includes Advance Care Planning (ACP) conversations is intended to improve quality of life 
and quality of care.3,4 However, for patients with COPD such care is not yet common.2,5 An 
important barrier is the identification of patients with COPD who might benefit from proactive 
palliative care.2
Identification for proactive palliative care is complicated by the unpredictable disease course of 
COPD.6 Stable phases in the disease course are interrupted by acute exacerbations; any one of 
which may be fatal.6 Although, general tools to identify patients for palliative care exist, they are 
not specifically intended or validated for identification of patients with COPD.7,8 In addition, 
models of survival in stable COPD have been developed to be able to adjust and optimize care.9,10 
Unfortunately, these population models are of limited value to predict survival for individual 
patients.11 This prognostic difficulty has led to a discussion among clinicians whether or not 
a transition point for the initiation of proactive palliative care exists.12-15 Some clinicians argue 
that more specific criteria of end stage COPD need to be explored.13 Others argue that, since 
such criteria may not exist, searching further may lead to prognostic paralysis.14,15 Instead, they 
promote early integration of palliative care according to needs.15 The focus in this discussion has 
been on whether or not we can accurately predict mortality instead of the intended objective; 
identifying patients with COPD in need of proactive palliative care. Since palliative care needs 
increase during the disease course of COPD,2 the prediction of mortality can be used as a proxy 
for the need of palliative care. To ensure minimal miss out of patients in need of such care, this 
tool should have a sensitivity near 100 with a high as possible specificity.
Hospitalizations for an acute exacerbation COPD (AECOPD) are associated with significant 
mortality and therefore create an opportunity to identify patients with poor prognosis in need 
of palliative care 16. Recently potential relevant variables have been identified to predict post-
hospital mortality in patients hospitalized for an AECOPD.16,17 This is the first prospective study 
to incorporated these variables with the objective to develop a multivariable prediction tool (the 
ProPal-COPD tool) to identify patients with COPD in need of proactive palliative care. Our 
objective was to assess the discriminating power of a set of indicators for proactive palliative 
care in predicting death for any cause within 1 year. This outcome was used as a proxy for the 
potential need of proactive palliative care in patients with COPD.
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PATIENTS AND METHODS
Source of data
Data for prognostic accuracy testing in patients hospitalized for an AECOPD were obtained 
from the PROLONG study.18 This prospective pragmatic cluster controlled trial was performed 
in six general hospitals in the Netherlands of which three were in the intervention and three in the 
control condition. All recruited patients hospitalized for an AECOPD received usual care while 
only patients in the intervention condition with poor prognosis additionally received proactive 
palliative care. In this trial poor prognosis was defined as meeting two or more predictors of a set 
of 11 predictors of poor prognosis. For the prognostic accuracy study, described in this study, we 
only used data of those patients recruited in the three hospitals in the control condition.
Participants
We screened for potential participants in three general hospitals in the Netherlands from Jan 
14, 2014 to Dec 29, 2014. All patients with the clinical diagnosis COPD, hospitalized for an 
AECOPD who were 18 years or older were eligible. An AECOPD was defined as ‘an acute 
worsening of the patient’s condition from the stable state, which is sustained and may warrant 
the patient to seek additional treatment’.19 Since the severity of airway obstruction and spectrum 
of pathogens in pneumonic and non-pneumonic exacerbations are similar,20 patients with 
COPD who had been hospitalized for an acute pneumonia accompanied by increased sputum 
and dyspnea, were also included. Patients who did not speak Dutch or had a severe cognitive 
disorder were excluded from participation. All patients received usual care for an AECOPD and 
the period thereafter.
The study was approved by the Medical Ethics Committee (METC) of the Radboud University 
Medical Center, Nijmegen (METC protocol number 2012/260). Thereafter we requested and 
received research approval in all three participating hospitals. All participants gave written 
informed consent before enrolment. 
Outcome
The outcome measure was death for any cause within 1 year. This outcome measure was used as 
a proxy for the potential need of proactive palliative care. To ensure minimal miss out of patients 
in need of such care, we were looking for a tool with a sensitivity near 100% and an as high as 
possible specificity.
Predictors
All 11 predictors are presented in Table 1. Each of them is a categorical variable indicating whether 
or not the participant meets the specific criteria for this predictor. References with the rationale to 
include the predictor in the multivariable prediction model are also presented in Table 1. Patients 
filled out demographics, the Medical Research Council dyspnea questionnaire (MRC dyspnea) and 
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the Clinical COPD Questionnaire (CCQ) on the sixth day of hospital stay or in case the patient 
was discharged earlier on the day before leaving the hospital. The MRC dyspnea is a questionnaire 
used for grading the effect of breathlessness on daily activities.27 The patient’s dyspnea score is rated 
from 1 to 5, and higher scores represent a more severe dyspnea. The patient was asked to rate the 
dyspnea severity as it was two weeks before hospital admission. The CCQ day version was used 
to measure health status of patients.28 The CCQ consists of 10 questions covering three domains 
(symptoms, functional status and mental state). The maximum total CCQ score is 6 and higher 
scores represent a worse health status. The treating pulmonologist thereafter filled out a checklist 
consisting of the remaining nine predictors. A year after the last patient was included the medical 
files of all participants were explored. Variables looked for were: if applicable, date of death and 
missing scores of predictors on the checklist. In case of uncertainty about death and/or date of death 
we contacted the general practitioner (GP) of the patient for information.
Sample size
In this prospective study we included all eligible patients willing to participate during the year 
2014 to maximize the power and generalizability of the results. 
Table 1 Set of 11 predictors of poor prognosis for patients hospitalized for an AECOPD and the references with the 
rational to include them in the prediction model
Predictors of poor prognosis References
1. Hypoxaemia (PaO2 < 8 kPa) or hypercapnia (PaCO2 > 6 kPa) at discharge 16,17
2. Treatment of the exacerbation with Non Invasive Ventilation (NIV) 21
3. Patient needs professional home care service for personal care after discharge 22
4. Negative answer to the surprise question: 
‘Would I (as pulmonologist) be surprised if this patient would die in the next year?
23
5. The diagnosis of a severe co-morbidity such as: 
a.   Non-curable malignancy or
b.   Cor pulmonale (proven or non proven) or 
c.   Proven CHF or 
d.   Diabetes mellitus with neuropathy or 
e.   Renal failure, clearance < 40 (GFR: in ml/min)
17,24
16
16,17
16,17
16,17
6. CCQ total, day version > 3 25
7. MRC dyspnea = 5 16,26
8. FEV1 (measured before AECOPD) < 30% of predicted 16,17
9. BMI < 21 or unplanned weight loss (> 10% in last 6 months or > 5% in last month) 16,17
10. Previous hospital admissions for AECOPD (last 2 years > 2 and/or last year > 1) 16
11. Age > 70 years 16,17
Notes: PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen.
Abbreviations: AECOPD, acute exacerbation Chronic Obstructive Pulmonary Disease; BMI, body mass index; 
CCQ, Clinical COPD Questionnaire; CHF, Chronic Heart Failure, FEV1, forced expiratory volume in 1 second; 
GRF, glomerular filtration rate; MRC dyspnea, Medical Research Council dyspnea questionnaire; NIV, non invasive 
ventilation.
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Missing data
Missing data were handled using complete-case analysis. Participant data were excluded from 
the analysis if a participant had missing information on any of the potential predictors. Possible 
reasons for missing data were a not or incomplete filled out questionnaire by the patient and/or 
an incomplete filled out checklist by the pulmonologist.
Statistical analyses
Baseline characteristics were described using frequencies for non-continuous data, means 
with standard deviation (SD) for continuous variables normally distributed and median with 
interquartile range (IQR) for continuous variables not normally distributed. The analysis plan 
consisted of two steps. The first step had a descriptive nature and was aimed at exploring the 
discriminating power of individual predictors in predicting death for any cause within 1 year. For 
all eleven predictors the area under the curve (AUC), sensitivity and specificity were calculated. 
The goal of the second step was to build an optimal prediction model and to assess its predictive 
performance using internal validation. The model was build using a Least absolute shrinkage 
and selection operator (Lasso) logistic regression model, with 20-fold cross validation for optimal 
shrinkage.29,30 By using the Lasso method, the risk of over-fitting was reduced, and at the same 
time a relatively simple prediction model was obtained. Because the performance of our optimal 
prediction model was validated in the same population used to construct it, its predictive 
performance was overestimated (“optimism”). To estimate this optimism, the procedure 
proposed by Steyerberg was followed.30 In short, using bootstrapping 500 new populations were 
created, and a prediction model was built for each population in a completely analogous way. 
The predictive performance of the model, as expressed by the AUC in both the bootstrapped 
population as well as in the original population was calculated. The mean difference between 
these two AUC values is an estimate of the optimism of our prediction model.
Risk groups
No risk groups were created.
RESULTS
Participants
The participant flow diagram is presented in Figure 1. Of all 174 participants , 155 participants 
were included in the analyses. The characteristics of the study populations are presented in Table 2.
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135 Pt assessed172 Pt assessed99 Pt assessed
Total 406 Pt assessed for eligibility
Hospital 3Hospital 2Hospital 1
60 Pt analysed53 Pt analysed42 Pt analysed
Total 155 Pt analysed 
65 Pt considered64 Pt considered45 Pt considered
Total 174 Pt considered
48 (17, 0, 31) Pt met exclusion criteria
1 (0, 1, 0) Pt died before consenting
183 (37, 107, 39) Pt refused
5 (1, 2, 2) Pt took part in other COPD 
related studies since inclusion date
1 (1, 0, 0) Pt had a lung transplant
13 (1, 9, 3) Pt had missing data
 Figure 1 Participant flow diagram.
Abbreviation: Pt, patient.
Model development
The numbers of participants that met the criteria of each predictor are presented in Table 2. In 
the study population 19.4% of the participants (30 of 155) died within 1 year.
The discriminating power of individual predictors in predicting death within 1 year is presented 
in Table 3.
Model specification and performance
The optimal prediction model, build using the Lasso method, and its predictive performance is 
presented in Table 4. This logistic regression model includes an intercept and the weighted sum 
of the value of each predictor. The weights are the regression coefficients (B). The value of each 
predictor is 1 when present and 0 when absent. 
A patient can be considered as in need of proactive palliative care when the total sum of the 
logistic regression models exceeds a certain cut-off point of the model. The choice of this cut-off 
is essentially a trade-off between sensitivity and specificity. A popular choice is to choose the cut-
off that considers sensitivity and specificity to be of equal importance, so maximizing the sum 
of sensitivity and specificity. In the setting of this study a cut-off that prioritizes sensitivity above 
specificity does make sense. Therefore, we also present the cut-off that maximizes the sum of 
specificity and 1.5 times the sensitivity. Possible cut-offs for both choices are presented in Table 5.
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The receiver operating characteristic (ROC) curve for prediction of death within 1 year with the 
optimal cut-offs considering different trade-offs between sensitivity and specificity are presented 
in Figure 2.
Table 2 Characteristics of the study population
Study population (N = 155)
Characteristics Mean (+SD)
Age 67.5 (+9.6)
Pack years (N = 148) 36.4 (+32.8)
N (%)
Sex
Male 68 (43.9)
Marital status*
Married 110 (71.0)
Unmarried 11 (7.1)
Divorced 13 (8.4)
Widow 18 (11.6)
Condition of living*
Single 34 (21.9)
Non single 111 (71.6)
Place of living*
Home, independent of homecare
Home, dependent of homecare
103
45
(66.5)
(29.0)
Residential home 2 (1.3)
Highest level of education*
No education
Elementary school
Secondary school
Primary education
Secondary education
Higher/University education
1
21
47
35
29
15
(0.6)
(13.5)
(30.3)
(22.6)
(18.7)
(9.7)
Gold stage*
0 8 (5.2)
I 10 (6.5)
II 41 (26.5)
III 52 (33.5)
IV 36 (23.2)
516939-L-bw-duenk
Processed on: 13-2-2018 PDF page: 123
DEVELOPMENT OF THE PROPAL-COPD TOOL
123
6
Predictors
Hypoxaemia or hypercapnia 62 (40.0)
NIV 11 (7.1)
Professional home care 50 (32.3)
Negative answer SQ 76 (49.0)
Co-morbidity 31 (20.0)
CCQ total, day version > 3 96 (61.9)
MRC dyspnea = 5 71 (45.8)
FEV1 < 30% of predicted 45 (29.0)
BMI < 21 or weight loss 26 (16.8)
Prev. hosp. AECOPD 62 (40.0)
Age > 70 years 62 (40.0)
Notes: *Because of missing values some numbers do not add up to 100%.  GOLD stage according to last known data 
in medical file; inclusion in the study was based on the judgment by pulmonologist.
Abbreviations: AECOPD, acute exacerbation Chronic Obstructive Pulmonary Disease; BMI, body mass index; CCQ, 
Clinical COPD Questionnaire; FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease; MRC dyspnea, Medical Research Council dyspnea questionnaire; NIV, non invasive 
ventilation; Prev. hosp., previous hospitalization; SQ, surprise question.
DISCUSSION
This study shows that we were able to develop a promising multivariable prediction tool to identify 
patients with COPD in need of proactive palliative care, the ProPal-COPD tool. Since palliative 
care needs increase during the disease course,2 and hospitalizations for AECOPD are associated 
with significant mortality risk,16 these hospitalizations create an opportunity for identification. 
This is why the prediction of death was used as a proxy for identification of patients in need of 
palliative care. In our study population 19.4% of participants died within 1 year. This number 
is in line with the 1 year mortality rate in other studies investigating patients hospitalized for 
AECOPD.31,32 Our optimal prediction model of death within 1 year had good discriminating 
power; the true AUC was 0.82 (95% CI 0.81 to 0.82), and the estimated optimism of 0.05 
indicated good internal validity. To ensure minimal miss out of patients in need of palliative care 
we propose a cut-off in the prediction model that prioritizes sensitivity above specificity. This 
optimal cut-off was -1.36, with a sensitivity of 0.90 and a specificity of 0.73. This implies that, 
when used, only 10% of patients in need of palliative care would be missed out and that of all 
patients identified for such care 84% would die within 1 year.
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Table 3 The discriminating power of individual predictors in predicting death within 1 year
Predictor Se Sp AUC
Hypoxaemia or hypercapnia 0.53 0.63 0.583
NIV 0.93 0.07 0.503
Professional home care 0.47 0.71 0.589
Negative answer SQ 0.80 0.58 0.692
Co-morbidity 0.43 0.86 0.645
CCQ total, day version > 3 0.83 0.43 0.633
MRC dyspnea = 5 0.80 0.62 0.712
FEV1 < 30% of predicted 0.43 0.64 0.589
BMI < 21 or weight loss 0.33 0.87 0.603
Prev. hosp. AECOPD 0.60 0.65 0.624
Age > 70 years 0.43 0.61 0.521
Note: Study population (N=155).
Abbreviations: AECOPD, acute exacerbation Chronic Obstructive Pulmonary Disease; AUC, area under the curve; 
BMI, body mass index; CCQ, Clinical COPD Questionnaire; FEV1, forced expiratory volume in 1 second; MRC 
dyspnea, Medical Research Council dyspnea questionnaire; NIV, non invasive ventilation; Prev. hosp., previous 
hospitalization; Se., sensitivity; Sp., specificity; SQ, surprise question. 
The ProPal-COPD tool is the first which is using specific predictors of mortality during AECOPD 
requiring hospitalizations. This tool relies on seven predictors: the surprise question (a general 
predictor), five markers of COPD severity, and the presence of specific co-morbidities proven 
to independently predict post-hospital mortality in AECOPD.24 Through the surprise question 
the tool incorporates clinical judgment of severity. The surprise question has shown to be a 
proven predictor of mortality in patients with advanced chronic diseases,33 and is recommended 
to be used in combination with other disease-specific predictors as screening tool for proactive 
palliative care.23 Those disease-specific predictors in the ProPal-COPD tool are five markers of 
COPD severity being; the CCQ (health status), MRC dyspnea, FEV
1
% of predicted value, BMI, 
and previous hospitalizations for an AECOPD. The presence of either one of the following co-
morbidities, non-curable malignancy, cor pulmonale, Chronic Heart Failure (CHF), diabetes 
mellitus with neuropathy or renal failure, is also incorporated in our tool. These co-morbidities, 
except non-curable malignancy, are conditions liable to acute decompensation especially during 
AECOPD, which may explain their association with an increased mortality risk.16
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Table 4 Optimal prediction model and its predictive performance of death within 1 year
Predictors in model B AUC True AUC 95%CI
(Intercept) -3.901
0.870 0.818 0.813 – 0.824
Hypoxaemia or hypercapnia ̷
NIV ̷
Professional home care ̷
Negative answer SQ 0.959
Co-morbidity 1.479
CCQ total, day version > 3 0.257
MRC dyspnea = 5 1.475
FEV1 < 30% of predicted 0.565
BMI < 21 or weight loss 1.005
Prev. Hosp. AECOPD 0.102
Age > 70 years ̷
Notes: Study population (N=155). B, weight in the model;  ̷ , not incorporated in the optimal prediction model.
Abbreviations: AECOPD, acute exacerbation Chronic Obstructive Pulmonary Disease, AUC, area under the curve; 
BMI, body mass index; CCQ, Clinical COPD Questionnaire; CI, confidence interval; FEV1, forced expiratory volume 
in 1 second; MRC dyspnea, Medical Research Council dyspnea questionnaire; NIV, noninvasive ventilation; Prev. hosp., 
previous hospitalization; SQ, surprise question.
Table 5 Possible cut-offs considering different trade-offs between sensitivity and specificity of the optimal prediction model
Cut-off Sensitivity Specificity Se + Sp 1.5 Se + Sp
-1.105 0.800 0.840 1.640 2.040
-2.896 0.967 0.328 1.295 1.778
-2.169 0.933 0.504 1.437 1.904
-1.362 0.900 0.728 1.628 2.078
Abbreviations: Se, sensitivity; Sp, specificity.
Most predictors of the ProPal-COPD tool are variables already used in clinical practice and do 
not need extra measurement.34 Only the surprise question, the CCQ and MRC dyspnea, which 
are short easy to use questionnaires, are often not documented and need to be specifically asked 
for.34 Besides, each predictor in our tool has an own weight (B). Those weights take into account 
the correlation with other predictors of the tool and therefore should not be interpreted as the 
individual importance of each predictor in the tool. Moreover, the Lasso method used for model 
development is looking for the most efficient model.30 In the trade-off between efficiency and 
effectiveness four predictors (hypoxaemia or hypercapnia, NIV, professional home care and age) 
were excluded from our optimal prediction model. This does not mean that those predictors 
were not predictive of death within 1 year. If we look at the predictor NIV, for example, it was 
noticeable that only 11 patients met the criteria of this predictor. Besides, NIV as an individual 
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predictor had high sensitivity (0.93) and low specificity (0.07), meaning that almost all patients 
who were treated with NIV died within 1 year but patient who were not treated with NIV also 
had a considerable risk of dying. The exclusion of the predictor NIV can therefore be explained 
by the limited number of patients involved and the high correlation with predictors incorporated 
in our optimal prediction model. The other three predictors, hypoxaemia or hypercapnia, 
professional home care and age, were merely excluded because of correlation.
The ProPal-COPD tool shows promise for identification of patient with COPD in need of 
proactive palliative care. The ROC analysis suggests that it has good prognostic performance 
with a prognostic capacity superior to the CODEX index (co-morbidity, age, obstruction, 
dyspnea and previous exacerbations). 35 The CODEX index has an AUC of 0.68 in predicting 
death within 1 year and is the only other multivariable model developed to evaluate post-hospital 
prognosis in patients with an AECOPD.35 However, the main objective of both tools is different. 
Our tool was developed to identify patients in need of proactive palliative care whereas the 
CODEX was developed to predict mortality and/or readmissions. In addition there are several 
substantive differences. First, our tool incorporates disease specific predictors of mortality in 
AECOPD requiring hospitalization, whereas the CODEX index was developed using disease 
specific predictors of mortality in stable COPD. Second, our tool contains specific co-morbidities 
proven to independently predict post-hospital mortality in AECOPD, whereas the evidence of 
the Charlson index (co-morbidity burden) used in the CODEX index in predicting post-hospital 
mortality in AECOPD is less consistent.16 Finally, each predictor in our tool has an own weight 
(B) in contrast to the predictors in the CODEX index. Those weights do not represent the 
individual importance of each predictor since they take into account the correlation with other 
predictors in the tool. Still, the own contribution of each predictor is better represented in our 
tool. It is possible that the above mentioned substantive differences between the ProPal tool and 
the CODEX index have contributed to the better prognostic performance of our tool.
Our study had several limitations that should be acknowledged. First, predicting post hospital 
mortality for patients with COPD is complex and this is reflected by the number of potential 
predictors incorporated in the original set of predictors. We only used already known predictors 
in this set and it is uncertain if all possible predictors were accounted for. In addition it is possible 
that certain predictors were underrepresented in the set of potential predictors. Anxiety and 
depression for example were represented as a subscale of the predictor CCQ. Second, to facilitate 
implementation in clinical practice we used dichotomized variables. Each potential predictor was 
given a clinical cut-off value based on literature. Such dichotomization of continuous predictors 
may lead to loss of information and reduction of power.36 Third. the use of the ProPal-COPD 
tool may require collection of data that are not always captured routinely (surprise question, 
CCQ, MRC dyspnea). Fourth, the ProPal-COPD tool was developed in the Netherlands. 
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Figure 2 The ROC curve for prediction of death within 1 year with the optimal cut-offs considering different trade-offs 
between sensitivity and specificity.
Abbreviations: ROC, receiver operating characteristic; se, sensitivity; sp, specificity.
International differences in hospital admission policy for patients with an AECOPD may 
affect the usefulness in other countries. Fifth, it is unknown whether the ProPal-COPD tool 
is also applicable in academic hospitals since it was developed using a population of patients in 
general hospitals. Finally, the ProPal-COPD tool was developed in a single population without 
validation in a different one. The external validity of our findings is therefore unknown and needs 
to be addressed in further research. Hence, other participant data need to be collected in a new 
prospective study performed in general and/or academic hospitals to evaluate the performance 
of the ProPal-COPD tool.
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CONCLUSION
The ProPal-COPD tool is a promising tool to identify patients with COPD for proactive palliative 
care with good discriminating power (AUC = 0.82). It relies on seven predictors; the surprise 
question (a general predictor), five markers of COPD severity, and the presence of specific co-
morbidities. The prediction of death within 1 year was used as a proxy for the potential need of 
proactive palliative care. To ensure minimal miss out of patients in need of proactive palliative 
care we propose a cut-off in the prediction model that prioritizes sensitivity over specificity. This 
optimal cut-off has a sensitivity of 0.90 and a specificity of 0.73. Each predictor in the tool has 
an own weight and only when the total sum of the model exceeds the specific cut-off point the 
patient can be considered in need of proactive palliative care. This prognostic equation can be 
easily integrated in the Electronic Patient Record (EPR) system. However, before clinical use of 
the ProPal-COPD tool the external validity should be addressed in further research.
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Dear Editor
We read with interest the recent article of Duenk et al. entitled “Development of the ProPal-
COPD tool to identify patients with COPD for proactive palliative care” recently published in 
the International Journal of COPD.1 We fully agree with the authors on the capital importance 
of proactive palliative care (PPC) in COPD, as well as its underutilization. Any article that 
contributes to bettering knowledge of PCC and its use with COPD patients who can benefit 
from it is to be celebrated. We also agree with the authors on the unpredictability of prognosis in 
COPD, especially the uncertain evolution of severe exacerbations and the impact of comorbidities. 
We believe that the article deserves some considerations. First and most important, in our 
opinion PPC should not be limited to the terminal phase of chronic diseases such as COPD; 
it can be delivered alongside standard therapies, according to the needs and preferences of 
patients regardless of the risk of death in the short or medium term. Obviously, this does not 
mean that prognostic prediction scales are not useful in prognosis prediction. Nevertheless, its 
exclusive use may exclude many patients who could benefit from PPC.2 For instance, in the 
model proposed by Duenk et al. seven dichotomic predictor variables were suggested to consider 
PPC based on their relationship with 1-year mortality. However, it seems clear that a COPD 
patient with severe airflow obstruction, disabling dyspnea and several previous hospitalizations, 
although strictly not meeting all the recommended criteria, is a candidate for PPC. In this patient 
PCC includes advanced care planning conversations, with their perspectives in case of a poor 
evolution in future exacerbations and preferences concerning the ceiling of treatment such as 
cardiopulmonary resuscitation, admission to the intensive care unit and invasive mechanical 
ventilation. Additionally, pharmacological and non-pharmacological measures for dyspnea or 
others symptom treatment should be considered and discussed with the patient. In this example, 
the onset of these measures should be independent of other predictor variables and of foreseeable 
life expectancy. Of note, PPC measures by themselves do not shorten life, but may be associated 
with increased survival.3 
Second, from a strictly methodological point of view, we cannot forget that the model is built 
from just 30 positive patients. Even by using most sophisticated statistical procedures we still 
having little information about the general behavior of this population and this is a strong 
limitation moreover due to the relevance of the topic and the final decisions taken. Additionally, 
all prognosis models must be validated in a different external cohort, to avoid the risk of 
overestimation inherent in development cohorts. In the present study only internal validation 
was performed. Finally, the exclusive use of the ROC curves and AUC for 1-year mortality 
limits consideration to the vital status of the patient 1 year after discharge, regardless of the time 
of death, and clearly survival time is relevant in this population. Cox regression analysis and 
Kaplan-Meier curves comparing patients with and without criteria would be of help to further 
clarify the results.
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Dear Editor
We thank Dr Almagro and Dr Martinez Camblor for their letter to the editor in response to our 
manuscript entitled “Development of the ProPal-COPD tool to identify patients with COPD 
for proactive palliative care”.1 We are pleased that both authors agree with us on the importance 
of proactive palliative care (PPC) in COPD as well as its underutilization in this patient group. 
We also fully support their view that PPC should not be limited to the terminal phase of chronic 
diseases such as COPD, but that it can be delivered alongside standard therapies, according to 
the needs and preferences of patients.
The authors’ main concern with respect to our recent article was about the exclusive use of 
prognosis prediction of mortality for the start of PPC in COPD. They worried that patients 
in need of PCC would be missed out, because a recent review showed that existing prognostic 
criteria were not sufficiently reliable.2 However, as mentioned in our manuscript, prediction of 
mortality or identification of the terminal phase was never our objective. Our actual objective 
was to develop a tool as additional aid to identify patients with COPD in need of PPC. Since 
palliative care needs increase during the disease course of COPD,3 we merely used the prediction 
of one year mortality as a proxy for the need of PPC. Moreover, to ensure minimal miss out of 
patients in need of PCC we looked for and also managed to develop a tool with a high sensitivity 
(0.90) and a high as possible specificity (0.73), while ensuring good discriminating power (AUC 
= 0·82, 95% CI 0·81 to 0·82).
Not all seven dichotomic criteria of the ProPal-COPD tool need to be fulfilled to be eligible for 
PPC, as suggested by the authors. Each criterion has an own weight and when the total sum of 
the model exceeds the specific cut-off point the patient can be considered in need of PPC. This 
means that different combinations of a few or more criteria may be indicative for the need of 
PPC. Of course, as also mentioned in our manuscript, before clinical use of the ProPal-COPD 
tool the external validity should be addressed in further research. This will be done in a nation-
wide project in the Netherlands.
PPC in COPD, which includes advance care planning (ACP) conversations, still hardly takes 
place although the need for PPC in this patient group has been recognized. This is not only 
due to the unpredictable disease course but also to the fact that both patients and physicians 
encounter barriers to initiate such conversations.4 A recent study examining the quality of 
ACP conversations in patients with advanced chronic organ failure suggests that facilitation of 
initiation of ACP conversations is the key to improve PPC. It seems that otherwise, even when 
the disease progresses, needs and preferences of patients are hardly being explored.4 Therefore, 
we believe that the development of the ProPal-COPD tool, for initiation of PPC in COPD, 
responds to the need of patients and physicians.5
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Patients with advanced COPD have a high symptom burden and poor quality of life.1,2 Towards 
the end of their lives most of them prefer a treatment with an emphasis on comfort rather than 
life prolongation but this kind of care is not common practice.3 Research even showed that 
referrals to palliative care were less likely for patients with COPD (20%) than for patients with 
cancer (60%), dementia (37%) or heart failure (34%).4 However, in the past decade the need for 
palliative care in this patient group has been recognized.5 Although the benefits of a proactive 
approach to palliative care on symptom burden and quality of life have been proven in other 
diseases,6-10 little research has been performed to demonstrate its benefits in COPD.11
The disease trajectory of COPD is unpredictable with a gradual functional decline punctuated by 
acute severe exacerbations any one of which may be fatal.12-14 This unpredictable course hinders 
the timely identification of patients with COPD requiring palliative care, and compromises the 
continuity of palliative care because of the different healthcare professionals involved during the 
acute and stable phases of the disease.5,15,16 Timely identification of patients requiring palliative 
care not only enables a proactive approach but also facilitates initiation of advance care planning 
(ACP) conversations as well as promotes communication between healthcare professionals 
necessary to ensure the continuity of proactive palliative care delivery.5,17 Nevertheless, it has not 
yet been determined how to identify patients with COPD in need of proactive palliative care 
and how to organize such a coordinated healthcare plan.18,19 Since pulmonologists have a central 
role in COPD management their view on this subject is important.20 Therefore, the objectives of 
this thesis were: to explore the views, needs, and wishes of pulmonologists concerning proactive 
palliative care for patients with COPD; to examine the effectiveness of proactive palliative care 
on the wellbeing of patients with COPD; and to examine the identification of patients with 
COPD for proactive palliative care.
In this chapter the main findings and methodological considerations of these studies are discussed 
and put into a broader perspective. I will also present recommendations for clinical practice, 
education and research in order to move towards the use of proactive palliative care for patients 
with COPD.
THE VIEW OF PULMONOLOGISTS
A survey study (Chapter 2) was performed to gain insights into the view of pulmonologists in the 
Netherlands regarding: 1) palliative care for patients with COPD in general; 2) the identification 
of patients with COPD for palliative care; 3) important aspects of palliative care for patients with 
COPD; and 4) the organization of palliative care for patients with COPD. 
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Almost all pulmonologists considered palliative care for patients with COPD to be desirable. 
In 2010, the Lung Alliance Netherland (LAN), the Dutch society for chronic lung diseases, 
developed a clinical guideline on palliative care for people with COPD, to ensure that the 
best available evidence would be translated into everyday clinical practice.21 About half of the 
pulmonologists did not use this guideline, most often because they were unaware of its existence. 
This is cause for concern since limited awareness and the resulting low adherence to clinical 
guidelines may result in potential suboptimal healthcare.22 In general, adherence to COPD 
guidelines is sub-optimal and barriers have been identified.22 Understanding these barriers may 
help with the optimization of strategies to ensure the better use of the clinical guideline on 
palliative care for people with COPD.
COPD is a chronic progressive life-threatening disease. Patients experience a gradual functional 
decline punctuated by acute severe exacerbations during which disease-oriented care remains 
necessary and the need for palliative care gradually increases.11,12 A clearly marked transition 
from disease-oriented care to palliative care is not present in COPD, leading some clinicians 
to argue that a palliative phase may not exist for this disease.23,24 Nevertheless, the majority of 
pulmonologists in our study (92.2%) indicated that they do distinguish a palliative phase in the 
COPD trajectory. 
At the time we performed our survey, validated evidence-based criteria to determine the prognosis 
in advanced COPD were not available.5,25 In order to facilitate timely identification of patients 
with COPD requiring palliative care, several criteria and tools had been proposed.5,25-28 The 
formulated 14 identification criteria in our survey were selected on the basis of this literature. 
All pulmonologists reported using several criteria, the combinations of which were different for 
each pulmonologist. Four criteria were mentioned by about three quarters of the pulmonologists: 
repeated hospital admissions for an acute exacerbation of COPD (AECOPD); feeling /experience 
of the pulmonologist that palliative care is needed; wish of the patient; and severe comorbidity. 
All other formulated criteria were mentioned by about one third of the pulmonologists while 
some pulmonologists also mentioned the additional aspects ‘no treatment options left’ and ‘a 
negative answer to the surprise question’ (would I, as pulmonologist, be surprised if my patient 
would die in the next year?). The fact that criteria of prognosis as well as curability and palliative 
needs were chosen by the pulmonologists reflected the absence of consensus about the way of 
identification of patients with COPD requiring palliative care.29
The pulmonologists also indicated which aspects of palliative care for patients with COPD they 
considered important and which aspects should be improved. Aspects described as important by 
over three-quarters of the pulmonologists were: Advance Care Planning (ACP) conversations, 
communication between pulmonologists and GPs, and the identification of patients for 
palliative care. For improvement only one aspect, the identification of patients for palliative 
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care, was mentioned by almost three quarters of the pulmonologists. The aspects thereafter 
mentioned for improvement by about two fifth of the pulmonologists were: ACP conversations, 
the organization of palliative care, communication between pulmonologists and GPs, and 
defining the coordinating role. These findings reveal that pulmonologists not only consider the 
identification of patients for palliative care vital, but also highlighted it as the most important 
aspect for improvement.
An integrated coordinated multidisciplinary model of palliative care, in which healthcare 
professionals of primary and secondary care work together to address the palliative care needs 
of patients with COPD, is increasingly recommended as best practice in the literature.11,18,19 
Almost three quarters of the pulmonologists answered in agreement of this, preferring a 
multidisciplinary cooperation between pulmonologists, GPs, and respiratory nurse specialists 
in the ambulatory setting. When asked who should organize palliative care for patients with 
COPD during hospitalization, more than half of the pulmonologists felt they themselves should 
be responsible. About three-tenth of the pulmonologists preferred to organize this in cooperation 
with a specialized palliative care team (SPCT) while about one-tenth mentioned that specialized 
pulmonologists should take part in SPCTs. The idea that SPCTs should hold the primary 
responsibility for care was almost never suggested, which is in line with the fact that, in practice, 
the input of an SPCT often is demanded for more complex disease trajectories.30 These findings 
show, that during hospitalization of patients with COPD, pulmonologists want to be involved in 
the organization of their palliative care, while there is also room for the involvement of an SPCT. 
Aside from differences in ideas about best practice, variations in palliative care delivery may also 
be influenced by factors such as the availability of facilities, access, and reimbursement issues.5,19 
In any case, as best practice, most pulmonologists preferred a model of integrated care, achieved 
through the collaboration of primary and secondary healthcare professionals. To successfully 
share the care of patients in need of proactive palliative care, good communication between 
the relevant healthcare professionals is essential.31 There is increasing consensus that respiratory 
nurse specialists would be best placed to fulfill a coordinating role to ensure the continuity 
of care across different settings.1,18 In addition, practical applications are proposed. In a recent 
study, the use of a Key Information Summary (KIS), a shared electronic medical record that 
captures the key points of proactive care plans, was explored, and was found not only to improve 
communication between healthcare professionals, but also to achieve earlier identification of 
patients (including patients with COPD) for palliative care.32 Currently, shared palliative care 
initiatives are being pilot-tested in several regions in the Netherlands.
Methodological considerations
The questionnaire we used in our survey was not validated. Therefore, it is possible that certain 
questions were not totally unambiguous and may not always have been interpreted in the same 
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way. Although comparable with other survey studies that investigate views of pulmonologists,33,34 
the overall response rate of 32% was low, raising concerns about whether the results can be 
generalized to the Dutch population of pulmonologists. Those pulmonologists who participated 
may have been more interested in palliative care in patients with COPD than the non-responders, 
and may have provided a more favorable view. For this reason, the low response rate will not have 
influenced our findings that the identification of patients with COPD for palliative care and the 
organization of such care need improvement. 
EFFECTIVENESS OF PROACTIVE PALLIATIVE CARE FOR PATIENTS 
WITH COPD
We were the first to examine the effectiveness of proactive palliative care on the wellbeing of 
patients with COPD (Chapter 5) by performing a pragmatic cluster controlled trial (quasi-
experimental design) with hospital as cluster (3 intervention, 3 control). Patients with poor 
prognosis were recruited during hospitalization for AECOPD. Poor prognosis was defined as 
meeting two or more indicators of a checklist of 11 indicators of poor prognosis. All patients 
received usual care while patients in the intervention condition received additional proactive 
palliative care in monthly meetings with an SPCT. Our primary outcome was change score in 
quality of life after 3 months using the St George Respiratory Questionnaire (SGRQ). Secondary 
outcomes were change in quality of life (SGRQ and McGill) after 3, 6, 9, and 12 months; 
change in psychological wellbeing (HADS) after 3, 6, 9, and 12 months; number and length of 
readmissions for an AECOPD; survival; and whether patients had made ACP choices during the 
one-year trial period. 
In total, 228 patients were recruited (90 intervention, 138 control) and at 3 months, 163 patients 
(67 intervention, 96 control) completed the SGRQ. We did not find an effect on our primary 
outcome, as the change in quality of life after 3 months using the SGRQ did not differ between 
groups. After six months however, patients receiving proactive palliative care experienced less 
impact of their COPD (SGRQ impact subscale) than patients receiving usual care. Moreover, 
there was a relevant difference in the number of patients who made ACP choices during the year 
of trial, in favor of the intervention group. The change in symptoms and activity level (SGRQ 
symptoms and activity subscale) were not different between groups at any of the time points. We 
did not find a difference in the other questionnaire outcomes, nor in the number and length of 
hospital admissions, or in survival between groups.
Several possible reasons related to our study plan, the characteristics of the COPD patient, the 
COPD disease course and/or palliative care interventions in general may have contributed to the 
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failure to demonstrate an improvement of quality of life in patients with COPD by means of 
proactive palliative care in our study:
Study plan
The study plan related reasons are at the level of identification, organization and outcome 
measure. First, only 22.8% of patients identified as having a poor prognosis died within one 
year; therefore, it seems that our criteria for poor prognosis were too broad. Second, patients with 
advanced COPD are often homebound until they enter an acute phase requiring hospitalization.35 
Continuity of palliative care can therefore only be achieved with a coordinated, multidisciplinary 
care approach in which primary and secondary health care professionals collaborate.36 Although 
GPs were informed about the intervention and the SPCT was encouraged to collaborate with 
GPs, we did not control for this aspect and it is unknown to what extent this occurred. Third, 
for some patients with advanced COPD, filling in questionnaires appeared to be too demanding. 
Although all enrolled patients did consent to fill out questionnaires, about one in five patients 
did not fully understand, complete, or return them. Incomplete data collection in advanced 
COPD has also been reported before.37,38 Perhaps in this population the use of a qualitative 
approach instead of or in addition to a quantitative approach is preferable for measuring changes 
in patient-reported outcomes.38
Characteristics of the COPD patient
Patients with COPD generally have a lower socioeconomic status (SES), i.e. on average a lower 
level of education and less financial means than other patient groups.39 These aspects have 
an impact on COPD health outcomes.39 Indeed, some patients in our study had difficulties 
understanding certain questions, which resulted in the return of incomplete questionnaires or 
obvious mistakes in answering questions. Additionally, some patients lacked the financial means 
to afford transportation to the hospital, physical therapy, or even a walker.
Characteristics of the COPD disease course
There are differences in the palliative trajectories of patients with cancer and those with COPD. 
First, the palliative trajectory of COPD is less predictable because episodes of gradual decline 
are punctuated by acute severe exacerbations.12 As a consequence, the quality of life will also 
fluctuate over time; therefore, these acute exacerbations may have influenced our findings, which 
were defined at fixed time points. Second, for patients with cancer, palliative care often starts 
when cure is no longer possible. Initially, the discontinuation of aggressive curative care, such 
as chemotherapy, may result in an improvement of the patients’ quality of life followed by a 
period of gradual decline. However, for patients with severe COPD in the palliative trajectory, 
‘curative care’ to manage the symptoms of COPD remains necessary until the last weeks of 
life. In our study, patients with COPD who received proactive palliative care for six months 
experienced less impact from their disease. Although this may have been a chance finding, as 
it was a secondary outcome, merely an effect on a quality of life subscale was also observed in 
the Glasgow supported self-management trial for patients with moderate to severe COPD.37 
Also Higginson and colleagues found no effect on quality of life from early introduction of 
516939-L-bw-duenk
Processed on: 13-2-2018 PDF page: 146
CHAPTER 7
146
a palliative breathlessness support service for patients with refractory breathlessness (including 
COPD), but these authors did find improved breathlessness mastery, a quality of life domain of 
the Chronic Respiratory Disease Questionnaire.40 As mentioned before, in contrast to patients 
with cancer in the palliative trajectory, disease-oriented care remains necessary for patients with 
advanced COPD in the palliative trajectory until the last weeks of life. Therefore, it is possible 
that resilience to improve overall quality of life (especially symptoms and activity) is exhausted 
in this patient group. 
Characteristics of palliative care interventions in general
Palliative care is a personalized intervention in which patients receive treatment according to their 
needs, which can be in the physical, psychological, social, and/or spiritual domains of quality of 
life. In this patient-centered approach some patients have, for instance, only physical problems, 
while other patients suffer from distressing conditions in the social and spiritual domain. Despite 
these different needs and the consequent personalized treatment of patients, the overall quality of 
life questionnaire, which includes all domains, is used as an outcome measure in palliative trials. 
It is therefore possible that, in palliative trials in general, the real but difficult-to-measure effect 
of palliative care on quality of life is being underestimated.41
In a recent systematic review and meta-analysis, the association between palliative care and 
different outcomes in patients with advanced incurable illness was determined.42 The meta-
analysis showed that palliative care was associated with improvements in quality of life. However, 
these trials mainly targeted patients with cancer (69.7%) and none of them focused on patients 
with COPD. One of the conclusions of this analysis was that additional studies are needed 
to examine the effects of palliative care in chronic nonmalignant diseases, such as COPD. 
Moreover, as in our study, no association was found between palliative care and survival.42 This 
is important because there is an unfounded belief among some clinicians and members of the 
lay public that palliative care may actually shorten survival.43,44 In addition, also in line with our 
study, the narrative synthesis demonstrated an association between palliative care and improved 
ACP conversations.42 
 
During ACP conversations, patients are informed about their diagnosis, prognosis, treatment 
options, and treatment consequences. Patients can also express their values and preferences for 
life-sustaining treatments with the goal of improving the quality of their end-of-life care.17 In 
our study, more patients with COPD in the intervention condition made ACP choices and 
consequently had ACP conversations during the year of the study. As the follow up period of 
patients was too short, we were not able to confirm earlier findings that those ACP conversations 
improved the quality of end-of-life care;45,46 and further research is needed. 
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Methodological considerations
For our intervention study, a cluster design was chosen to prevent contamination and to facilitate 
recruitment by minimizing the ethical concerns of patients and clinicians with respect to 
randomization and gate keeping.47,48 At the time of hospital recruitment, a minority of hospitals 
in the Netherlands had an available SPCT. Since only four hospitals with an SPCT were willing 
to participate, it was not possible to create comparable groups through cluster randomization in 
our trial. Instead, we performed a pragmatic cluster controlled trial (quasi-experimental design) 
in which three hospitals with an SPCT were selected for the intervention and three hospitals 
without an SPCT for the control condition. To control for confounding variables at hospital 
level, a pre-trial assessment was performed, in which hospitals were compared on baseline 
characteristics over the year before trial. All outcome measures were taken at patient level and 
patients performed a pre- and post-intervention measurement.
Although our pragmatic cluster controlled design completely ruled out contamination, this 
design was subject to selection bias at hospital level. However, using the outcomes of a pre-trial 
assessment we were able to control for hospital level confounders. Next, pulmonologists were 
aware of the treatment allocation, which may have caused bias. Our baseline data suggest that in 
the intervention condition pulmonologists included patients with more advanced COPD since 
those patients would profit from extra support, whereas pulmonologists in the control condition 
included patients with less advanced COPD, so as not to additionally burden more vulnerable 
patients. We used these differences in the patients’ baseline characteristics to control for 
confounders at patient level. However, it is unclear whether all important differences were taken 
into account and the true effect may therefore be underestimated in this study. Furthermore, 
attrition is common in long trials testing palliative interventions and does not necessarily reflect 
poor design or conduct.49 The proportion of missing data typically increases with study duration.49 
However, our proportion of missing data (28.5% at 3 months) was relatively low compared 
to the weighted estimate for missing data at primary endpoint of the palliative interventions 
(23.1% at 28 days, median time), reported in a systematic review.49 Nevertheless, the width of 
8 of the 95% CI of the primary outcome indicated that, if present, our study had the power 
to detect the necessary minimal important difference (MID) of 4.50 Since the attrition rates in 
both conditions were comparable, the threat to compromise the internal validity was minimal.49 
We also have no reason to assume that the participating hospitals are not representative of other 
hospitals; consequently, our findings can be generalized to other general hospitals.
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IDENTIFICATION OF PATIENTS WITH COPD FOR PROACTIVE 
PALLIATIVE CARE
The identification of patients for proactive palliative care is complicated by the unpredictable 
disease course of COPD.51 Although general tools to identify patients for palliative care exist, 
they are not specifically intended or validated for use with patients with COPD.29,52 Despite the 
development of models of survival in stable COPD to enable the adjustment and optimization 
of care,53,54 these population models are unfortunately of limited value for the prediction of 
the survival of individual patients.25 A discussion has begun among clinicians about whether or 
not a transition point for the initiation of proactive palliative care exists.24,55-57 Some clinicians 
argued that more specific criteria of end stage COPD need to be explored,56 while others argued 
that, since such criteria may not exist, this search may result in prognostic paralysis, and instead 
promoted the early integration of palliative care according to patient needs,24,57 The focus of this 
discussion has been whether or not it is possible to accurately predict mortality instead of the 
intended objective; identifying patients with COPD in need of proactive palliative care. Since 
palliative care needs increase during the disease course of COPD,11 we used the prediction of 
mortality as a proxy for the need of proactive palliative care. To ensure minimal miss out of 
patients in need of such care, a potential identification tool should have a sensitivity near 100 
with as high a specificity as possible.
Hospitalizations for an AECOPD are associated with significant mortality and therefore create 
an opportunity to identify patients with poor prognosis in need of palliative care.26 Recently 
potentially relevant variables were identified to predict post-hospital mortality in patients 
hospitalized for an AECOPD.5,26,27,58-62 We incorporated these variables in our study with the 
objective of developing a multivariable prediction tool to identify patients with COPD in need 
of proactive palliative care (Chapter 6). Our objective was to assess the discriminating power of 
a set of indicators for proactive palliative care in predicting death by any cause within one year. 
This outcome was used as a proxy for the potential need for proactive palliative care in patients 
with COPD.
We first performed a pilot study to examine whether the 11 potentially relevant variables were 
documented consistently in the medical records (Chapter 4). In a retrospective medical record 
review of 33 patients, we found that five variables, noninvasive ventilation (NIV), comorbidity, 
body mass index (BMI), previous admissions for AECOPD, and age were always documented. 
Three variables, hypoxaemia and/or hypercapnia, professional home care, and actual FEV1% were 
documented in more than half of the records, while answers to the Clinical COPD Questionnaire 
(CCQ),63,64 the Medical Research Council dyspnea questionnaire (MRC dyspnea),65 and the 
surprise question59 were never registered. Most variables were therefore fairly consistently 
documented in the medical records suggesting that pulmonologists already used these variables 
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in clinical practice. Only an answer to the surprise question, the CCQ and the MRC dyspnea 
were variables never documented. For our prospective study this would imply that these variables 
should be specifically asked for and measured. However, the surprise question, the CCQ and the 
MRC dyspnea are short, easy-to-use questionnaires. In addition, these questionnaires provide 
valuable information about, respectively, the view of the pulmonologist, the severity of dyspnea 
and the health status of the patient. Therefore, we decided to include them in the concept set of 
indicators used in our prospective pragmatic controlled trial.
Data for prognostic accuracy testing in patients hospitalized for an AECOPD were obtained 
from the three hospitals in the control condition of our prospective pragmatic cluster controlled 
trial (Chapter 6). An optimal prediction model was assessed using Lasso logistic regression,66,67 
with 20-fold cross validation for optimal shrinkage. Missing data were handled using complete 
case analysis. 
We were the first to develop a promising multivariable prediction tool to identify patients with 
COPD in need of proactive palliative care, the ProPal-COPD tool (Table 1). Our optimal 
prediction model of death within one year has good discriminating power; the true AUC was 
0.82 (95% CI 0.81 to 0.82), and the estimated optimism of 0.05 indicates good internal validity. 
To ensure minimal miss out of patients in need of palliative care we proposed a cut-off in the 
prediction model that prioritizes sensitivity 1.5 times above specificity. This optimal cut-off is 
-1.36, with a sensitivity of 0.90 and a specificity of 0.73. This implies that, when used, only 10% 
of patients in need of palliative care would be missed out and that of all patients identified for 
such care, 84% would die within one year. However, before clinical use of the ProPal-COPD 
tool, the external validity should be addressed in further research.
The ProPal-COPD tool relies on seven predictors: the surprise question (a general predictor), five 
markers of COPD severity, and the presence of specific co-morbidities proven to independently 
predict post-hospital mortality in AECOPD.60 Through the surprise question, the tool incorporates 
clinical judgment of severity. The surprise question has been shown to be a reasonable predictor 
of mortality in patients with advanced chronic diseases, and its use has been recommended in 
combination with other disease-specific predictors as a screening tool for proactive palliative 
care.59,68,69 Those disease-specific predictors in the ProPal-COPD tool are five markers of 
COPD severity: the CCQ (health status), MRC dyspnea, FEV1% of predicted value, BMI, and 
previous hospitalizations for an AECOPD. The presence of the following co-morbidities is also 
incorporated in our tool: non-curable malignancy, cor pulmonale, Chronic Heart Failure (CHF), 
diabetes mellitus with neuropathy and/or renal failure. These co-morbidities, except non-curable 
malignancy, are conditions liable to acute decompensation especially during AECOPD, which 
may explain their association with an increased mortality risk.26
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Table 1 The ProPal-COPD tool with its predictors, predictive performance, and optimal cut-off 
Predictors in model B AUC True 
AUC
95%CI Optimal 
cut-off
Se Sp
(Intercept) -3.901
0.870 0.818 0.813 – 0.824 -1.365 0.900 0.728
Negative answer SQ 0.959
Co-morbidity 1.479
CCQ total, day version > 3 0.257
MRC dyspnea = 5 1.475
FEV1 < 30% of predicted 0.565
BMI < 21 or weight loss 1.005
Prev. hosp. AECOPD 0.102
Notes: B, weight in the model.
Abbreviations: AECOPD, acute exacerbation Chronic Obstructive Pulmonary Disease, AUC, area under the curve; 
BMI, body mass index; CCQ, Clinical COPD Questionnaire; CI, confidence interval; FEV1, forced expiratory volume 
in 1 second; MRC dyspnea, Medical Research Council dyspnea questionnaire; Prev. hosp, previous hospitalization; Se, 
sensitivity; Sp, specificity; SQ, surprise question.
Each dichotomic predictor in our tool has its own weight (B), and only when the total sum of 
the model exceeds the specific cut-off point can the patient be considered in need of proactive 
palliative care. This means that not all predictors need to be fulfilled and that different numbers 
and combinations of predictors may be indicative of the need of proactive palliative care. Besides, 
the weights take into account correlation with other predictors in the tool and therefore should 
not be interpreted as the individual importance of each particular predictor. Moreover, the 
Lasso method used for model development identifies the most efficient model.67 In the trade-off 
between efficiency and effectiveness, four predictors were excluded from our optimal prediction 
model. However, this does not mean that these predictors were not predictive of death within 
one year. The exclusion of these predictors can be explained by the limited number of patients 
involved (NIV) and/or the high correlation with predictors incorporated into our optimal 
prediction model (hypoxaemia or hypercapnia, NIV, professional home care and age). 
Some researchers worried that patients with COPD in need of proactive palliative care would be 
missed out by use of the ProPal-COPD tool (Chapter 6). Their concern was based on a recent 
review on prognosis in COPD, which showed that existing prognostic criteria of mortality were 
not sufficiently reliable.70 Instead these authors promoted the delivery of proactive palliative 
care according to the needs and preferences of the patient. However, we believe that the ProPal-
COPD tool is suited to and needed for the identification of patients with COPD who require 
proactive palliative care because the tool has good prognostic performance, ensures minimal 
miss out of patients in need of proactive palliative care, and facilitates the initiation of ACP 
conversations:
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Good prognostic performance
The prognostic performance of the ProPal-COPD tool seems good and is superior to criteria 
and tools incorporated in the review. The better prognostic performance may be explained by 
substantive differences. First, the ProPal-COPD tool incorporates disease-specific predictors 
of mortality in AECOPD requiring hospitalization, whereas the tools examined in the review 
incorporate disease-specific predictors of mortality in stable COPD. Second, each predictor in 
the ProPal-COPD tool has an own weight (B), in contrast to the tools examined in the review. 
Although those weights do not represent the individual importance of each predictor, the own 
contribution of each predictor may be better represented in our tool.
Minimal miss out of patients in need of proactive palliative care
The objective of our tool was not to predict mortality but to identify patients with COPD in 
need of proactive palliative care. Since palliative care needs increase during the disease course of 
COPD,11 we merely used the prediction of mortality as a proxy of the need for palliative care. 
Our main concern was to ensure minimal miss out of patients in need of proactive palliative 
care. Therefore, we looked for and managed to develop a tool with high sensitivity (0.90) and 
specificity as high as possible (0.73), while ensuring good discriminating power.
Facilitation of the initiation of ACP conversations 
Proactive palliative care in COPD, which includes ACP conversations, still hardly takes place 
despite the recognized need for such care in this patient group.5 This results not only from 
the unpredictable disease course, but also from the fact that both patients and physicians 
encounter barriers to initiating ACP conversations.71 A recent study examining the quality of 
ACP conversations in patients with advanced chronic organ failure suggested that facilitation of 
initiation of ACP conversations is the key to improving proactive palliative care.72 It seems that 
otherwise, even when the disease progresses, the needs and preferences of patients are hardly 
explored.72 We therefore believe that the development of the ProPal-COPD tool responds to the 
need of patients and physicians. 
Methodological considerations
This study had several limitations. First, predicting post-hospital mortality for patients with 
COPD is complex, which is reflected by the number of potential predictors incorporated in the 
original set of predictors. We only used known predictors in this set, and it is therefore uncertain 
whether all possible predictors were accounted for. In addition, it is possible that certain predictors 
were underrepresented in the set of potential predictors; for example, anxiety and depression 
were represented as a subscale of the predictor CCQ. Second, to facilitate implementation in 
clinical practice we used dichotomized variables. Each potential predictor was given a clinical 
cut-off value based on literature. Such dichotomization of continuous predictors may lead to 
loss of information and reduction of power.73 Third, the use of the ProPal-COPD tool may 
require collection of data that are not always captured routinely (surprise question, CCQ, MRC 
dyspnea). Fourth, the ProPal-COPD tool was developed in the Netherlands, so international 
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differences in hospital admission policies for patients with an AECOPD may affect its usefulness 
in other countries. Fifth, it is unknown whether the ProPal-COPD tool can also be applied in 
academic hospitals, since it was developed using a population of patients in general hospitals. 
Finally, the ProPal-COPD tool was developed in a single population without validation in a 
different one. The external validity of our findings is therefore unknown and will be addressed 
in further research.
RECOMMENDATIONS
Recommendations for clinical practice
To accomplish a proactive approach to palliative care for patients with COPD, I have the 
following recommendations for clinical practice:
1.  The LAN is urged to take the “barriers to guideline adherence in COPD” into account 
to optimize strategies and ensure the effective implementation of the clinical guideline on 
palliative care for patients with COPD.
2.  Clinicians involved in the care of patients with COPD should read and use this clinical 
guideline “palliative care for patients with COPD” to optimize palliative care delivery in this 
patient group.
3.  The ProPal-COPD tool should be used by pulmonologists as an additional aid in the 
identification of patients with COPD who require proactive palliative care.
4.  The implementation of an integrated multidisciplinary approach to proactive palliative care 
is strongly advised for patients with COPD. This could be accomplished by shared care 
through cooperation and good communication of relevant healthcare professionals in the 
different settings involved.
5.  Respiratory nurse specialists should fulfill a coordinating role in the organization of proactive 
palliative care in COPD to ensure continuity of care across these different settings involved.
6.  To improve the delivery of proactive palliative care in COPD during hospitalization 
pulmonologists should improve their palliative care skills and members of the SPCT should 
be better informed about the management of COPD.
Recommendations for education and training
For education and training I have the following recommendations:
1.  More attention should be paid to palliative care in general in the educational program of all 
medical and nursing students. This will enable each medical professional to develop basic 
knowledge about proactive palliative care.
2.  During the educational program to become a medical specialist, the elaboration of the 
specifics of the early identification of palliative patients and proactive palliative care planning 
for malignant as well as nonmalignant life-threatening diseases is strongly advised.
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3.  Based on the input of pulmonologists, it is recommended to emphasize the following 
aspects of palliative care in COPD in education and training: organization of palliative care, 
communication between pulmonologists and GPs, definition of the coordinating role, and 
initiation and performance of ACP conversations.
4.  ACP conversations encompass more than just communicating bad news. In order to initiate 
and take part in these conversations, clinicians should develop skills in anticipatory care and 
shared decision-making. Since the development of these skills is not yet part of the medical 
curriculum, this should be incorporated into the educational program of medical students.
Recommendation for research
Based on the results presented in this thesis, I have the following recommendations for research:
1.  Before the clinical use of the ProPal-COPD tool, its external validity should be addressed in 
further research. This research is planned to be carried out in a current nationwide project 
in the Netherlands, led by the LAN, Leiden University Medical Center, and Radboud 
University Medical Center. 
2.  It is possible that, for patients with advanced COPD, filling in the SGRQ or questionnaires 
in general is too demanding. I therefore recommend the development and evaluation of 
a shorter, easier to use quality of life questionnaire specifically for patients with advanced 
COPD and/or the use of a qualitative approach for measuring changes in quality of life of 
this patient group. By using (additional) qualitative research, one might explore whether and 
how proactive palliative care affects patients with COPD. 
3.  It is possible that resilience to improve overall quality of life (especially symptoms and 
activity) is exhausted in patients with advanced COPD. Future research should therefore 
explore the effects of proactive palliative care in COPD on the different individual aspects of 
quality of life, such as the physical, emotional, social, and/or spiritual wellbeing of patients.
4.  Proactive palliative care is a complex intervention composed of several components. The 
delivery of proactive palliative care is patient centered according to their needs, and patients 
may benefit from pharmacological and/or non-pharmacological components, such as 
rehabilitation, or social support. However, it is still unknown which components are most 
useful and for whom. I therefore recommend that future research focuses on identification 
of the key components of proactive palliative care in COPD that are most effective and those 
patients most likely to benefit.
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Since the World Health Organization (WHO) introduced a new definition of palliative care in 
2002, the clinical use of a proactive approach to palliative care has been promoted for all patients 
with a life-threatening illness. However, at the start of my PhD study “proactive palliative care 
for patients with COPD”, palliative care was still often associated with terminal care only, was 
mainly limited to a reactive approach and was mainly restricted to patients diagnosed with 
cancer. Although the guideline ‘palliative care for patients with COPD’ had been published, no 
tools were given to identify patients in need of palliative care. In practice patients with COPD 
rarely received palliative care. That is why the most important goals of my graduate studies 
were to raise awareness of the need for proactive palliative care in patients with COPD and to 
promote this kind of support. Therefore, we explored the views of pulmonologists, we developed 
an identification tool and we examined the effectiveness of proactive palliative care in patients 
with COPD. In the meantime, there have been several developments in the fields of palliative 
care, COPD, and healthcare in general that needs to be discussed to give an impression of the 
context of our research.
Palliative care is often associated with terminal care only.44 Research showed that a name change 
from palliative care to supportive care was associated with more inpatient referrals and earlier 
referrals in the outpatient setting.74 Hence, the stigma associated with the term palliative care can 
be an impediment for a proactive approach to palliative care and may deprive patients of the full 
benefits of palliative care.74 As a consequence, a discussion has started whether a name change 
should be considered.44,75 However, it is not yet decided if a name change or a change in social 
view on palliative care is required.75
The traditional Global initiative of Chronic Obstructive Lung Disease (GOLD) classification 
of COPD severity is based on the degree of airflow limitation.76 However, several studies have 
shown that the severity of symptoms, functional impairment and quality of life are poorly related 
to the degree of airflow limitation.77-79 That is why, recently, different COPD assessments have 
been developed to understand the impact of the disease on an individual patient.80-82 These 
different COPD assessment tools are: the Nijmegen Clinical Screening Instrument (NCSI), 
the Assessment of Burden of COPD (ABC) scale, and the GOLD 2017 ABCD assessment 
tool, which all assess the integrated health status of the patient with COPD in order to guide 
treatment.80-82 However, it is not yet decided when during these assessments the focus should 
include proactive palliative needs of patients, in which the patient and professional caregiver plan 
ahead on future needs and ACP conversations take place. The LAN, who was involved in the 
development of the ABC scale, has just started a four-year nationwide project in the Netherlands 
with the objective to make palliative care as usual available care for patients with COPD. During 
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this project, which has been made possible thanks to financial support of ZonMW, the external 
validity of the ProPal-COPD tool will also be aassessed.
Assessments of the integrated health status of the patient with COPD fits into the recent shift 
in healthcare from a doctor-centered to a patient-centered approach. Within a patient-centered 
approach, patients are well informed about their health status, establish their own treatment 
goals, and collaborate with healthcare providers.83 This patient empowerment with the emphasis 
on communication, health promotion, and partnership has become necessary because of the 
aging of the population. In this manner, the quality of care can be improved while at the same 
time the cost for healthcare can be reduced. The recent shift to patient-centered care links in with 
the new perception of health, as the ability to adapt and self manage in the face of social, physical, 
and emotional challenges, instead of the old WHO definition of health as complete wellbeing.84
Within the concept of patient centered care the patients’ capability of self management is vital.83 
If patients are to participate fully in their care and in the management of a long-term condition, 
such as COPD, good communication is essential.85 However, it is likely that in the population 
of patients with COPD, the proportion of people with low health literacy is relatively high, 
as they are an older population with a lower average SES.86 Increased awareness of low health 
literacy in COPD is necessary to assist clinicians to improve patients’ knowledge of their disease 
and adherence to healthcare recommendations.87 In addition, I advise to examine to which level 
patients with COPD, especially those with low health literacy, are capable of self management 
of their disease. 
Modern medicine has made major breakthroughs. However, there is a reverse side to the 
improvement of the possibilities to cure diseases and to extend lives. Certain treatments are 
very radical, cause serious side effects and even have damaging consequences. In my opinion, 
the discussion regarding treatment in the final phase of life should therefore certainly include 
the consequences of treatment on quality of life and quality of dying. This way patients can 
make choices that are congruent with their wishes and values. Thankfully, small steps in the 
societal discussion concerning this subject have recently been made through a report titled ‘not 
everything that is possible needs to be done’, which promotes appropriate care for patients in 
their final phase of life.88 
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SUMMARY
Chronic Obstructive Pulmonary Disease (COPD) is a progressive life-threatening lung disease. 
Patients with advanced COPD have a high symptom burden and poor quality of life. Their 
quality of life is equally or sometimes even worse than that of patients with lung cancer. Research 
has shown that early or proactive palliative care can improve the quality of life of patients in the 
palliative phase. Up till now, this kind of care has been reserved mostly for patients with cancer 
and is not very common for patients with COPD. But the World Health Organization (WHO) 
states in its 2002 definition that palliative care should be available for all patients with a life-
threatening disease. So, also patients with COPD may profit of such care. However, because 
of a difference in disease trajectory patients with COPD require another approach to palliative 
care compared to patients with cancer. The disease trajectory of COPD is less predictable with 
a gradual functional decline, often punctuated by acute severe exacerbations any one of which 
may be fatal. This unpredictable disease trajectory not only complicates timely identification 
of patients who may profit of palliative care but also compromises continuity of palliative care 
delivery, since during stable phases of the disease often different healthcare professionals are 
involved than during the acute phases. The lack of a valid prognostic tool to identify patients 
for proactive palliative care may hinders adequate care, communication and organization in 
the palliative phase. Whereas, at this point, a well-coordinated, multidisciplinary approach is 
needed to guarantee continuity of palliative care. However, it has not been determined how this 
coordinated care should be successfully organized. Since pulmonologist have a central role in 
COPD management, they seem to be the appropriate professionals to take the lead in organizing 
this coordinated, multidisciplinary approach to palliative care. Therefore, the objectives of 
this thesis were to explore the view, needs and wishes of pulmonologists concerning proactive 
palliative care for patients with COPD, to examine identification of patients with COPD for 
proactive palliative care and to examine the effectiveness of proactive palliative care on the well-
being of patients with COPD (Chapter 1).
Since pulmonologists have a central role in COPD management, their view on palliative care 
for patients with COPD is important. In Chapter 2 we describe the results of a survey study 
performed by members (pulmonologists) of the Netherlands Association of Physicians for Lung 
Diseases and Tuberculosis. (NVALT). The 256 respondents (32%) covered 85.9% of the hospital 
organizations in the Netherlands. Almost all pulmonologists indicated that palliative care for 
patients with COPD is desirable. However, about half of the pulmonologists mentioned not to 
use the clinical guide line on palliative care for patients with COPD, most often because they 
were not aware of its existence. We therefore recommend that more attention should be paid to 
the implementation of this guideline. Most pulmonologists (92.2%) indicated to distinguish a 
palliative phase in the COPD trajectory, but there was no consensus about the different criteria 
used for its identification. All pulmonologists mentioned using several criteria, the combinations 
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of which were different for each pulmonologist. These were different criteria concerning prognosis, 
curability and palliative needs to mark the start of palliative care in COPD. We also asked the 
pulmonologists about the content of palliative care for patients with COPD. Aspects considered 
most important were: advance care planning (ACP) conversations (82%), communication 
between pulmonologist and general practitioner (77%), and identification of the palliative phase 
(75.8%), while the latter was considered the most important aspect for improvement (67.6%). 
We therefore recommended to conduct further research into more specific criteria to timely 
initiate the palliative trajectory. With respect to the organization of care, pulmonologists indicated 
to prefer organizing palliative care for hospitalized patients with COPD themselves (55.5%), 
while 30.9% indicated to prefer cooperation with a Specialized Palliative Care Team (SPCT). 
Since palliative care in COPD is not common practice, we recommended pulmonologists to 
improve their skills of palliative care and members of the SPCT to be better informed about 
the management of COPD. In the ambulatory setting a multidisciplinary cooperation between 
pulmonologist, general practitioner and a respiratory nurse specialist was preferred (71.1%). 
Because pulmonologist also indicated ACP conversations and communication between 
pulmonologist and GP as important improvement aspects (respectively 46.5% and 40.6%), we 
recommended to emphasize these aspects in training for professionals involved in palliative care 
for this group of patients.
In Chapter 3 the study protocol of a pragmatic cluster controlled trial (quasi-experimental design) 
was provided in which the background and the methodology of our study were explained. The 
main objectives of the study were: 1) to assess the discriminating power of a set of indicators for 
poor prognosis in order to identify patients with COPD for proactive palliative care (indicator 
study), and 2) to assess the effects of proactive palliative care for qualifying patients with COPD 
on the wellbeing of these patients (intervention study). A cluster design was chosen to prevent 
contamination and to minimize ethical concerns of patients and clinicians with respect to 
randomization and gate keeping. At the time of hospital recruitment, a minority of hospitals in 
the Netherlands had the availability of an SPCT and randomization of these hospitals was not 
possible. Therefore, hospitals were selected for the intervention condition based on the presence 
of an SPCT. In total, six general hospitals participated, three hospitals in the control and three 
in the intervention condition. In order to control for confounders on hospital level, a pre-trial 
assessment was performed in which hospitals were compared on baseline characteristics over the 
year before trial. All outcome measures were on patient level and patients performed a pre and 
post intervention measurement.
The planned study population consisted of patients with COPD. Patients would be included 
during hospitalization for an acute exacerbation COPD (AECOPD). All patients in the study 
would receive usual care, while only patients in the intervention condition who had a poor 
prognosis according to our set of indicators additionally would receive proactive palliative 
care provided by an SPCT. Poor prognosis was defined as meeting two or more indicators of a 
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checklist of 11 indicators of poor prognosis. This set of indicators were, a priori, selected based 
on literature. For data analysis of the indicator study we planned to use all the data collected in 
the hospitals in the control condition. In the intervention study we planned to compare the data 
of patients with COPD with poor prognosis between the hospitals in the intervention and the 
control condition. Innovative aspects of the study were: the use of a set of indicators for proactive 
palliative care, the active involvement of an SPCT, and the use of a patient-tailored proactive 
palliative care plan.
Before starting a prospective study, we performed a pilot study to get an indication of the 
applicability of the set of 11 indicators in our prospective study (Chapter 4). Since we wanted 
to develop a doctor-friendly and patient-convenient tool that is easy to implement, our objective 
was to examine whether these indicators were documented consistently in the medical records 
of patients hospitalized for an AECOPD. A retrospective medical record review showed that 
five indicators, namely non invasive ventilation (NIV), comorbidity, body mass index (BMI), 
previous admissions for AECOPD and age were always documented. The presence or absence 
of hypoxaemia and/or hypercapnia at discharge was documented in 85% of the records. No 
documentation in most cases meant that the patient was not hypoxaemic or hypercapnic at 
admission. Professional home care and actual FEV1% of predicted value were documented half 
of the time. A possible explanation of lack of documentation about the need for professional 
home care might be that this is not documented if the patient does not have such care. An 
explanation of the absence of actual FEV1% might be that if unknown at admission it cannot 
be assessed truthful in an instable phase such as an AECOPD. Only an answer to the surprise 
question, the Clinical COPD Questionnaire (CCQ) and MRC dyspnea were never documented 
and should be specifically asked for. However, these three questionnaires are short and easy to 
use. Therefore, we concluded that in our prospective study the use of the set of concept indicators 
for proactive palliative care appeared to be user-friendly and feasible.
Chapter 5 describes the results of the intervention study of our pragmatic cluster controlled 
trial. Although, in general, research of patients in the palliative phase has difficulties with 
recruitment, we were able to include the necessary number of patients with advanced COPD. 
We did not find, though, an effect of proactive palliative care on our primary outcome: the 
change in quality of life measured with the St George Respiratory Questionnaire (SGRQ) 
from baseline to 3 months was not different between groups. This result may be explained by 
several possible reasons on identification, organization, patient, outcome measure, and disease 
course level. First, it is possible that our criteria for poor prognosis were too broad. Second, 
it is unknown to what extend collaboration between GPs and the SPCT, necessary to ensure 
continuity of palliative care, was implemented. Third, the in general, lower Social Economic 
Status (SES) of patients with COPD may have affected study outcomes, since some patients in 
our study had difficulties understanding the questionnaires and /or lacked the financial means 
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to afford necessary additional support. Fourth, for some patients with advanced COPD filling 
in questionnaires may have been too demanding. Finally, outcomes of measurements in COPD 
are influenced by acute exacerbations and this may have influenced findings in our study defined 
on fixed time points. 
However, patients receiving proactive palliative care experienced less impact of their COPD 
(SGRQ impact subscale) at 6 months than patients receiving usual care. In contrast to patients 
with cancer in the palliative trajectory, for patients with advanced COPD who receive palliative 
care disease oriented care remains necessary until the last weeks of life. We concluded that it 
is possible that resilience to improve overall quality of life (especially symptoms and activity) 
is exhausted in this patient group and that further research is needed to test this hypothesis. 
Moreover, there was a relevant difference in number of patients that made ACP choices during 
the year of trial, in favor of the intervention group. Since research has shown that such choices 
increase the quality of end-of-life care, we suggested that proactive palliative care in COPD should 
place emphasis on supporting patients through ACP conversations. Finally, other questionnaire 
outcomes, number and length of hospital admissions nor in survival were not different between 
groups.
In Chapter 6 we report the development of the ProPal-COPD tool to identify patients with 
COPD for proactive palliative care. Data of 11 potential predictors of poor prognosis, a priori 
selected based on literature, were collected during hospitalization for an acute exacerbation 
COPD (AECOPD). Since palliative care needs increase during the disease course of COPD, 
the prediction of mortality within one year was used as a proxy for need of proactive palliative 
care. After one year the medical files were, if applicable, explored for date of death. An optimal 
prediction model was assessed by a Lasso logistic regression, with 20-fold cross validation 
for optimal shrinkage. The optimal prediction model was internally validated and had good 
discriminating power (AUC = 0·82, 95% CI 0·81 to 0·82). This model relied on seven predictors: 
the surprise question, MRC dyspnea, Clinical COPD Questionnaire (CCQ), FEV1% of 
predicted value, Body Mass Index (BMI), previous hospitalizations for AECOPD, and specific 
co-morbidities. To ensure minimal miss out of patients in need of proactive palliative care we 
proposed a cut-off in the model that prioritized sensitivity over specificity (respectively 0·90 over 
0·73). Our model (ProPal-COPD tool) was a stronger predictor of mortality within one year 
than the CODEX index (AUC = 0.68). Each predictor in the tool has an own weight and only 
when the total sum of the model exceeds the specific cut-off point the patient can be considered 
in need of proactive palliative care. This prognostic equation can be easily integrated in the 
Electronic Patient Record (EPR) system. However, before clinical use of the ProPal-COPD tool 
we recommended to address the external validity in further research.
In response to our paper, some authors wrote a letter to the editor, in which they expressed their 
worries that patients with COPD in need of proactive palliative care would be missed out by use 
of the ProPal-COPD tool. Their concern was based on a recent review on prognosis in COPD, 
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which showed that existing prognostic criteria of mortality were not sufficiently reliable. Instead 
these authors promoted the delivery of proactive palliative care according to the needs and 
preferences of the patient. Ideally, this should be the case, but in practice there are patient and 
doctor centered barriers to start ACP conversations, implying that many patients don’t receive 
palliative care at all. Therefore, we believe that the ProPal-COPD tool is suited and needed for 
the identification of patients with COPD who require proactive palliative care because the tool: 
has good prognostic performance, ensures minimal miss out of patients in need of proactive 
palliative care, and on top of that facilitates the initiation of ACP conversations. 
In Chapter 7, the final chapter of this thesis, the main findings and strengths and weaknesses 
of the studies are discussed and placed in a wider perspective. Next, recommendations are given 
for clinical practice, education and training, and research. This chapter ends with a societal 
discussion on the topic of our thesis “Proactive palliative care for patients with COPD”. 
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SAMENVATTING
Chronic Obstructive Pulmonary Disease (COPD) is een progressieve levensbedreigende 
longziekte. In een gevorderd stadium van deze ziekte, hebben patiënten vaak een hoge 
symptoomlast en een slechte kwaliteit van leven. Hun kwaliteit van leven is gelijk aan, of 
soms zelfs slechter dan, die van patiënten met longkanker. Onderzoek heeft aangetoond dat 
vroege of proactieve palliatieve zorg de kwaliteit van leven kan verbeteren van patiënten in de 
palliatieve fase. Tot nu toe is deze zorg vooral toegepast bij patiënten met kanker en is niet 
erg gebruikelijk voor patiënten met COPD. De Wereldgezondheidsorganisatie (World Health 
Organization, WHO) verklaart echter in de definitie van palliatieve zorg (2002) dat deze zorg 
beschikbaar moeten zijn voor alle patiënten met een levensbedreigende ziekte. Dit betekent dat 
patiënten met COPD ook baat zouden kunnen hebben bij deze zorg. Vanwege een verschil 
in ziekteverloop, hebben patiënten met COPD echter een andere aanpak van palliatieve zorg 
nodig dan patiënten met kanker. Het ziekteverloop van COPD is minder voorspelbaar met een 
geleidelijke functionele afname onderbroken door ernstige acute longaanvallen (exacerbaties), 
die ieder fataal kunnen zijn. Dit onvoorspelbare ziekteverloop bemoeilijkt niet alleen tijdige 
identificatie van patiënten die baat kunnen hebben bij palliatieve zorg maar brengt ook de 
continuïteit van de palliatieve zorgvoorziening in gevaar. Immers, tijdens de stabiele fase van 
de ziekte zijn vaak andere gezondheidszorg professionals betrokken dan in de acute fase. Het 
gebrek aan een valide, prognostisch instrument ter identificatie van patiënten met COPD voor 
proactieve palliatieve zorg belemmert mogelijk adequate zorg, communicatie en organisatie in de 
palliatieve fase. Terwijl een goed gecoördineerde, multidisciplinaire aanpak nu juist nodig is om 
de continuïteit van palliatieve zorg te kunnen waarborgen. Het is echter nog niet duidelijk hoe 
deze gecoördineerde zorg zou moeten worden georganiseerd. Aangezien longartsen een centrale 
rol hebben in COPD management, lijken zij de geëigende professional te zijn om een leidende 
rol op zich te nemen in de organisatie van deze gecoördineerde, multidisciplinaire aanpak van 
palliatieve zorg. Vandaar dat de doelstellingen van dit proefschrift waren: het exploreren van de 
zienswijzen, de behoeften, en de wensen van longartsen betreffende proactieve palliatieve zorg 
voor patiënten met COPD, het ontwikkelen van een instrument ter identificatie van patiënten 
met COPD voor proactieve palliatieve zorg, en het onderzoeken van de effectiviteit van proactieve 
palliatieve zorg op het welzijn van patiënten met COPD (Hoofdstuk 1). 
Aangezien longartsen een centrale rol hebben in COPD management, wilden we weten hoe zij 
aankijken tegen palliatieve zorg bij COPD. In Hoofdstuk 2 beschrijven we de resultaten van 
een vragenlijstonderzoek uitgevoerd bij leden (longartsen) van de Vereniging van Artsen voor 
Longziekten en Tuberculose (NVALT). De 256 respondenten (32%) omvatten 85,9% van de 
ziekenhuisorganisaties in Nederland. Bijna alle longartsen gaven aan dat palliatieve zorg voor 
patiënten met COPD wenselijk is. Ongeveer de helft van de longartsen gaf echter aan dat zij 
de klinische richtlijn palliatieve zorg voor patiënten met COPD niet gebruikten, veelal omdat 
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zij niet van het bestaan afwisten. We raadden daarom aan om meer aandacht te schenken aan 
de implementatie van deze richtlijn. De meeste longartsen gaven aan dat zij een palliatieve fase 
onderscheiden in het COPD traject, maar er was geen consensus over de verschillende criteria die 
gebruikt werden voor de identificatie van deze fase. Alle longartsen gaven aan meerdere criteria te 
gebruiken maar iedere longarts noemde een andere combinatie van criteria. Dit waren criteria met 
betrekking tot prognose, behandelbaarheid en palliatieve behoefte om de start van de palliatieve 
fase te markeren. We hebben de longartsen ook gevraagd naar de inhoud van palliatieve zorg 
bij COPD. Aspecten die het belangrijkste gevonden werden waren: gesprekken met de patiënt 
over voorkeuren ten aanzien van levensverlengende behandelingen (82%), communicatie tussen 
longarts en huisarts (77%), en identificatie van de palliatieve fase (75,8%), terwijl het laatste 
werd beschouwd als het belangrijkste aspect voor verbetering (67,6%). We raadden daarom 
aan om verder onderzoek te verrichten naar meer specifieke criteria voor een tijdige start van 
de palliatieve fase. Met betrekking tot de organisatie van zorg gaven de meeste longartsen aan 
zelf verantwoordelijk te willen zijn voor palliatieve zorgverlening bij patiënten met COPD die 
zijn opgenomen in het ziekenhuis (55,5%), terwijl 30,9% aangaf de voorkeur te geven aan 
samenwerking met een consultteam palliatieve zorg. Aangezien palliatieve zorg bij COPD niet 
gebruikelijk is, raadden we longartsen aan hun palliatieve zorg vaardigheden te verbeteren en 
leden van het consultteam palliatieve zorg om beter geïnformeerd te zijn over de behandeling 
van COPD. In de ambulante setting werd de voorkeur gegeven aan een multidisciplinaire 
samenwerking tussen longarts, huisarts en de verpleegkundig specialist longgeneeskunde (71,1%). 
Omdat longartsen als aspecten voor verbetering ook aangaven: gesprekken met de patiënt over 
voorkeuren ten aanzien van levensverlengende behandelingen (46,5%), en communicatie tussen 
longarts en huisarts (40,6%), raadden wij aan deze aspecten te benadrukken tijdens trainingen 
voor zorgprofessionals die te maken hebben met palliatieve zorg in deze patiëntengroep.  
In Hoofdstuk 3 is het studieprotocol beschreven van de pragmatische cluster gecontroleerde 
studie (quasi-experimenteel design) waarin de achtergrond en de methodologie van dit 
onderzoek zijn uiteengezet. De belangrijkste doelstellingen van het onderzoek waren: 1) het 
vaststellen van het discriminerend vermogen van een set van indicatoren voor slechte prognose 
ter identificatie van patiënten met COPD voor proactieve palliatieve zorg (indicatorenstudie), en 
2) het vaststellen van de effectiviteit van proactieve palliatieve zorg bij daarvoor in aanmerking 
komende patiënten met COPD, op het welzijn van deze patiënten (interventiestudie). Er was 
gekozen voor een cluster design om contaminatie te voorkomen en om ethische bezwaren te 
beperken van patiënten en clinici met betrekking tot randomisatie en selectie. Aangezien op het 
moment van werving van de ziekenhuizen (2013) slechts enkele ziekenhuizen in Nederland de 
beschikking hadden over een consultteam palliatieve zorg was randomisatie van deze ziekenhuizen 
niet mogelijk. Vandaar dat ziekenhuizen werden toegewezen aan de interventieconditie op 
basis van de aanwezigheid van een consultteam palliatieve zorg. In totaal namen zes algemene 
ziekenhuizen deel, drie in de controle- en drie in de interventieconditie. Om te controleren voor 
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verstorende factoren (confounders) op ziekenhuisniveau werd een voormeting uitgevoerd waarbij 
ziekenhuizen werden vergeleken op baseline karakteristieken over het jaar voorafgaande aan de 
studie. Alle uitkomsten waren op patiëntniveau en patiënten voerden eenzelfde meting voor en 
na de interventie uit. 
De geplande studiepopulatie bestond uit patiënten met COPD, die geïncludeerd zouden worden 
tijdens een ziekenhuisopname voor een acute exacerbatie COPD (AECOPD). Alle patiënten 
in het onderzoek zouden gebruikelijke zorg ontvangen, terwijl uitsluitend patiënten in de 
interventieconditie die volgens onze set van indicatoren een slechte prognose hadden, extra 
proactieve palliatieve zorg zouden ontvangen van een consultteam palliatieve zorg. Een slechte 
prognose werd gedefinieerd als het voldoen aan twee of meer indicatoren van een set van 11 
indicatoren voor slechte prognose. Deze set van indicatoren waren, voorafgaande aan de studie, 
geselecteerd op basis van de literatuur. Voor data-analyse van de indicatorenstudie planden we 
alle data te gebruiken die we hadden verzameld in de ziekenhuizen in de controleconditie. In 
de interventiestudie planden we om de data van alle patiënten met een slechte prognose in 
de interventie- en de controleconditie met elkaar te vergelijken. Innovatieve aspecten van de 
studie waren: het gebruik van een set van indicatoren voor proactieve palliatieve zorg, de actieve 
betrokkenheid van een consultteam palliatieve zorg, en het gebruik van een persoonlijk op de 
patiënt toegesneden proactief palliatief zorgplan.
Voorafgaande aan de start van de prospectieve studie, voerden we een pilot studie uit om een 
indicatie te krijgen van de toepasbaarheid van de set van 11 indicatoren in onze prospectieve 
studie (Hoofdstuk 4). Aangezien we een instrument wilden ontwikkelen dat zowel voor de arts 
als de patiënt gebruikersvriendelijk is en daardoor makkelijk te implementeren, was ons doel te 
onderzoeken of deze indicatoren consequent gedocumenteerd waren in de medische dossiers 
van de patiënten die opgenomen waren in het ziekenhuis voor een AECOPD. Een retrospectief 
medisch dossier onderzoek liet zien dat vijf indicatoren, te weten noninvasieve ventilatie (NIV), 
comorbiditeit, body mass index (BMI), eerdere opnames voor AECOPD en leeftijd altijd waren 
gedocumenteerd. De aan- of afwezigheid van hypoxaemia en/of hypercapnia bij ontslag was 
in 85% van de dossiers gedocumenteerd. Geen documentatie betekende in de meeste gevallen 
dat tijdens opname de patiënt niet hypoxaemisch of hypercapnisch was. Professionele thuiszorg 
en actuele FEV1% van voorspelde waarde waren in de helft van de dossiers gedocumenteerd. 
Een mogelijke verklaring voor de afwezigheid van documentatie betreffende de behoefte aan 
professionele thuiszorg is dat dit niet gedocumenteerd wordt als de patiënt deze zorg niet nodig 
heeft. Een mogelijke verklaring voor de afwezigheid van  FEV1% van voorspelde waarde is 
dat indien dit onbekend is bij opname het niet nauwkeurig gemeten kan worden tijdens een 
instabiele fase zoals een AECOPD. Alleen een antwoord op de surprise question, de Clinical 
COPD Questionnaire (CCQ) en de MRC dyspnea waren nooit gedocumenteerd en zouden 
extra afgenomen moeten worden. Deze drie vragenlijsten zijn echter kort en makkelijk in 
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gebruik. Vandaar dat we concludeerden dat in onze prospectieve studie het gebruik van de set 
van concept indicatoren voor proactieve palliatieve zorg gebruikersvriendelijk en haalbaar lijkt.
Hoofdstuk 5 beschrijft de resultaten van de interventiestudie van onze pragmatische cluster 
gecontroleerde studie. Hoewel onderzoek van patiënten in de palliatieve fase over het algemeen 
te maken heeft met wervingsproblemen, is het ons gelukt het noodzakelijke aantal patiënten 
met gevorderd COPD in een jaar tijd te includeren in de studie.  We vonden geen effect van 
proactieve palliatieve zorg op de primaire uitkomstmaat: de verandering in kwaliteit van leven 
gemeten met de St George Respiratory Questionnaire (SGRQ) van baseline tot 3 maanden 
was niet verschillend tussen de beide groepen. Factoren op identificatie-, organisatie-, patiënt-, 
uitkomstmaat-, en ziekteverloopniveau zouden aan dit uitblijven van effect kunnen hebben 
bijgedragen. Ten eerste is het mogelijk dat onze inclusiecriteria wat betreft ‘slechte prognose’ 
te ruim waren. Ten tweede is het onduidelijk in welke mate de beoogde samenwerking tussen 
de huisartsen en het consultteam palliatieve zorg daadwerkelijk heeft plaatsgevonden. Deze 
samenwerking was nodig om continuïteit van palliatieve zorg te waarborgen. Ten derde is het 
mogelijk dat de, over het algemeen, lage sociaal economische status (SES) van patiënten met 
COPD de uitkomsten van de studie heeft beïnvloed, aangezien sommige patiënten in onze 
studie de vragen van de vragenlijsten niet begrepen en/of niet de financiële middelen hadden 
om zich de noodzakelijke extra ondersteuning te kunnen permitteren. Ten vierde is het invullen 
van vragenlijsten voor sommige patiënten met gevorderd COPD mogelijk te veeleisend geweest. 
Tenslotte beïnvloeden acute exacerbaties de uitkomsten van metingen bij COPD. Omdat de 
metingen in onze studie plaatvonden op vooraf vastgestelde momenten, kan dit zeker onze studie 
hebben beïnvloed.
Patiënten die proactieve palliatieve zorg ontvingen, ervoeren echter wel minder impact van hun 
COPD (SGRQ impact subschaal) na 6 maanden dan patiënten die gebruikelijke zorg ontvingen. 
In tegenstelling tot palliatieve patiënten met kanker, blijft voor patiënten met gevorderd COPD 
ziektegerichte zorg noodzakelijk tot de laatste weken van hun leven. Vandaar dat we concludeerden 
dat in deze patiëntengroep mogelijk de veerkracht ontbreekt om de overall kwaliteit van leven 
(in het bijzonder, symptomen en activiteiten) te verbeteren en dat vervolgonderzoek nodig is 
om deze hypothese te testen. Bovendien was er een relevant verschil in het aantal patiënten 
dat ACP keuzes maakten in het jaar van de studie, in het voordeel van de interventiegroep. 
Omdat onderzoek heeft aangetoond dat dergelijke keuzes de kwaliteit van eindleven zorg kan 
verbeteren, raadden we in de palliatieve fase aan  patiënten met COPD te ondersteunen  door 
ACP gesprekken te voeren. Tenslotte vonden we geen verschillen tussen beide groepen in de 
uitkomsten van andere vragenlijsten, aantal en duur van de ziekenhuisopnames en in overleving. 
In Hoofdstuk 6 rapporteren we de ontwikkeling van het ProPal-COPD instrument ter 
identificatie van patiënten met COPD voor proactieve palliatieve zorg. Data van 11 potentiële 
predictoren van slechte prognose, vooraf geselecteerd op basis van literatuur, werden verzameld 
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tijdens ziekenhuisopname voor een AECOPD. Aangezien palliatieve zorgbehoeften toenemen 
tijdens het ziektetraject van COPD werd de voorspelling van sterfte binnen één jaar gebruikt 
als afgeleide (proxy) van de behoefte aan proactieve palliatieve zorg. Na één jaar werden, indien 
van toepassing, de medische dossiers onderzocht op datum van sterfte. Een optimaal predictie 
model werd verkregen door een Lasso logistieke regressie, met 20-voudige cross validatie voor 
optimale krimping. Het optimale predictie model was intern gevalideerd en had een goed 
discriminerend vermogen (AUC = 0,82, 95% CI 0,81 to 0,82). Het model bestond uit zeven 
predictoren: de surprise question, MRC dyspnea, CCQ, FEV1% van voorspelde waarde, BMI, 
eerdere ziekenhuisopnamen voor AECOPD, en specifieke comorbiditeiten. Om ervoor te zorgen 
dat zo min mogelijk patiënten die proactieve palliatieve zorg nodig hebben gemist worden, 
stelden we een afkappunt in het model voor waarbij meer waarde wordt gehecht aan sensitiviteit 
dan specificiteit (respectievelijk 0,90 en 0,73). Ons model (het ProPal-COPD instrument) 
was een betere voorspeller van sterfte binnen één jaar dan de CODEX index (AUC = 0,68). 
Iedere predictor van dit instrument heeft een eigen gewicht en alleen als de totale som van het 
model hoger is dan het specifieke afkappunt kan de patiënt beschouwd worden als behoeftig aan 
proactieve palliatieve zorg. Deze prognostische optelsom kan gemakkelijk worden geïntegreerd in 
het Elektronische Patiënten Dossier (EPD). Echter, voor klinisch gebruik van het ProPal-COPD 
instrument raden we aan om eerst de externe validiteit te bepalen in vervolgonderzoek.  
In antwoord op ons artikel hebben een aantal auteurs een brief aan de editor geschreven waarin zij 
hun zorgen uitten over het mogelijk missen van patiënten met COPD die proactieve palliatieve 
zorg nodig hebben bij gebruik van het ProPal-COPD instrument. Hun bezorgdheid was gebaseerd 
op een recente review over prognose in COPD, die aantoonde dat bestaande prognostische 
criteria van sterfte niet voldoende betrouwbaar waren. In plaats daarvan promootten deze auteurs 
het aanbieden van proactieve palliatieve zorg die afgestemd is op de behoefte en voorkeur van 
de patiënt. Idealiter, zou dit natuurlijk het geval moeten zijn, maar in werkelijkheid spelen er 
zowel bij iedere patiënt als bij de behandelaar allerlei barrières om het ACP gesprek aan te gaan, 
waardoor dit bij een flink deel van de patiënten tot op heden in het geheel niet plaatsvindt. Wij 
geloven daarom dat het  ProPal-COPD instrument geschikt en van belang is ter identificatie 
van patiënten met COPD voor  proactieve palliatieve zorg aangezien het instrument: een goed 
prognostisch vermogen heeft, ontwikkeld is om zo min mogelijk patiënten die proactieve 
palliatieve zorg nodig hebben te missen, en bovendien de initiatie van ACP gesprekken faciliteert.
In Hoofdstuk 7, het laatste hoofdstuk van dit proefschrift, worden de belangrijkste bevindingen 
en de sterke en zwakke kanten van de studies besproken en in een breder perspectief geplaatst. 
Vervolgens worden aanbevelingen gegeven voor de klinische praktijk, onderwijs en training, en 
wetenschappelijk onderzoek. Dit hoofdstuk eindigt met een maatschappelijke discussie over het 
onderwerp van mijn proefschrift “Proactieve palliatieve zorg voor patiënten met COPD”.
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Aan het onderzoek en de totstandkoming van dit proefschrift hebben veel mensen bijgedragen. 
Een aantal van hen wil ik in het bijzonder daarvoor bedanken.
Op de eerste plaats, wil ik mijn supervisor, copromotor en promotoren bedanken.
Stans Verhagen, wat ben ik blij dat je mijn supervisor hebt willen zijn. Vanaf dag één ben je 
intensief bij het onderzoek betrokken geweest. Je input als medisch specialist en onderzoeker 
waren van grote waarde. Van jouw ervaring en immens uitgebreide kennis op het gebied van 
palliatieve zorg heb ik enorm veel geleerd. 
Yvonne Engels, ik heb me altijd door jou gesteund gevoeld. Dank voor je vertrouwen, 
benaderbaarheid, optimisme en humor. Je was gul met complimenten en stond klaar met 
opbouwend en scherpzinnig commentaar. Wat heb ik geboft met jou als copromotor.
Yvonne Heijdra, ondanks je drukke programma was je enorm betrokken en kon ik altijd bij je 
aankloppen. Je gedrevenheid en doelgerichtheid zorgden ervoor dat we niet in de filosofische 
modus bleven steken maar dat er besluiten werden genomen. Veel dank daarvoor. 
Kris Vissers, dank voor je vertrouwen in mij. Door jouw helikoptervisie op het gebied van 
palliatieve zorg heb ik dit proefschrift op een hoger niveau weten te tillen. Jouw kritische vragen 
hebben tot vele goede discussies en daardoor verhelderende inzichten geleid.  
Bart Kiemeney mijn mentor, aan jouw luisterend oor en advies heb ik veel gehad.
Ook Richard Dekhuijzen wil ik bedanken voor zijn input op belangrijke momenten in het 
promotietraject.
Een speciale dank voor Jeroen Fokke. Samen gingen wij op pad om de trainingen ‘palliatieve zorg 
bij COPD’ te verzorgen in de deelnemende ziekenhuizen. Wat heb ik tijdens die dagen genoten 
van je goede gezelschap, fijne gesprekken en droge humor. 
Ewald Bronkhorst, ook voor jou een speciaal woord. Als statisticus wist jij de lastige analyses en 
de interpretaties daarvan voor mij begrijpelijk te maken. Door jouw enthousiasme en vrolijke 
manier van doen heb ik veel plezier beleefd aan onze samenwerking.
In het bijzonder, wil ik alle patiënten en hun naasten bedanken die hebben meegewerkt aan dit 
onderzoek. Zonder hen zou dit onderzoek niet hebben kunnen plaatsvinden. 
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Alle hoofdonderzoekers (medisch specialisten), trialcoördinatoren, verpleegkundig specialisten 
en verpleegkundigen van de zes deelnemende ziekenhuizen wil ik hartelijk danken voor de 
enthousiaste deelname aan het onderzoek. Van het Jeroen Bosch Ziekenhuis te Den Bosch zijn 
dit: Marielle, Lucyl, Paulien, Sylvia en Marisa. Van het Slingeland Ziekenhuis te Doetinchem: 
Gerrit en Maritha. Van het Rijnstate Ziekenhuis te Arnhem: Frank, Patricia, Els, Anouschka en 
Josien. Van het Amphia Ziekenhuis te Breda: Remco, Brigitte en Ilse. Van het Meander MC te 
Amersfoort: Saskia, Erica, Willeke en Justine. Tenslotte, van het Gelre Ziekenhuizen te Zutphen: 
Ernst, Willy, Susan, Sabine en Dianne.
Voor het verzamelen en/of invoeren van data wil ik de volgende onderzoeksassistenten en 
stagiaires bedanken: Klasminda, Anne, Mireille, Charlotte en Aisha.
Marlieke, m’n kamergenoot, hoe vaak hebben we niet samen een ommetje gemaakt naar de 
koffieautomaat om daarbij werk- maar vooral ook privéperikelen te bespreken. Dank voor je 
vriendschap, aan die momenten heb ik veel plezier beleefd. Ook heb ik veel gezelligheid en 
ondersteuning ervaren van alle andere collega’s, eerst op ‘de omloop’ en nu op de 4de verdieping: 
Patrick, Jelle, Nienke, Anne, Hans, Yvonne, Rianne, Marieke, Jeroen, Marianne, Tijn, Jackie, 
Monique, Elvira, Annick, Annette, Bregje, Nasira, Kalinka, Jasper, Maaike, Herma, Loes, Inge 
en Agnes. Bovendien heb ik veel geleerd van de collega’s die aanwezig waren bij de Topp Stuk 
en de Journal Club bijeenkomsten: Cis, Milou, Maud, Anne, Bram en Lieve. Allen heel erg 
bedankt. Daarnaast wil ik Leon, Anneke, Bianca, Nicole, Rina, Rob en Hilda bedanken voor de 
administratieve ondersteuning tijdens mijn promotietraject. 
Mijn familie en vrienden wil ik bedanken voor de onvoorwaardelijke steun en vriendschap. 
Eetclubvrienden, hoe waardevol zijn onze culinaire bijeenkomsten waarin we al vele jaren de 
hele wereld en onszelf bespreken! Tennisvrienden, fantastisch dat we al zoveel jaren wekelijks met 
elkaar op de baan staan en elkaar door dik en dun steunen! Studie- en “buitenland“-vrienden, 
hoe lang kennen we elkaar al niet, dank voor jullie jarenlange vriendschap, wat ben ik blij met 
jullie. 
Kirsten en Annick, wat geweldig dat jullie mijn paranimfen willen zijn. Lieve Kirsten, Ik ben 
blij dat ik je tijdens de studie Psychologie heb leren kennen. Ik bewonder je authenticiteit en 
ruimdenkendheid. Er zijn maar weinig mensen waarmee ik zo ongedwongen over van alles kan 
praten en waarmee ik zoveel plezier heb. Lieve Annick, ook met jou ervaar ik een klik. Ik kan me 
nog goed herinneren dat ik als collega op de afdeling Anesthesiologie aan je werd voorgesteld. 
Niet alleen door gemeenschappelijke interesses maar vooral door jouw warme karakter en 
oprechte belangstelling geniet ik elke keer weer van ons lunch- en tennisafspraken. 
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Jart, Koen en Hidde, ik ben enorm trots op jullie. Wat een voorrecht om jullie te zien opgroeien 
en betrokken te zijn bij jullie wel en wee en de belangrijke keuzes in jullie leven. Dank voor jullie 
interesse, steun en vele gezellige afleidingen tijdens de afgelopen promotiejaren. 
Tot slot, mijn allerliefste….. Joop. Met je warme en zorgzame karakter, positieve levensinstelling, 
prettige relativeringsvermogen en geweldige gevoel voor humor lever je een onmisbare bijdrage 
aan alles in mijn leven. Zonder jouw steun was dit promotietraject niet haalbaar geweest. Ik ben 
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Ria G. Duenk werd geboren op 14 augustus 
1960 in Hengelo (O). In 1978 behaalde ze 
haar VWO diploma aan het Ichthus College in 
Enschede. Na twee keer te zijn uitgelood voor de 
studie Geneeskunde is zij gestart met de studie 
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totaal 15 jaar als fysiotherapeut gewerkt heeft in 
zowel ziekenhuizen als particuliere praktijken. 
In 1999 keerde zij met haar gezin terug naar 
Nederland en vond zij een baan als fysiotherapeut 
in gezondheidscentrum de Kroonsteen in Malden. 
Tijdens haar werkzaamheden ondervond ze dat gedragsverandering bij cliënten de sleutel was 
tot lange termijn therapiesucces. Om cliënten beter te kunnen begeleiden in het proces van 
gedragsverandering heeft ze zich gespecialiseerd als psychosomatisch fysiotherapeut. 
Sindsdien nam haar interesse in “wat mensen beweegt” alleen maar toe. Uiteindelijk heeft ze 
in 2006 de knoop doorgehakt en is Psychologie gaan studeren aan de Radboud Universiteit in 
Nijmegen. Tijdens deze studie, die ze in 2010 cum laude afrondde, ontwikkelde ze een passie 
voor mensgebonden toepassingsgericht wetenschappelijk onderzoek. 
Vandaar dat ze allereerst als waarnemend onderzoekscoördinator werkzaam is geweest bij het 
IRAS van de Universiteit Utrecht alvorens een PhD positie te aanvaarden. In 2012 is zij gestart 
met haar promotieonderzoek naar proactieve palliatieve zorg bij patiënten met COPD op de 
afdeling Anesthesiologie, Pijn en Palliatieve Geneeskunde van het Radboud Universitair Medisch 
Centrum in Nijmegen. 
Ria is getrouwd met Joop Hageman. Samen hebben zij drie kinderen Jart (1992), Koen (1994) 
en Hidde (1996). 
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